SUDDEN DEATH in EPILEPSY FORENSIC AND CLINICAL ISSUES
SUDDEN DEATH in EPILEPSY FORENSIC AND CLINICAL ISSUES EDITED BY...
86 downloads
673 Views
11MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
SUDDEN DEATH in EPILEPSY FORENSIC AND CLINICAL ISSUES
SUDDEN DEATH in EPILEPSY FORENSIC AND CLINICAL ISSUES EDITED BY
CLAIRE M. LATHERS PAUL L. SCHR AEDER MICHAEL W. BUNGO JAN E. LEESTMA
Boca Raton London New York
CRC Press is an imprint of the Taylor & Francis Group, an informa business
CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2011 by Taylor and Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-13: 978-1-4398-0223-6 (Ebook-PDF) This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http:// www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com and the CRC Press Web site at http://www.crcpress.com
To (DS) a 4-year old boy with a history of nocturnal seizures who found hidden Christmas presents, including the one he wanted most of all, a remote control car two weeks before Christmas. The next morning he was found dead in bed. He and other victims of SUDEP challenge all of us to find preventive measures as quickly as possible. (CML) To Carol and Richard Lathers and to Marcel J. Lajoy for their love, support, and words of wisdom while completing this endeavor. (CML) To two university students (MB) and (AG) who were victims of SUDEP and to their courageous families who helped to found Epilepsy Bereaved in the United Kingdom. (PLS) To my patient wife Barbara and daughters Maria and Ellen who dealt with my many hours of editorial distraction with forbearance, encouragement and love. (PLS) To my grandson, Lucas, who missed quality time, so that this endeavor could be completed. (MWB)
Table of Contents
Foreword by Samuels Foreword by Schachter Preface Acknowledgments Editors Contributors
xv xvii xxi xxv xxvii xxxi
Section I Forensics of Sudden Death
1
Neurocardiologic Mechanistic Risk Factors in Sudden Unexpected Death in Epilepsy
3
Claire M. Lathers, Paul L. Schraeder, and Michael W. Bungo
2
Forensic Considerations and Sudden Unexpected Death in Epilepsy
37
Jan E. Leestma
3
Omega-3 Fatty Acids in Sudden Unexpected Death in€Epilepsy: Guardian of the Brain–Heart Connection
57
Fulvio A. Scorza, Esper A. Cavalheiro, Ricardo M. Arida, Vera C. Terra, Carla A. Scorza, Eliza Y. F. Sonoda, and Roberta M. Cysneiros
4
Unanswered Questions: SUDEP Studies Needed
67
Claire M. Lathers, Paul L. Schraeder, and Michael W. Bungo
5
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome: Implications in SUDEP David S. Paterson
vii
77
viii Table of Contents
6
Forensic Case Identification
95
Paul L. Schraeder, Elson L. So, and Claire M. Lathers
7
Sudden Unexpected Death in Epilepsy: Future Research Directions
109
Simona Parvulescu-Codrea
8
Forensic Postmortem Examination of Victims of Sudden Unexpected Death in Epilepsy
131
Claire M. Lathers, Paul L. Schraeder, Steven A. Koehler, and Cyril H. Wecht
9
One-Year Postmortem Forensic Analysis of Deaths in Persons with Epilepsy
145
Steven A. Koehler, Paul L. Schraeder, Claire M. Lathers, and Cyril H. Wecht
10
Drug Abuse and SUDEP
159
Steven B. Karch
11
Cocaine-Induced Seizures, Arrhythmias, and Sudden Death
169
Claire M. Lathers, Michelle M. Spino, Isha Agarwal, Laurie S. Y. Tyau, and Wallace B. Pickworth
12
Risk Factors for Sudden Death in Epilepsy
187
Thaddeus S. Walczak
13
EEG Findings in SUDEP
201
Maromi Nei and Nicole Simpkins
14
Severity of Seizures as a Forensic Risk and Case Reports
209
Edward H. Maa, Michael P. Earnest, Mark C. Spitz, and Jacquelyn Bainbridge
15
Intractable Epilepsy in the Setting of Malformations of Cortical Development as a Mechanism for SUDEP
221
Lara Jehi and Imad Najm
16
Neurogenic Cardiac Arrhythmias Howan Leung and Anne Y. Y. Chan
235
Table of Contents
17
Stress and SUDEP
ix
253
Claire M. Lathers and Paul L. Schraeder
18
Genetics of Sudden Death in Epilepsy
267
Neeti Ghali and Lina Nashef
19
Cardiac Channelopathies and Sudden Death
285
Benito Herreros
20
Sodium Channel Dysfunction: Common Physiopathologic Mechanism Associated with Sudden Death ECG Abnormalities in Brugada Syndrome and Some Types of€Epilepsy: Case Histories
303
Claire M. Lathers, Paul L. Schraeder, and Michael W. Bungo
21
Not Seizure but Syncope
311
Saumya Sharma, Trieu Ho, and Bharat K. Kantharia
22
Syncope, Seizures, and SUDEP: Case Histories
325
Claire M. Lathers, Paul L. Schraeder, and Michael W. Bungo
23
Sudden Death in Epilepsy: Relationship to the Sleep–Wake Circadian Cycle and Fractal Physiology
333
John D. Hughes and Susumu Sato
24
SUDEP: Medicolegal and Clinical Experiences
347
Braxton B. Wannamaker
Section II SUDEP Animal Models: MECHANISMS OF RISKS
25
Sudden Death: Animal Models to Study Nervous System Sites of Action for Disease and Pharmacological Intervention Claire M. Lathers
363
x Table of Contents
26
Synaptic Plasticity of Autonomic Ganglia: Role of Chronic Stress and Implication in Cardiovascular Diseases and Sudden Death
395
Karim A. Alkadhi and Karem H. Alzoubi
27
Animal Model for Sudden Cardiac Death: Autonomic Cardiac Sympathetic Nonuniform Neural Discharge
427
Claire M. Lathers
28
Animal Model for Sudden Unexpected Death in Persons with Epilepsy
437
Claire M. Lathers and Paul L. Schraeder
29
A Characterization of the Lockstep Phenomenon in Phenobarbital-Pretreated Cats
465
Jeffrey M. Dodd-O and Claire M. Lathers
30
Relationship of the Lockstep Phenomenon and Precipitous Changes in Blood Pressure
481
Amy Z. Stauffer, Jeffrey M. Dodd-O, and Claire M. Lathers
31
Interspike Interval Histogram Characterization of€Synchronized Cardiac Sympathetic Neural Discharge and€Epileptogenic Activity in the Electrocorticogram of€the€Cat
495
Daniel K. O’Rourke and Claire M. Lathers
32
Power Spectral Analysis: A Procedure for Assessing Autonomic Activity Related to€Risk Factors for Sudden and Unexplained Death in€Epilepsy
513
Animal Model for Sudden Cardiac Death: Sympathetic Innervation and Myocardial Beta-Receptor Densities
539
Stephen R. Quint, John A. Messenheimer, and Michael B. Tennison
33
Claire M. Lathers and Robert M. Levin
34
Antiepileptic Activity of Beta-Blocking Agents
551
Claire M. Lathers, Kam F. Jim, William H. Spivey, Claire Kahn, Kathleen Dolce, and William D. Matthews
Table of Contents
35
Arrhythmias Associated with Epileptogenic Activity Elicited by Penicillin
xi
567
Claire M. Lathers and Paul L. Schraeder
36
Role of Neuropeptides in the Production of Epileptogenic€Activity and Arrhythmias
577
Claire M. Lathers
37
Sudden Epileptic Death in Experimental Animal Models
591
Ombretta Mameli and Marcello Alessandro Caria
38
Sympathetic Nervous System Dysregulation of Cardiac Function and Myocyte Potassium Channel Remodeling in Rodent Seizure Models: Candidate Mechanisms for SUDEP 615 Steven L. Bealer, Cameron S. Metcalf, Jason G. Little, Matteo Vatta, Amy Brewster, and Anne E. Anderson
39
The Urethane/Kainate Seizure Model as a Tool to Explore€Physiology and Death Associated with Seizures
627
Mark Stewart
40
Acute Cardiovascular Response during Kindled Seizures
645
Jeffrey H. Goodman, Richard W. Homan, and IsAac L. Crawford
41
DBA Mice as Models of Sudden Unexpected Death in€Epilepsy
659
Carl L. Faingold, Srinivasan Tupal, Yashanad Mhaskar, and Victor V. Uteshev
Section III Clinical Issues of Sudden Death
42
Cardiac and Pulmonary Risk Factors and Pathomechanisms€of Sudden Unexplained Death in Epilepsy€Patients Josef Finsterer and Claudia Stöllberger
679
xii Table of Contents
43
Neurocardiac Interactions in Sudden Unexpected Death in€Epilepsy: Can Ambulatory Electrocardiogram-Based Assessment of Autonomic Function and T-Wave Alternans Help to Evaluate Risk?
693
Richard L. Verrier and Steven C. Schachter
44
Arrhythmogenic, Respiratory, and Psychological Risk Factors for Sudden Unexpected Death and Epilepsy: Case Histories
711
Claire M. Lathers
45
Sudden Arrhythmic Death Syndrome: Underlying Cardiac Etiologies, Their Implications, and the Overlap with SUDEP
721
Paramdeep S. Dhillon and Elijah R. Behr
46
Odds Ratios Study of Antiepileptic Drugs: A Possible Approach to SUDEP Prevention?
743
Claire M. Lathers, Paul L. Schraeder, and H. Gregg Claycamp
47
Antiepileptic Drugs Benefit/Risk Clinical Pharmacology: Possible Role in Cause and/or Prevention of SUDEP
755
Claire M. Lathers and Paul L. Schraeder
48
Clinical Pharmacology and SUDEP
789
Claire M. Lathers and Paul L. Schraeder
49
Experience-Based Teaching of Therapeutics and Clinical€Pharmacology of Antiepileptic Drugs: Sudden Unexplained Death in Epilepsy: Do Antiepileptic Drugs Have a Role?
801
Claire M. Lathers and Paul L. Schraeder
50
Clinical Pharmacology of Antiepileptic Drug Use: Clinical Pearls about the Perils of Patty
827
Paul L. Schraeder and Claire M. Lathers
51
Compliance with Antiepileptic Drug Treatment and the€Risk of Sudden Unexpected Death in Epilepsy Torbjörn Tomson
845
Table of Contents
52
SUDEP Clinical Case Histories: Typical and Atypical
xiii
853
Paul L. Schraeder
53
Cardiac Antiarrhythmic Agents: Pharmacological Basis for Their Antiarrhythmic and Proarrhythmic Effects
861
Saumya Sharma, Trieu Ho, and Bharat K. Kantharia
54
Could Beta–Blocker Antiarrhythmic and Antiseizure Activity Help Prevent SUDEP?
877
Claire M. Lathers
55
Decision Analysis and Risk Management
887
H. Gregg Claycamp
56
Epilepsy Surgery and the Prevention of SUDEP
905
Ryan S. Hays and Michael R. Sperling
57
Challenges in Overcoming Ethical, Legal, and Communication Barriers in SUDEP
915
Jane Hanna and Rosemary Panelli
58
Bereavement and Sudden Unexpected Death in Epilepsy
937
Lina Nashef and Lene Sahlholdt
59
SUDEP: A Clinical and Communicative Conundrum
943
Paul L. Schraeder and Claire M. Lathers
60
Epilepsy and SUDEP: Lessons Learned: Scientific and Clinical Experience
953
Claire M. Lathers and Paul L. Schraeder
61
SUDEP: A Mystery Yet to Be Solved
967
Claire M. Lathers and Paul L. Schraeder
62
Forensic Evidence and Expert Witnesses: Scientific Evidence: Getting It in and Keeping It Out
973
Thomas L. Bohan
Index
983
Foreword by Samuels
Epilepsy is one of the most prevalent neurological diseases in the world. Known for ages and clearly described in some of the oldest medical treatises, it was greatly feared in the ancient world because of the belief that it could cause sudden death. As reasonable treatments arose—ἀrst bromides, then phenobarbital, and, in the mid-twentieth century, phenytoin, the ἀrst modern antiepileptic drug—the mainstream of the medical community came to believe that epileptic seizures themselves were relatively harmless. During my own training in internal medicine in the 1970s, it was widely taught that the best treatment for a convulsion was to simply place the patient in a safe environment and let the seizure take its course. With the development of newer, safer treatments that include drugs and nonpharmacological approaches such as surgery and, more recently, vagal and deep brain stimulation, it became progressively more apparent that the ancients were, in fact, correct. Epilepsy, a state of recurrent unprovoked seizures, itself indeed carried with it an increased risk for sudden unexpected death and the term SUDEP (sudden unexpected death in epilepsy) was born. SUDEP now joins a long list of sudden death syndromes, including sudden death in middle aged men, sudden unexpected nocturnal death syndrome (SUNDS), sudden death from fright, sudden infant death syndrome (SIDS), sudden death in young athletes, sudden death associated with drug use, sudden death from heart disease, sudden death during sedative drug (including alcohol) withdrawal, sudden death during delirium, sudden death from stroke (including subarachnoid hemorrhage), and sudden death from head injury. With the advent of long-term monitoring of various physiological parameters, including the electrocardiogram, arterial oxygen saturation, and the electroencephalogram, it became apparent that some of these sudden death syndromes had in common a capacity to produce malignant cardiac arrhythmias, respiratory arrest, or both. In his landmark paper of 1942, “Voodoo” Death, the eminent physiologist Walter B. Cannon recounted stories of sudden death from the anthropological literature and posited an autonomic storm as the unifying hypothesis. In the past half-century, much has been learned about the capacity of the brain to damage the visceral organs, but many features of SUDEP remain an enigma. Despite all of the advances in the diagnosis and treatment of seizure disorders, the threat of sudden death still hovers over the epileptic patient, much as it did in ancient times. In Sudden Death in Epilepsy: Forensic and Clinical Issues, four of the most eminent experts in SUDEP, Claire Lathers, Paul Schraeder, Michael Bungo, and Jan Leestma, have put together an impressive tome representing the state of this art and science. The book’s three sections, Forensics of Sudden Death, SUDEP Animal Models: Mechanisms of Risk, and Clinical Issues in Sudden Death, are written by a veritable who’s who in the ἀeld. The interested reader can ἀnd chapters on the history, diagnosis, phenomenology, mechanisms, genetics, animal models, pathology, physiology, and even the social repercussions of this devastating phenomenon. Books written by so many authors inevitably create a challenge with regard to organization and thematic coherence, but the four editors, themselves xv
xvi
Foreword by Samuels
each major contributors to the literature on SUDEP, have done an admirable job pulling together the disparate array of experts into a volume that holds together and is readable. Sudden Death in Epilepsy: Forensic and Clinical Issues should be of great interest to neurologists, psychiatrists, neurosurgeons, internists, cardiologists, neuroscientists, and cardiovascular specialists. Epileptologists and their trainees will ἀnd the content invaluable in their day-to-day lives of counseling and treating people with epilepsy. Taken as a whole, the content acts as a roadmap to those who hope to someday fully understand and prevent this dramatic and tragic event. Martin A. Samuels, MD, FAAN, MACP, DSc (hon) Chairman, Department of Neurology Brigham and Women’s Hospital and Professor of Neurology Harvard Medical School Boston, Massachusetts
Foreword by Schachter
If sudden death in epilepsy is the most feared and serious consequence of epilepsy, why is it seldom discussed and woefully under-researched? The editors point to many reasons for this in the Preface—inadequate animal models and basic understanding, lack of clinical recognition from treating physicians and medical examiners, inability to eliminate the possibility of sudden death in the nearly one in three patients with epilepsy whose seizures are drug-resistant, and continuing reluctance among physicians to discuss sudden death with patients and their families. Compounding these issues is the silo-style infrastructure of academic medicine, which creates intrinsic barriers to establishing clinical and research collaborations across relevant disciplines, such as epidemiology, neurology, cardiology and pulmonology, as well as between physicians and applied scientists, including electrical, mechanical, and computer engineers. Despite these and other problems, there are reasons to be optimistic that research will begin to solve the mysteries posed by Drs. Lathers and Schraeder at the end of this book. First, creative and passionate researchers are dedicated to eradicating sudden death in epilepsy, perhaps most of all the editors of this volume, who have put together the most comprehensive and current treatise on the topic. The like-minded authors span numerous disciplines and their chapters challenge current paradigms and suggest new ways of thinking about sudden death in epilepsy. Second, the National Institute of Neurological Disorders and Stroke (NINDS) is actively engaged. Curing Epilepsy 2007: Translating Discoveries into Therapies, organized by the NINDS, and attended by more than 400 researchers, health care professionals, patients, and family members, affirmed sudden death in epilepsy as a major target for research, with the development and validation of at least one prevention strategy to decrease its occurrence as a short-term goal, and identiἀcation of the responsible mechanisms, including effects of seizures on autonomic functioning, particularly cardiac and respiratory, as a longer-term goal. The NINDS also sponsored a workshop on sudden death in epilepsy, held in November, 2008, which brought together researchers, clinicians, and patient advocacy groups to discuss strategies and to make plans for research and outreach. Third, professional epilepsy societies have recently established committees and taskforces with patient advocacy organizations, and have committed resources to work together to educate epilepsy professionals, doctors in training, and patients and families about sudden unexpected death in epilepsy (SUDEP), and to chart research agendas. The recommendations of one such task force include “convening a multidisciplinary workshop to reἀne current lines of investigation and to identify additional areas of research for mechanisms underlying SUDEP; performing a survey of patients and their families and caregivers to identify effective means of education that will enhance participation in SUDEP research; conducting a campaign aimed at patients, families, caregivers, coroners, and medical examiners that emphasizes the need for complete autopsy examinations for patients with suspected SUDEP; and securing infrastructure grants to fund a consortium xvii
xviii
Foreword by Schachter
of centers that will conduct prospective clinical and basic research studies to identify preventable risk factors and mechanisms underlying SUDEP” [1]. Fourth, numerous patient advocacy groups and family survivors are talking openly and urgently about sudden death in epilepsy at conferences and on Web sites. In addition, these groups are aggressively funding research projects with the hope of uncovering answers that will move the ἀeld forward. Indeed, these and other developments will likely enable critically important progress to be made in the understanding of sudden death in epilepsy and its prevention. These answers cannot come soon enough. And yet answers alone are not sufficient. If lack of seizure control is a signiἀcant risk factor for sudden death in epilepsy, then we must also urgently address the treatment gap in epilepsy, both by making treatments available to the tens of millions of persons with epilepsy in developing countries who currently have no access to anticonvulsants, and by ensuring that all patients everywhere with epilepsy have access to state-of-the-art care, including the full range of pharmacological and nonpharmacological treatment options. Even if researchers identify the underlying mechanism(s) of sudden death in epilepsy and patients have full access to comprehensive care, there will still remain one major barrier—lack of effective communication between physicians and their patients. Here are the agonizing reflections of a physician about whether to inform patients about sudden death€[2]: As a doctor and an epileptologist, I experience the deepest frustration when I am notiἀed of the sudden and unexpected death of one of my patients. Often these patients have been found dead in bed, lying dead on the floor of their apartment, or drowned in the bathtub. They are invariably young and are often at the beginning of their lives. I never forget them, and I feel that I have truly and ultimately failed them. . . . one of my young patients, a 25-year-old man, died last year while in bed. His parents had encouraged him to live alone so that his life would be as normal as possible. They had visited him that evening and had eaten dinner with him. He had a girlfriend, but she had not been there that night. The next morning he was found lying face down on his bed, fully dressed. No one was sure whether or not he had experienced a seizure. When his parents called me, we talked about the problem of sudden death and epilepsy. They wondered why his other doctors and I had not told them or their son that this could occur. I asked them if they thought he would have lived any differently if he had known. If we told every patient with epilepsy about this possibility, some might not dare live independent lives or might be burdened by anxiety, knowing that they might not awake in the morning. To this day, I do not know if my answer was appropriate.
This challenge must be addressed and solved before the discoveries of research can be translated to patient care if we are ever to end the scourge of sudden death. As physicians caring for patients with epilepsy, we should not wait for all the answers. We must accept the imperfect state of knowledge and inform our patients and, where appropriate, their families in a meaningful and compassionate way about sudden death, and work with them as much as possible to reduce the risk factors, especially by completely controlling generalized convulsive seizures. The editors and authors of Sudden Death in Epilepsy: Forensic and Clinical Issues have produced a landmark book that holds extraordinary promise for meaningful progress, bringing us closer to the day when sudden death will be fully preventable. Until then, my
Foreword by Schachter
xix
hope is that this book will inspire researchers, and give some measure of comfort to the bereaved and hope to those living with epilepsy and to their loved ones. Steven C. Schachter, M.D. Departments of Neurology Beth Israel Deaconess Medical Center Harvard Medical School Chief Academic Officer Center for Integration of Medicine and Innovative Technology Boston, Massachusetts
References 1. So EL, Bainbridge J, Buchhalter JR, et al. Report of the American Epilepsy Society and the Epilepsy Foundation Joint Task Force on sudden unexplained death in epilepsy. Epilepsia 2009;50: 917–922. 2. Schachter SC, ed. Epilepsy in our experience: Accounts of health care professionals. Oxford: Oxford University Press; 2008, pp. 7–8.
Preface
This book should be considered a sequel to, rather than a substitute for, the 1990 book Epilepsy and Sudden Death, edited by Lathers and Schraeder. Much of the material in the 1990 book, especially the discussion of animal research data, is still timely, as little additional animal-based work is extant. In addition, the epidemiological, behavioral, and drug-abuse-related data is also currently relevant. This current volume is an expansion rather than an updated sequel to the previous book on sudden unexpected death in epilepsy (SUDEP). These statements are based on our extensive review of the literature for this current book, which indicates that most of the research questions regarding evaluation of mechanisms and prevention of SUDEP have, to date, not been adequately addressed. When the previous book was published, the phenomenon of sudden unexpected/unexplained death in persons with epilepsy was considered to be a controversial topic or a very rare phenomenon by clinicians and pathologists alike. The public had little or no knowledge of the phenomenon. However, one positive consequence of the work done in SUDEP over the ensuing years is that now the phenomenon is widely referred to as SUDEP and it is accepted as a complication of epilepsy worldwide. SUDEP is one of the most common causes of death in young adults with a history of epilepsy, and presents a spectrum of dilemmas to forensic experts, clinicians, and researchers. At a most basic level, as determined in a national survey of coroners and medical examiners and discussed in this book, even in self-evident cases, SUDEP is infrequently used on death certiἀcates as a ἀnal diagnosis or medical cause of death. Ironically, this survey found that the majority of those same coroners and medical examiners who did not routinely use SUDEP on death certiἀcates, nonetheless acknowledged its validity as a diagnosis in a theoretical case in which no cause of death in a person with epilepsy could be found on postmortem examination. This disconnect between intellectual acknowledgment of its existence, and actual use of SUDEP as a death certiἀcate diagnosis, in all likelihood, results in signiἀcant underreporting of the prevalence of this tragic phenomenon. It is hoped that this book will prove to be an important resource to improve the knowledge of coroners and medical examiners about the use of the term SUDEP in appropriate cases. Since a portion of this new book addresses forensic issues, it is intended to be a resource for forensic pathologists, attorneys, coroners, and medical examiners as they struggle to determine the cause of death in persons with epilepsy. Because most other clinical and research aspects of SUDEP are also addressed, neurologists, experts in epilepsy, cardiologists, clinical pharmacologists, pharmacists, nurses, students, and persons with epilepsy or with a family member so diagnosed should all ἀnd sections of interests. Over the past two decades, many more basic and clinical scientists doing research in the ἀeld of epilepsy are focusing on the problem of SUDEP, as it is one of the most common causes of death associated with having epilepsy. However, to date, most research has focused on clinical and epidemiological data, with relatively few investigators using xxi
xxii
Preface
animal models. In addition, there has been little effort to determine whether there are common links between the risk of SUDEP and sudden cardiac deaths. While cardiologists are focusing increasingly on genetic risk factors for potentially life-threatening arrhythmias in young persons without coronary artery disease, there has been little effort to establish collaboration between neuroscience investigators interested in SUDEP and cardiology researchers interested in unraveling the genetically determined risk factors for potentially fatal arrhythmias. This book will be of help in directing neurological and cardiologic investigators to common areas of interest, especially as relates to the unanswered question of why some persons with epilepsy seem to be at risk for neurogenically induced fatal cardiac events. The basic science of epilepsy as relates to SUDEP is updated and expanded in this book. The role of alcohol and other drugs as seizure enhancing or producing conditions are discussed. The role of medication, compliance with prescribed antiepileptic drugs, or lack thereof, is an even more important problem today and is addressed in several chapters. The relevance of epidemiological studies of SUDEP is also presented. Sudden death in the pediatric population is also reviewed. The neurocardiological aspects of SUDEP are addressed in some detail. While SUDEP remains a major unsolved problem, thanks to the efforts of those who have conducted animal and epidemiological studies, what was once denied and called a myth is an acknowledged reality that has to be dealt with as a multidisciplinary issue. To solve the mystery of SUDEP, a global focus is required. Persons at risk must be identiἀed and preventive treatment regimens developed to decrease the occurrence of SUDEP. Clinical chapters emphasize that sophisticated simultaneous ambulatory EKG and EEG telemetry and respiratory function monitoring of patients at risk for sudden death will help identify cardiac, respiratory, and epileptogenic interactions in order to decrease the risk of SUDEP. Basic scientiἀc research programs and clinical and epidemiology studies are needed. Multidisciplinary teams working in clinical settings and with laboratories must address the global issues of SUDEP. Forensic chapters in this book discuss the fact that if the correct term “SUDEP” is used on autopsy reports, and if postmortem verbal autopsies are conducted when needed, the true incidence of SUDEP well may be determined to be much higher than previously thought. Drug development can justify the need for new antiepileptics and drugs in other pharmacological classes that address the reduction of the risk of SUDEP. Animal model chapters discuss new data gleaned by building on the previously utilized models and the lessons learned during the last quarter century. The use of animal models continues to be one of the most useful approaches to better understanding SUDEP. Discussion in various chapters may be summarized by stating that it is important to “think out of the box” when evaluating an established animal model that has the potential, with modiἀcation(s), to investigate possible mechanisms of SUDEP. Various authors of the animal model chapters presented in this book emphasize that multiple models are needed to investigate the pathophysiology of SUDEP, to hypothesize about effective treatments, to develop pilot studies in persons with epilepsy, and to conduct conἀrmatory large-scale clinical trials. The ἀelds of pharmacology, clinical pharmacology, and cardiology have much to offer as we work to improve compliance, develop new antiepileptic drugs, and apply different categories of drugs that hopefully attenuate the chances of occurrence of SUDEP. Authors address the possible overlapping mechanisms that may apply to the risk of sudden
Preface
xxiii
unexpected death occurring in epilepsy and in cardiac disease. Several chapters explore the interaction between the central and peripheral autonomic nervous systems and the cardiopulmonary systems. Included is a discussion of the potential interactive role of genetically determined subtle cardiac risk factors for arrhythmias, with a predisposition for seizurerelated cardiac arrhythmias. The possible mechanisms that are operant in producing both epileptogenic and cardiogenic arrhythmias are addressed. Several chapters examine proposed mechanistic factors in SUDEP, listing risk categories of arrhythmogenic, respiratory, and hypoxia, and psychological factors and discussing mechanisms for risks associated with each category. Several chapters discuss patients with Brugada syndrome and an interesting, interpretive presentation of a hypothesis to explain a common pathophysiologic mechanism associated with sodium channel dysfunction that may be common to clinical electrophysiological abnormalities and some types of epilepsy. Clariἀcation of risk factors and establishment of the mechanism of SUDEP are important to establish preventative measures for SUDEP and emphasize the need to strive for full seizure control. Several chapters discuss the importance of encouraging patients with epilepsy to receive nonmedical, common sense, lifestyle-modifying interventions that have generally accepted public health beneἀts, even though there is as yet no consensus that they may or may not prevent sudden death. Cardiac patients, psychiatric patients, and certain ethnic groups experiencing acute stressful circumstances are at risk for unexpected sudden death. The impact of adverse emotional states on the autonomic control of cardiac rhythm is an established factor leading to cardiac dysrhythmias in humans and other species. Although stress is associated with changes in autonomic neural function, its role as a potential risk factor for SUDEP has not been investigated. The association of epilepsy with depression and anxiety indicates that emotional stress should be evaluated as a potential risk factor for SUDEP. The interactions between emotional factors and the arrythmogenic potential of epileptiform discharges, and the possibility of beneἀt from stress management intervention need investigation. Prospective studies of patients are needed to determine how we can identify which persons with epilepsy are at risk for SUDEP. In a number of chapters, the authors speculate about common potential preventive measures to minimize the risk of both sudden unexpected death in epilepsy and sudden cardiac death. Several chapters address the issue of clinicians who treat persons with epilepsy, manifesting reluctance to discuss the possibility of SUDEP with their patients. This reluctance seems to be the result of concern that even introducing the topic to the patient and family would be stressful for them. However, for the most part, families of SUDEP victims express disappointment that they had not known of this possibility and call for widespread acknowledgment of the potential for occurrence of sudden death in association with epilepsy. Epilepsy Bereaved in the United Kingdom, an organization founded by families of SUDEP victims, has been particularly successful in raising the level of awareness of SUDEP in persons with epilepsy and their families, and within the medical profession and the general public. This kind of advocacy and dissemination of information will serve to increase the availability of resources used to solve the tragic mystery of SUDEP. A primary purpose of this book is to provide clinicians with the knowledge necessary to improve their comfort level in discussing SUDEP with patients and families and thereby to allow for freer dissemination of information about minimizing the known risk factors for SUDEP (e.g., erratic compliance in taking prescribed antiepileptic drugs). Committed investigators in research must solve the mystery of SUDEP using a leadership philosophy foundation that provides innovative vision and approaches for SUDEP
xxiv
Preface
research and teaching programs. The interaction of teaching and research is essential. While a student is learning how to conduct research, that person must simultaneously learn to become a teacher. Academic fellowships and competitions and grant funding for medical students, postdoctoral fellows, residents, and faculty will attract medical and graduate trainees to work on SUDEP and move the SUDEP knowledge base forward. As self-learning exercises, we have incorporated a variety of case studies of sudden death within chapters and as standalone chapters as practical teaching exercises. Clinical and basic science investigators must provide vision and a fertile environment to teach students to become tomorrow’s leaders in the struggle to solve the mystery of SUDEP. Claire M. Lathers Paul L. Schraeder Michael W. Bungo Jan E. Leestma
Acknowledgments
I wish to acknowledge the dedication and hard work of co-editor Claire Lathers. (JEL) We would not have been able to complete this book in a timely manner without the diligent secretarial assistance of Marie Faiola. (CML, PLS, MWB, JEL).
xxv
Editors
Claire M. Lathers, PhD, FCP, has been credentialed as a Senior Biomedical Research Scientist by the U.S. Food and Drug Administration (FDA) for international recognition of her work in the two areas of cardiovascular autonomic dysfunction associated with sudden death in persons with epilepsy and with space flight. The primary focus of her international cardiovascular pharmacology research career has centered on autonomic peripheral and central mechanisms involved in the control and regulation of blood pressure, heart rate and rhythm, and the electroencephalogram. Dr. Lathers and Dr. Schraeder have collaborated and published numerous studies and two books focusing on epilepsy and sudden unexplained death. Dr. Lathers served the FDA for a total of 11 years, including four years as the Senior Advisor for Science to the director in the Center for Veterinary Medicine and director of the Office of New Animal Drug Evaluation and ἀve years in the Center for Drug Evaluation and Research as a pharmacology reviewer. Claire also served as a special government expert for 2 years. Dr. Lathers spent 14 years working as a visiting scientist at NASA/ USRA, collecting data from subjects in ground-based studies and from astronauts and cosmonauts before, during and after space flight. Dr. Lathers earned a BS in pharmacy from Albany College of Pharmacy, Union University and her PhD in pharmacology from the State University of New York at Buffalo School of Medicine. She completed an NIH funded two-year postdoctoral fellowship at the Medical College of Pennsylvania. Her academic faculty experience includes working at the Medical College of Pennsylvania (15 years), Albany College of Pharmacy (two years as president, dean, and tenured professor); Uniformed Services University of the Health Sciences (three years part time); and Gwynedd Mercy College (11 years part time). Dr. Lathers is currently collaborating with a number of academicians on scientiἀc issues of the nexus between human and veterinary medicine clinical pharmacology, antimicrobial resistance, food safety, and biodefense measures. In addition to her academic and government service, Dr. Lathers has worked in the pharmaceutical industry. She served as chief scientiἀc officer of Barr Pharmaceuticals for three years and worked part time with four other pharmaceutical companies during a 15-year period. Dr. Lathers has authored or co-authored over 300 publications and abstracts, has edited three books, and has presented data at over 140 international meetings. She is an emeritus fellow, an honorary member of the Board of Regents, and a past president of the American College of Clinical Pharmacology, having served as regent, treasurer, and president. Dr. Lathers also served as the section editor of the educational series entitled: “Innovative Teaching Methods in Clinical Pharmacology” for the Journal of Clinical Pharmacology for 17 years. Claire served as a member of the Board of the Annapolis Center, charged to evaluate risk assessments, and worked on the epidemiology, toxicology, and food safety workshops and accords. In recognition of her work, Dr. Lathers has been the recipient of numerous awards and honors. xxvii
xxviii Editors
Paul L. Schraeder, MD, FAAN, is professor emeritus of neurology at Drexel University College of Medicine, former chief of neurology at the Medical College of Pennsylvania Hospital, Philadelphia, Pennsylvania and former professor of medicine and neurology at the Robert Wood Johnson School of Medicine in Camden, New Jersey; head of the Division of Neurology at Cooper Hospital/University Medical Center, Camden, New Jersey; and former associate professor of neurology at the Medical College of Pennsylvania. He is a member of the Philadelphia Neurological Society, the American Epilepsy Society, and a fellow of the American Academy of Neurology. He has served on the professional advisory board of the Epilepsy Foundation of Southeastern Pennsylvania and the Epilepsy Foundation of America and as medical advisor to Epilepsy Bereaved, a support organization for surviving friends and family of victims of sudden unexplained death in epileptic persons (SUDEP) in the United Kingdom. Dr. Lathers and Dr. Schraeder co-edited the ἀrst book addressing the topic of Epilepsy and Sudden Death (Marcel Dekker, 1990). Dr. Lathers and he have collaborated for over three decades studying and investigating the mystery of SUDEP and developed the ἀrst experimental animal models of this fatal phenomenon. Dr. Schraeder organized a collaborative nationwide survey of how coroners and medical examiners evaluate the deaths of persons with a history of epilepsy. Dr. Schraeder received the AB€ degree from Bucknell University, Lewisburg, Pennsylvania and the MD degree from€Jefferson Medical€College, Philadelphia, Pennsylvania. He completed his residency in neurology and fellowship in electroencephalography and experimental epilepsy at the University of Wisconsin. Michael W. Bungo, MD, FACC, FACP, has agreed to serve as the third co-editor of this new book. After residency and fellowship training in cardiology at Harvard Medical School programs in Boston, Dr. Bungo worked full time for NASA as director of the Space Biomedical Research Institute at the Johnson Space Center. During his time at NASA, Dr. Bungo ἀrst cataloged arrhythmias occurring in spaceflight crews and hypothesized that the unique physiological and psychological environments of space flight may be arrhythmogenic. The Aerospace Medical Association awarded him the Louis H. Bauer Founders Award and NASA awarded him the NASA Medal for Exceptional Scientiἀc Achievement for his pioneering research work concerning the heart’s adaptation to zero gravity. While at NASA, Dr. Bungo served on the Joint U.S.–U.S.S.R. Working Group that developed the now combined space station science program for these prior competitors. He left NASA to assume the positions of director of the Heart Station, Division of Cardiology and vice chair for Inpatient Affairs, Department of Internal Medicine at the University of Texas Medical Branch in Galveston. Dr. Bungo subsequently moved to the University of Texas Medical School in Houston and served as chief of staff at the LBJ General Hospital, CEO of UT-Physicians, and vice dean for Clinical Affairs. He is currently a professor of medicine in the Division of Cardiology at that same institution. Dr. Bungo’s current research project funded by NASA is entitled “Cardiac Atrophy and Diastolic Dysfunction during and after Long Duration Spaceflight: Functional Consequences for Orthostatic Intolerance, Exercise Capacity, and Risk of Cardiac Arrhythmias.” In addition to numerous publications and presentations, Dr. Bungo and Dr. Lathers have collaborated since 1989 and have co-authored seven published papers. In 2008, Dr. Bungo has co-authored three papers and one book chapter with Drs. Lathers and Schraeder on the mystery of SUDEP. Dr.€Bungo has delivered scientiἀc presentations at three international symposiums organized by Dr.€Lathers.
Editors
xxix
Jan E. Leestma, MD, MM, is the lead author of the second edition of Forensic Neuropathology. He received the MD degree from the University of Michigan School of Medicine in 1964, and a Masters of Management (MM) degree from the J.L. Kellogg Graduate School of Management of Northwestern University, Evanston, Illinois in 1986. He completed residency training in anatomic pathology and neuropathology at the University of Colorado Medical Center, Denver, Colorado and a neuropathology fellowship at the€Albert Einstein College of Medicine, Bronx, New York. He is certiἀed in both anatomic pathology and neuropathology by the American Board of Pathology (1970). He served in the United States Air Force Medical Corps at the Armed Forces Institute of Pathology, Washington, D.C. (1968–1971) and was honorably discharged with the rank of major, USAF MC. He was an assistant and associate professor of pathology and neurology at Northwestern University School of Medicine (1971–1986) and served as chief of neuropathology at both Northwestern Memorial Hospital and the Children’s Memorial Hospitals, Chicago, Illinois. He was professor of pathology and neurology, and dean of students for the Division of the Biological Sciences and the Pritzker School of Medicine at the University of Chicago, Chicago, Illinois (1986–1987). He was an assistant medical examiner and neuropathology consultant to the Office of the Medical Examiner, Cook County, Illinois (1977–1987). He was a guest researcher at the Karolinska Institutet, Huddinge University Hospital, Pathology Institute, Stockholm, Sweden (1981–1982). He was associate medical director and chief of neuropathology at the Chicago Institute of Neurosurgery and Neuroresearch in Chicago (1987–2003). He has had a private consulting practice in forensic neuropathology since the early 1970s which continues to the present time. He has given expert testimony in more than 30 U.S. states, Canada, and the United Kingdom. He is the author of more than 100 professional publications including numerous book chapters in texts. He was the author of Forensic Neuropathology (ἀrst edition), Raven Press, New York, 1988. He is a member of the American Association of Neuropathologists, and of the American Academy of Forensic Sciences. Dr. Leestma wrote some chapters in Epilepsy and Sudden Death, edited by Drs. Lathers and Schraeder. Thus it is a natural extension of this collaboration for these three editors to work with co-editor Dr. Bungo and CRC Press is to expand the focus of forensics and clinical issues. The diverse scientiἀc expertise and endeavors of each of the four editors, working in the different ἀelds of forensics, neurology, cardiology, and clinical pharmacology, have united in this edition to produce a book with a special emphasis on the forensics and clinical issues associated with neurocardiology, epilepsy, arrhythmias, and sudden death.
Contributors
Isha Agarwal
Medical College of Pennsylvania Philadelphia, Pennsylvania
Karim A. Alkadhi, PhD
Department of Pharmacological and Pharmaceutical Sciences University of Houston Houston, Texas
Karem H. Alzoubi
Department of Clinical Pharmacy Jordan University of Science and Technology Irbid, Jordan
Anne E. Anderson, MD
Departments of Pediatrics, Neurology, Neuroscience Baylor College of Medicine Houston, Texas
Ricardo M. Arida
Departamento de Fisiologia Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Jacquelyn Bainbridge, PharmD, FCCP School of Pharmacy University of Colorado Health Sciences Center Denver, Colorado
Steven L. Bealer, PhD
Department of Pharmacology and Toxicology University of Utah Salt Lake City, Utah
Elijah R. Behr, MD
Cardiac and Vascular Division St. George’s University of London London, United Kingdom
Amy Brewster
Department of Pediatrics Baylor College of Medicine Houston, Texas
Michael W. Bungo, MD, FACC, FACP,€CPE
Division of Cardiology University of Texas Medical School at Houston Houston, Texas
Esper A. Calvalheiro
Disciplina de Neurologia Experimental Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Marcello Alessandro Caria
Department of Biomedical Sciences Human Physiology Division Sassari, Italy
Anne Y. Y. Chan
Department of Medicine and Therapeutics Chinese University of Hong Kong and Prince of Wales Hospital Hong Kong SAR, China
H. Gregg Claycamp, PhD
Center for Drug Evaluation and Research Office of Compliance U.S. Food and Drug Administration Silver Spring, Maryland
Isaac L. Crawford
Department of Neurology Southwestern Regional Epilepsy Center Veterans Administration Medical Center University of Texas Southwestern Medical Center Dallas, Texas
Thomas L. Bohan, PhD, JD, F-AAFS, D-IBFES MTC Forensics Peaks Island, Maine
xxxi
xxxii
Roberta M. Cysneiros
Programa de Pós-Graduação em Distúrbios do Desenvolvimento do Centro de Ciências Biológicas e da Saúde da Universidade Presbiteriana€Mackenzie São Paulo, Brasil
Paramdeep S. Dhillon
Cardiac and Vascular Sciences St. George’s University of London London, United Kingdom
Contributors
Benito Herreros, MD, PhD
Cardiology Department Hospital Universitario Rio Hortega Valladolid, Spain
Trieu Ho, MD
Division of Cardiology University of Texas Medical School at Houston Houston, Texas
Richard W. Homan, MD
Department of Physiology Johns Hopkins University Baltimore, Maryland
Department of Neurology University of Texas Southwestern Medical Center Southwestern Regional Epilepsy Center Veterans Administration Medical Center Dallas, Texas
Kathleen Dolce
John D. Hughes, MD
Jeffrey M. Dodd-O, MD
Department of Drug Metabolism Smith Kline & French Laboratories King of Prussia, Pennsylvania
Michael P. Earnest, MD Department of Neurology Denver Health and Hospitals Denver, Colorado
Carl L. Faingold, PhD
Department of Pharmacology Southern Illinois University School of Medicine Springἀeld, Illinois
Josef Finsterer
Krankenanstalt Rudolfstiftung Vienna, Austria
Neeti Ghali
Department of Clinical Genetics Guy’s Hospital London, United Kingdom
Jeffrey H. Goodman, PhD
Department of Physiology and Pharmacology State University of New York Brooklyn, New York
Jane Hanna, OBE, MA, BCL Epilepsy Bereaved Wantage, United Kingdom
Ryan S. Hays
Department of Neurology Thomas Jefferson University Philadelphia, Pennsylvania
National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda, Maryland
Richard Hughes
Department of Neurology Denver Health and Hospitals Denver, Colorado
Lara Jehi, MD
Department of Neurology Cleveland Clinic Neurological Institute Cleveland, Ohio
Kam F. Jim, PhD
Clinical Documentation Sanoἀ-Aventis Great Valley, Pennsylvania
Claire Kahn, PhD
Department of Drug Metabolism Smith Kline & French Laboratories King of Prussia, Pennsylvania
Bharat K. Kantharia, MD
Division of Cardiology University of Texas Medical School at Houston Houston, Texas
Steven B. Karch, MD, FFFLM, FFDov Berkeley, California
Steven A. Koehler
Office of the Coroner of Allegheny County Pittsburgh, Pennsylvania
Contributors
Claire M. Lathers, PhD, Emeritus FCP Albany, New York
xxxiii
Lina Nashef, MBChB, MD, FRCP
Chicago, Illinois
Departments of Neurology and Clinical Neurosciences King’s College Hospital London, United Kingdom
Howan Leung
Maromi Nei, MD
Robert M. Levin
Daniel K. O’Rourke, MD
Albany College of Pharmacy Albany, New York
Medical College of Pennsylvania Philadelphia, Pennsylvania
Jason G. Little
Rosemary Panelli, PhD
Jan E. Leestma, MD
Department of Medicine and Therapeutics Chinese University of Hong Kong Hong Kong SAR, China
Department of Neurology Jefferson Comprehensive Epilepsy Center Philadelphia, Pennsylvania
Department of Pharmacology and Toxicology University of Utah Salt Lake City, Utah
Joint Epilepsy Council of Australia Seymour, Australia
Edward H. Maa, MD
Graduate School of Nursing University of Virginia Newport News, Virginia
Neurology Denver Health and Hospitals Denver, Colorado
Ombretta Mameli, MD
Department of Biomedical Sciences Human Physiology Division Sassari, Italy
William D. Matthews, PhD
Department of Drug Metabolism Smith Kline & French Laboratories King of Prussia, Pennsylvania
John A. Messenheimer, MD
Department of Neurology University of North Carolina School of Medicine Chapel Hill, North Carolina
Cameron S. Metcalf
Department of Pharmacology and Toxicology University of Utah Salt Lake City, Utah
Yashanad Mhaskar
Department of Pharmacology Southern Illinois University School of Medicine Springἀeld, Illinois
Imad Najm, MD
Department of Neurology Cleveland Clinic Neurological Institute Cleveland, Ohio
Simona Parvulescu-Codrea, MD, PhD
David S. Paterson, PhD Department of Pathology Children’s Hospital Boston Boston, Massachusetts
Wallace B. Pickworth, PhD Addiction Research Center National Institute on Drug Abuse Baltimore, Maryland
Stephen R. Quint, PhD
Department of Neurology University of North Carolina Chapel Hill, North Carolina
Lene Sahlholdt
Danish Epilepsy Centre Dianalund, Denmark
Martin Allen Samuels, MD Brigham and Women’s Hospital Harvard Medical School Boston, Massachusetts
Susumu Sato, MD
Office of Clinical Director National Institute of Neurological Disorders and Stroke Bethesda, Maryland
xxxiv
Steven C. Schachter, MD
Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts
Paul L. Schraeder, MD, FAAN
Department of Neurology (emeritus) Drexel University College of Medicine Philadelphia, Pennsylvania
Carla A. Scorza
Disciplina de Neurologia Experimental Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Fulvio Alexandre Scorza
Disciplina de Neurologia Experimental Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Saumya Sharma, MD
Division of Cardiology University of Texas Medical School at Houston Houston, Texas
Nicole Simpkins
Jefferson Comprehensive Epilepsy Center Thomas Jefferson University Philadelphia, Pennsylvania
Elson L. So, MD
Section of Electroencephalography Mayo Clinic College of Medicine Rochester, Minnesota
Eliza Y. F. Sonoda
Disciplina de Neurologia Experimental Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Michael R. Sperling, MD
Jefferson Comprehensive Epilepsy Center Thomas Jefferson University Philadelphia, Pennsylvania
Michele M. Spino
Medical College of Pennsylvania Philadelphia, Pennsylvania
Mark C. Spitz, MD Health Science Center University of Colorado Aurora, Colorado
Contributors
William H. Spivey, MD (deceased) Medical College of Pennsylvania Philadelphia, Pennsylvania
Amy Z. Stauffer, MD
Medical College of Pennsylvania Philadelphia, Pennsylvania
Mark Stewart, MD, PhD
Department of Physiology/Pharmacology and Neurology State University of New York Brooklyn, New York
Claudia Stöllberger
Second Medical Department Krankenanstalt Rudolfstiftung Vienna, Austria
Michael B. Tennison
School of Medicine University of North Carolina Chapel Hill, North Carolina
Vera C. Terra
Departamento de Neurologia, Psiquiatria e Psicologia Médica Universidade de São Paulo. Ribeirão Preto São Paulo, Brasil
Torbjörn Tomson
Department of Neurology Karolinska University Hospital Stockholm, Sweden
Srinivasan Tupal
Department of Pharmacology Southern Illinois University School of Medicine Springἀeld, Illinois
Laurie S. Y. Tyau, MD
Medical College of Pennsylvania Philadelphia, Pennsylvania
Victor V. Uteshev
Department of Pharmacology Southern Illinois University School of Medicine Springἀeld, Illinois
Matteo Vatta
Department of Pediatrics Baylor College of Medicine Houston, Texas
Contributors
Richard L. Verrier, PhD, FACC Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts
ἀ addeus S. Walczak, MD MINCEP Epilepsy Care Minneapolis, Minnesota
xxxv
Braxton B. Wannamaker, MD Epilepsy Services and Research, Inc. Orangeburg, South Carolina
Cyril H. Wecht, MD, JD
Office of the Coroner of Allegheny County Pittsburgh, Pennsylvania
Forensics of Sudden Death
I
Neurocardiologic Mechanistic Risk Factors in Sudden Unexpected Death in Epilepsy
1
Claire M. Lathers Paul L. Schraeder Michael W. Bungo
Contents 1.1 Introduction 1.2 Risk Factors for SUDEP 1.3 SUDEP Animal Models 1.3.1 Therapies as Factors 1.4 Case of SUDEP with a Premorbid Diagnosis of Nonepileptic Seizures 1.5 Discussion 1.5.1 Future Steps References
3 3 15 24 24 26 26 26
1.1â•…Introduction There are at least three categories of factors that may be operative in the mechanisms for sudden unexpected death in epilepsy (SUDEP) (Lathers et al. 2008a): arrhythmogenic, including changes in autonomic neural and cardiac function, respiratory and hypoxia, and psychological. Each of these main risk factor categories, in all likelihood, includes many subcategories. For example, the arrhythmogenic category includes pharmacological drug effects, genetic ion channelopathies, and acquired heart disease. The psychological factors include stress, anxiety, and depression states. This list of three primary areas of mechanism for SUDEP was expanded to include eight topics (Lathers et al. 2008b, 2008c).
1.2â•…Risk Factors for SUDEP The risk factors for SUDEP are as follows:
1. Pathophysiological mechanisms: cardio/autonomic 2. Respiratory/autonomic factors and hypoxia 3. Syncope 4. Genetic/structural mechanistic factors 5. Risk factors for SUDEP 6. Therapies: increased or decreased risk 7. Psychological factors 8. Unusual factors possibly modifying risk 3
4 Sudden Death in Epilepsy: Forensic and Clinical Issues
The pathophysiological mechanisms of SUDEP are not extant (see Table 1.1). From a cardiac standpoint, there is no question that the sympathetic component of cardiac innervation is involved in the production of potentially fatal tachyarrhythmias. It has also been established that postganglionic cardiac sympathetic innervation is altered in association with temporal lobe epilepsy and may be a pathophysiological risk factor for SUDEP (Druschky et al. 2001). These clinical data correlate with animal studies that found epiÂ� leptiform discharge–related postganglionic cardiac sympathetic abnormalities that were associated with cardiac conduction disturbances and arrhythmias (Lathers and Schraeder 1982, 1987, 1990a; Schraeder and Lathers 1983, 1989; Lathers 2010a, 2010b; Lathers et€al. Table 1.1â•… Pathophysiological Mechanisms Model, Symptoms, and/or Changes Nonuniform autonomic cardiac postganglionic neural discharge associated with coronary occlusion of left anterior descending coronary artery and/or ouabain toxicity in cats.
Arrhythmia monitoring of pacemaker patients. Cardiac beta receptor distribution: Beta receptor density right atria signiἀcantly lower than left atria; right ventricle signiἀcantly lower than left ventricle; density in ventricles higher than atria; beta receptor density of distal distribution of left anterior descending coronary artery signiἀcantly higher than proximal distribution. These regional density differences are related to the cardiac contractile strength of different areas of heart. Regional differences in beta adrenoreceptor densities reflect differences in postganglionic cardiac sympathetic innervation of the myocardium (Randall et al. 1977, 1978, 1984). Regulation of cardiac neural discharge is a new paradigm in the management of sudden cardiac death.
Mechanisms of Sudden Death Nonuniform (increases, decreases, and/or no change) autonomic neural postganglionic cardiac sympathetic discharge traveling through the stellate ganglia causes cardiac€arrhythmias, ventricular ἀbrillation, and/or SUD in the manner described by Han and Moe (i.e., nonuniform recovery of excitability in ventricular muscle). Suggested neural discharge site for drugs to modify occurrence of arrhythmia and death (Lathers et al. 1974a, 1974b, 1977a, 1977b, 1978, 1981, 1988; Lathers 1980, 1981, 1982; Lathers and Roberts 1980, 1985; Spivey and Lathers 1985; Han and Moe 1964). Revealed tachycardias, most likely ventricular tachycardia, related to SUD, give insight into terminal event mechanisms (Wichter et al. 2005; Nagele et al. 2007). A correlation with the release of norepinephrine at sympathetic nerve terminals in the heart in a manner to produce arrhythmia. Innervation density is high in subepicardium and central conduction system. Nonuniform postganglionic cardiac sympathetic cardiac innervation is related to nonuniform beta sympathetic receptor locations in the heart and affects cardiac contractility and development of arrhythmias and/or death. In diseased hearts, cardiac innervation density varies and may lead to sudden cardiac death (Lathers et al. 1986, 1986b, 1988, 1990, 2010a, 2010b, 2010c). These data were conἀrmed by Druschky et al. (2007), Ieda et al. (2006, 2007, 2008), and Kimura et al. (2007). These site differences will vary release of norepinephrine in various sites of the heart. This modiἀes cardiac contractile function and may trigger development of arrhythmias and/or sudden death. Site difference, in part, is one component of the mechanism(s) involved in sudden cardiac death. The heart is extensively innervated and its performance is regulated by the balance of discharges within and between the autonomic nervous system divisions (Ieda et al. 2008; Lathers et al. 1977a, 1977b, 1978; Lathers 1980, 1981). (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
5
Table 1.1â•… Pathophysiological Mechanisms (Continued) Model, Symptoms, and/or Changes Nonuniform autonomic cardiac postganglionic neural discharge associated with pentylenetetrazol-induced interictal epileptogenic activity in cats. Lockstep phenomenon (LSP): Cardiac postganglionic sympathetic and vagal discharges were synchronized one for one with both ictal and interictal discharges and premature ventricular contractions, ST/T changes, and conduction blocks, and precipitous changes in blood pressure occurring concurrent with interictal spikes.
Blockading GABAergic and glycinergic receptors in medulla slices of newborn rats evoked intermittent seizure-like ἀring of cardiac parasympathetic neurons, suggesting the seizure-like pattern of ἀring during an epileptic attack may cause neurogenic ictal bradyarrhythmias, cardiac asystole, or even sudden death in persons with epilepsy (Wang et al. 2006). Cardiac postganglionic denervation in patients with epilepsy examined to evaluate ictal asystole because tachyarrhythmias are common during epileptic seizures, while bradyarrhythmias or asystoles occur less frequently (Kerling et al. 2009).
Chaos science: Simple systems that manifest periodic activity are easily perturbed, and are less able to return to the preperturbed state.
Mechanisms of Sudden Death Nonuniform autonomic neural discharge, autonomic neural imbalance of postganglionic cardiac sympathetic, and vagal discharge causes cardiac arrhythmias, ventricular ἀbrillation, and/or asystole and/or SUDEP (Lathers and Schraeder 1982, 1987; Schraeder and Lathers 1983, 1988; Lathers et al. 1984, 1990, 1993; Carnel et al. 1985; Tumer et al. 1985). Lockstep phenomenon is considered to be one potential mechanism for SUDEP (Lathers et al. 1987; Lathers and Schraeder 1990a, 1990b; Stauffer et al. 1989, 1990; Dodd-O and Lathers 1990; O’Rourke and Lathers 1990). 1. Spatial and temporal summation of neuronal discharges in a subcortical center producing a stimulus strong enough to overcome the cortical and ganglionic threshold (Dodd-O and Lathers 1990). 2. Increased synaptic recruitment, resulting in ampliἀcation of subcortical stimuli along their path, so when reaching the cortex and sympathetic ganglion, they are capable of causing susceptible neurons in these regions to discharge. 3. Increased irritability of all neurons so that subcortical impulses could stimulate cortical and ganglionic neurons (Dodd-O and Lathers 1990). Provides supporting data for the lockstep phenomenon ἀnding of Lathers et al. (1987) and colleagues. It is to be determined if the predisposition of central PNS ἀring correlates with electrical remodeling of myocardium, possibly secondary to epileptogenic activity related cardiac neural discharges (LSP).
Single-photon emission computed tomography examined I-(123)-meta-iodobenzylguanidine as a marker of postganglionic cardiac norepinephrine uptake. Pronounced reduction in cardiac single-photon emission computed tomography uptake in asystolic patients indicated postganglionic cardiac catecholamine disturbance. Impaired sympathetic cardiac innervation limits adjustment and modulation of heart rate and may increase the risk of asystolic events and, eventually, SUDEP (Kerling et al. 2009). Data of Kerling et al. support the ἀndings of Lathers et al. (1986a, 1986b, 1987, 1990), Lathers and Levin (2010), and those of Han and Moe (1964). A periodic rhythm in the brain, where normally rich complexity exists, implies a susceptibility to failure that may result in death (Gleick 1987). (continued)
6 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.1â•… Pathophysiological Mechanisms (Continued) Model, Symptoms, and/or Changes Mode locking: Epileptic focus and medullary cardiac center may be locked one to one during state of LSP in the manner suggested by Gleick (1987).
Power spectral analysis (Quint et al. 1990).
Sympathetic innervation is critical for effective cardiac function (Saffitz 2008). Developmental and regulatory mechanisms determining density and pattern of cardiac sympathetic innervation are unclear, as is role of innervation in arrhythmogenesis. Sema3a establishes cardiac sympathetic innervation patterning. Sema3a is abundantly expressed in the trabecular layer in early-stage embryos but is restricted to Purkinje ἀbers after birth, forming an epicardial-to-endocardial transmural sympathetic innervation pattern. Sema3a(−/−) mice lacked a cardiac sympathetic innervation gradient and exhibited stellate ganglia malformation, leading to marked sinus bradycardia due to sympathetic dysfunction. Sympathetic dysfunction: altered postganglionic cardiac sympathetic innervation found postmortem in patients with chronic temporal lobe epilepsy (Druschky et al. 2001).
Mechanisms of Sudden Death Occurrence of a very regular oscillator in the brain is theoretically dangerous, regardless of mechanism. Fractal processes are ubiquitous in biological systems, include brain electrical depolarizations, and are systems that convey different information. Complexity of a fractal process may at times depreciate into a simple periodic process representing decay of the system and dramatic change (Goldberger et al. 1985; Winfree 1987). Causes of death include failure of the brain and heart. If the brain sends a message to the heart triggering a fatal arrhythmia, or if the heart enters an arrhythmia via its own initiative, sudden death will occur. Perturbations of cardiac electrical depolarization may have several mechanisms, any or several of which may be operations (O’Rourke and Lathers 1990). Time-frequency domain analyses of heart rate variability in patients with epilepsy and time-frequency mapping of R–R intervals during partial seizure may provide procedures to assess autonomic activity related to risk factors for SUDEP (Novak et al. 1999; Everengul et al. 2005; Persson et al. 2007). Cardiac-speciἀc overexpression of Sema3a in transgenic mice (SemaTG) associated with reduced sympathetic innervation and attenuation of the epicardial-to-endocardial innervation gradient. SemaTG mice demonstrated sudden death and susceptibility to ventricular tachycardia, due to catecholamine supersensitivity and prolongation of the action potential duration. Concluded appropriate cardiac Sema3a expression is needed for sympathetic innervation patterning and is critical for heart rate control (Ieda et al. 2007).
Altered postganglionic cardiac sympathetic innervation may increase risk of cardiac abnormalities and/or SUDEP (Lathers et al. 1990, Chapter 22).
(continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
7
Table 1.1â•… Pathophysiological Mechanisms (Continued) Model, Symptoms, and/or Changes Amygdaloid kindled seizure effect on cardiovascular system was examined in rats. An abrupt 50% increase in mean arterial pressure (BP) lasting 20–30 s after initiation of seizure occurred with profound bradycardia, characterized by a rate about half of that recorded before stimulation. Changes in heart rate and BP observed during amygdaloid kindled seizures are similar to those observed during secondary spontaneous seizures. Effects apparently are independent of kindling stimulus because stimulusinduced cardiovascular changes were not present at the beginning of kindling. Use of electrical stimulation as a therapy for epilepsy is currently being studied in experimental animals and in patients with epilepsy. This study examined the effect of preemptive, low-frequency, 1-Hz sine wave stimulation (LFS) on incidence of amygdala kindled seizures in rats. Amygdaloid kindled seizures in unanesthetized rats induced abrupt elevation of blood pressure accompanied by a signiἀcant decrease in heart rate.
Mechanisms of Sudden Death Results suggest the kindling seizure model is useful to study underlying mechanisms of seizure-induced cardiac arrhythmias and possibly the clinical phenomenon of SUDEP (Vindrola et al. 1984; Goodman et al. 2005).
Dramatic decrease in incidence of stage 5 seizures in fully kindled animals after preemptive LFS suggests low-frequency stimulation may be an effective therapy for prevention of seizures in patients with epilepsy (Gary-Bobo and Bonvalette 1977). Muscarinic receptor blockade with atropine (1 mg/kg, i.v. abolished seizure-induced bradycardia. Seizure-induced hypertension was unaffected by beta-adrenergic blockade with timolol (1 mg/kg, i.v.), but reduced by phentolamine (5€mg/kg, s.c., an alpha-adrenergic receptor antagonist). Chemical sympathectomy was induced with 6-hydroxydopamine (100 mg/kg, i.v.), an agent that does not cross the blood–brain barrier, eliminated the pressor response but did not completely block seizure-induced bradycardia. Effectiveness of 6-hydroxydopamine was tested with tyramine (0.5 mg/kg, i.v.), an agent that releases endogenous catecholamines. Results indicate amygdaloid kindled seizures activate both branches of the autonomic nervous system. Bradycardia was mediated by the parasympathetic system; the pressor response was caused by an increase in peripheral resistance due to alpha-adrenergic receptor activation. Findings show kindling is a useful seizure model for future studies on the effect of seizures on cardiovascular function and possible mechanisms of seizure-related sudden unexplained death (Goodman et al. 1989, 1990).
Source: Lathers, C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
8 Sudden Death in Epilepsy: Forensic and Clinical Issues
1986a, 1986b, 1986c, 1987, 1993, 2008a, 2008b, 2008c). In addition to the risk of neurogenically induced arrhythmias, neurogenic apnea could be associated with SUDEP. Table 1.2 summarizes the SUDEP risk factors of respiratory/autonomic changes and hypoxia. Rare clinical case reports describe incidences of apnea associated with epileptiform activity (So et al. 2000). Additionally, a well-known sheep model of epilepsy (Simon et al. 1982; Table 1.2â•…Respiratory Factors and Hypoxia Model, Symptoms, and/or Change Postmortem found multiple areas of pulmonary punctuate hemorrhages and large areas of gross hemorrhage and edema in animals dying after induced epileptogenic activity, asystole, or ventricular ἀbrillation (Lathers and Schraeder 1982; Lathers et al. 1984; Carnel et al. 1985; Schraeder and Lathers 1983). In addition to the general and neurological risk factors, there is increasing evidence that cardiac (Aurlien et al. 2009; Kerling et al. 2009; Pezzella et al. 2009; Strzelczyk et al. 2008) and pulmonary (Scorza et al. 2007; Tavee and Morris 2008) changes additionally predispose a person to SUDEP. As with neurological risk factors, cardiac and pulmonary risk factors have neither been investigated by prospective observational follow-up studies nor by intervention studies. The pathomechanisms are still not established (Johnston and Smith 2007). Finsterer and Stöllberger (2010, this book) discuss recent ἀndings and practical implications concerning potential cardiac and pulmonary risk factors and pathomechanisms of SUDEP.
Changes in cardiac function alter cerebral blood flow, which, in turn, produces central hypoxia resulting in epileptogenic activity.
Mechanisms of Sudden Death Tissue hypoxia, hypercarbia, and alterations in acid–base balance may have contributed to the results in our model of experimental epilepsy. Acid–base balance was maintained only within physiological range before the initiation of epileptogenic activity.
So far, there is minimal evidence that any primary pulmonary disease could be a deἀnite risk factor for SUDEP (Finsterer and Stöllberger, 2010, this book). It is also unknown if patients with muscular respiratory insufficiency are at increased risk not to survive a tonic–clonic seizure. These patients appear particularly endangered because they often also have epilepsy and their epilepsy is often difficult to treat. Despite this uncertainty about pulmonary risk factors, there are frequent reports about patients who develop severe pulmonary problems during or after seizures, such as ictal hypoxemia or hypercapnia (Bateman et al. 2008), apnea (Bell and Sander 2006; Jehi and Najm 2008; Ryvlin et al. 2009), acute neurogenic pulmonary edema (Jehi and Najm 2008), or postictal laryngospasm (Tavee and Morris 2008). In a prospective autopsy series on 52 SUDEP patients, 80% had pulmonary congestion and edema (Leestma et al. 1989). It is uncertain if these abnormalities are due to primary pulmonary, cardiac, or laryngeal mechanisms. It is also unclear if only patients with previous lung disease, as opposed to previously healthy subjects, develop such problems. There is little information available about the effects of generalized tonic–clonic seizures on the respiratory system in general. Do generalized seizures induce bronchospasm or loss of tone of the muscles involved in respiration? Recent investigations have shown that at least the vital capacity, forced vital capacity, and forced expiratory volume within the ἀrst second (FEV1 etc.), are not signiἀcantly different between healthy subjects and epilepsy patients (Scorza et al. 2007) (Finsterer and Stöllberger 2010, this book). Some patients exhibit changes in cardiovascular status preceding the onset of convulsions (Schott et al. 1977; Schraeder et al. 1983). (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
9
Table 1.2â•…Respiratory Factors and Hypoxia (Continued) Model, Symptoms, and/or Change The pulmonary edema model of status epilepticus in unanesthetized, chronically instrumented sheep in which sudden death and pulmonary edema occur.
Audiogenic seizures: respiratory arrest. Central alveolar hypoventilation syndrome (Ondine’s curse). Failure of automatic involuntary respiration with preservation of voluntary respiratory drive (Ondine’s curse) is rare, reported following a variety of morphologic lesions near respiratory centers in the lower brainstem. Risk factors include uncontrolled convulsive seizures, as well as respiratory and cardiac factors relating to treatment and supervision.
Epilepsy-related hypoxia. Ictal apnea. Postictal central apnea appears to be one potential mechanism for SUDEP. A 55-s convulsive seizure occurred in a 20-year-old female as she underwent video-EEG monitoring (So et al. 2000). Persistent apnea then developed. Electrocardiogram monitoring rhythm was not altered for the
Mechanisms of Sudden Death Catecholamine levels and seizure type and duration did not differ between animals dying suddenly or those surviving. Benign arrhythmias were generated in all animals; in no case did an arrhythmia account for death of an animal. Striking hypoventilation demonstrated in sudden death group but not in surviving animals. Differences in peak left atrial and pulmonary artery pressures, and in extravascular lung water; pulmonary edema did not account for the demise of sudden death animals. Thus, this model of epileptic sudden death supports a role of central hypoventilation in etiology of sudden unexpected death and shows an association, albeit not fatal, with pulmonary edema. The importance of arrhythmia in its pathogenesis is not conἀrmed (Simon et al. 1982; Johnston et al. 1995, 1997). Respiratory arrest mechanisms, modulated in part by serotonin, may cause SUDEP (Tupal and Faingold 2006a, 2006b). Central alveolar hypoventilation syndrome causes sudden death in a 39-year-old woman with heterotopia of the inferior olive (Matschke and Laas 2007). Neuropathologic examination disclosed preexisting malformation of the lower brain stem and acute local subarachnoid bleeding. Both respiratory and cardiac mechanisms are important. The apparent protective effect of lay supervision supports a role for respiratory factors, in part amenable to intervention by simple measures. Malignant tachyarrhythmias are rare during seizures and sinus bradycardia/arrest, although infrequent, occurs. Both types of cardiac arrhythmias can have a genetic basis as a contributory factor. Authors explore the potential of coexisting liability to cardiac arrhythmias as a contributory factor, but acknowledge that bridging evidence between inherited cardiac gene determinants and SUDEP is lacking (Terrence et al. 1981; Coulter 1984; Schraeder 1987; Nashef et al. 2007). Central apnea with seizures (Schraeder 1987) and neurogenic pulmonary edema and adult distress syndrome (Terrence et al. 1981). (Penἀeld and Jasper 1954; Bobo and Bonvallet 1975) So et al. (2000) note that although epileptic seizures may be associated with arrhythmogenic actions at the heart, in this patient the mechanism of marked central suppression of respiratory activity after seizures was clearly involved and almost resulted in sudden death. This case and Dr. Schraeder’s (1983) case highlight that both respiratory and cardiac changes do occur in persons with epilepsy. The (continued)
10 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.2â•…Respiratory Factors and Hypoxia (Continued) Model, Symptoms, and/or Change ἀrst 10 s, then it gradually and progressively slowed and stopped 57 s later. Cardiorespiratory resuscitation was successful. No evidence of airway obstruction or pulmonary edema was noted. One previous cardiorespiratory arrest after a complex partial seizure without secondary generalization had been reported for this patient. Postictal respiratory arrest was induced by serotonin receptor inhibition and prevented by selective serotonin reuptake inhibitor drugs (Tupal and Faingold 2006a, 2006b). Audiogenic seizure in mice. Obstructive sleep-apnea–induced cardiovascular complications.
Likely processes of the sudden infant death syndrome (SIDS) are identiἀed (apnea, failed arousal, failed autoresuscitation, etc.). The way in which epidemiological risk factors, genetics, neurotransmitter receptor defects, and neonatal cardiorespiratory reflex responses interact to lead to sudden death during sleep is unclear. 5-HT SIDS: Role of medullary 5-HT abnormalities in pathogenesis of SIDS, putative in utero origin of these abnormalities, and environmental and genetic factors interact to ultimately result in sudden death of the infant (Patterson 2010, this book).
Mechanisms of Sudden Death timing of events such as seizures, respiratory and/or laryngospasm, and cardiac EKG changes do vary in different patients.
The role of serotonin in SUDEP must be examined in future animal studies, including the DBA mice model of SUDEP (Faingold et al. 2010, this book). Suggested for use to study postictal respiratory arrest (So 2008). Implicated in pathogenesis of various cardiovascular diseases, including systemic hypertension, coronary artery disease, congestive heart failure, pulmonary hypertension, stroke, and cardiac arrhythmias. Mechanisms by which obstructive sleep apnea affects the cardiovascular system may involve mechanical effects on intrathoracic pressure, increased sympathetic activation, intermittent hypoxia, and endothelial dysfunction (Malow et al. 2000; Jain 2007). It is hypothesized that the neurophysiological basis of SIDS resides in a persistence of fetal reflex responses into the neonatal period, such as ampliἀcation of inhibitory cardiorespiratory reflex responses and reduced excitatory cardiorespiratory reflex responses. Explores ways in which multiple subtle abnormalities interact to lead to sudden death and emphasizes difficulty of ante-mortem identiἀcation of infants at risk for SIDS (Leiter and Böhm 2007). Underlying vulnerability involves a developmental defect in brainstem serotonergic (5-HT) systems that results in failure of protective cardiorespiratory responses to potentially life-threatening, but normally occurring events (e.g., hypoxia, hypercapnia), in the infant during sleep (Patterson 2010, Chapter 5, this book).
Source: Lathers C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
Johnston et al. 1995, 1997) found that although neurogenic pulmonary edema was commonly observed, the mechanism of death in the animals was central neurogenic hypoventilation. Likewise, syncope is a factor for sudden death (Table 1.3). It is evident that, in all likelihood, there are multiple contributing risk factors that, in unfortuitous combinations (including environmental circumstances) in individuals with epilepsy, may result in unexpected death (Nashef et al. 1998). This chapter consists of summary tables highlighting possible risk categories and mechanisms for risks. The reader is encouraged to use the table
Neurocardiologic Mechanistic Risk Factors in SUDEP
11
Table 1.3â•… Syncope Symptoms and/or Changes Syncope is a transient loss of consciousness and postural tone. Usually due to temporary, self-terminating global cerebral hypoperfusion. Important to differentiate from other nonsyncopal transient loss of consciousness attacks (Chen et al. 2008).
Although arising suddenly from prolonged recumbency or returning from weightlessness to earth’s gravity can result in syncope from orthostatic or vasovagal effects, there are many other possible causes. Cardiac causes are more likely to occur in the elderly; noncardiac causes are more common in the younger population. Cases described illustrate often unexpected mechanisms of syncope in otherwise healthy individuals. Cases of sudden collapse. At times, there are obvious cardiac etiologies or central nervous system etiologies; at other times, there are interactive cause and effects with cardiac disorders leading to central nervous system effects or visa versa. However, all too often there are subtle interplays with genetic predispositions, environmental interaction, therapeutic interventions, or unknown organic disease. As consequences are extreme, a thorough investigation and understanding of the mechanisms leading to syncope are of paramount importance. Psychogenic syncope and psychogenic seizures are common disorders but are difficult to identify. Headupright, tilt-table testing evaluates vasovagally mediated syncope and convulsive syncope. In eight patients with syncope and/or tonic–clonic motor activity, without changes in blood pressure and heart rate, transcranial Doppler cerebral blood flow velocity, and EEG monitoring revealed they were, in all instances, psychogenic or malingering. Combined long term ECG and EEG monitoring. Isolated cardiac rhythm abnormalities were noted in 21 patients, but none were symptomatic and no deἀnitive arrhythmias occurred. Isolated EEG abnormalities were noted in 11 patients, 5 of whom had EEG abnormalities consistent with seizure disorders. Simultaneous EEG and ECG abnormalities were seen in four patients. In two, a previously unsuspected etiology for syncope was found: seizures in one patient with heart disease and sinus pauses in another thought to have a seizure disorder.
Mechanisms of Sudden Death The most important screening tool in identifying mechanism(s) of syncope is a detailed history emphasizing a search for underlying disease, speciἀc associated circumstances, and pre- and post-event symptoms. The type of diagnostic studies (i.e., cardiac or neurologic) undertaken should be based on historical data. Seizures must be considered as a possible mechanism of otherwise unexplained loss of consciousness in nonelderly persons, including air crew members (Schraeder et al. 1994; Williams and Frenneaux 2007). Review recent research relevant to managing syncope in adults: syncope evaluation in the emergency department, effectiveness of a structured and standardized approach to syncope, role of the implantable loop recorder, and efficacy of nonpharmacological physical treatments (Chen et al. 2008; Bungo et al. 2010, this book). Clinical cases briefly explore the interactions of disordered electrical potentials in the brain and disordered electrical potentials in the heart (Lathers et al. 2010b, Chapter 22, this book).
It was concluded that patients who pass out or convulse during head-upright tilt without any change in physiologic parameters can be presumed psychogenic in origin and may be referred for psychiatric evaluation without further expensive diagnostic studies (Grubb et al. 1992). Combined ambulatory EEG/ECG monitoring may prove useful in evaluation of some patients with syncope (Beauregard et al. 1991).
(continued)
12 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.3â•… Syncope (Continued) Symptoms and/or Changes Vasovagal syncope. Much of the natural history is unknown. Study determined whether patients presenting for care had a recent increase in worsened syncope frequency. Insufficient cerebral perfusion is a common cause leading to a loss of consciousness with a critical reduction of blood flow to the reticular activating system. In neurally mediated syncope, a paradoxical reflex can occur that induces an increase in cerebrovascular resistance and contributes to the critical reduction of cerebral blood flow.
Mechanisms of Sudden Death Many syncope patients present for care after a recent worsening of their frequency of syncope (Franco 2007; Sheldon et al. 2007). Outlined anatomic structures involved in cerebral autoregulation, its mechanisms in normal and pathologic conditions, and noninvasive neuroimaging techniques used to study cerebral circulation and autoregulation. Emphasis placed on description of autoregulation pathophysiology in orthostatic and neurally mediated syncope (Franco 2007).
Source: Modiἀed and updated from Lathers C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
of contents of this book to identify which chapters are pertinent to a given topic within each table. The reader is referred especially to chapters in this book discussing risks for SUDEP by Walczak (2010), arrhythmias (Lathers and Schraeder 1982, 1987; Lathers et al. 1987), LSP (Schraeder and Lathers 1983, 1989), respiratory issues (Scorza et al. 2007; Finsterer and Stöllberger 2010; Lathers and Schraeder 1982; Carnel et al. 1985), syncope (Sharma et al. 2010, Chapter 21, this book; Lathers et al. 2010b, Chapter 22, this book), genetics (Herreros 2010), stress (Lathers and Schraeder 2006), therapies (Lathers and Schraeder 2002, 2010; Lathers et al. 2003a, 2003b, 2003c; Tompson 2008, 2010; Ryvlin et al. 2009), and unusual factors that may modify SUDEP risk (Scorza et al. 2008a, 2008b, 2010a, 2010b; Calderazzo et al. 2009; Terra-Bustamante et al. 2009). All are encouraged to read Brodie and Holmes (2008) and the chapter presenting how to educate persons with epilepsy about their risk factors and how to help families and survivors of SUDEP deal with the unexpected loss of a person with epilepsy (Hanna and Panelli, 2010, Chapter 57). There is general agreement that central nervous and autonomic nervous system/cardiorespiratory interactions include arrhythmias and apnea (Tables 1.1 and 1.2). Complicating the nervous system/cardiac relationship are relatively recent discoveries of genetically determined predispositions to arrhythmias that may result in seizure-like events at the time of the acute cardiac dysfunction (Table 1.4). How these genetic cardiac predispositions interact with the central and autonomic nervous systems is not understood. It is generally accepted that certain associated clinical circumstances [e.g., male gender (Table 1.5), poorly controlled generalized tonic clonic seizures, use of multiple antiepileptic drugs, changing doses or drugs, withdrawal of antiepileptic drugs, and poor compliance with antiepileptic drug use] are associated with an increased risk of SUDEP (Table 1.6). That psychogenic factors associated with life stresses are risk factors for cardiac arrhythmias and sudden death is well recognized by cardiologists (Lathers and Schraeder 2006). Also, certain ethnic groups have an increased incidence for stress-related sudden deaths [e.g., bangungut in healthy Filipino men (Table 1.7)]. There has been almost no organized effort to determine the role of stress as a risk factor for SUDEP. The stress response involves acute or chronic increases in sympathetic neural activity. Furthermore, Scorza and colleagues have identiἀed unusual factors that may modify the risk for SUDEP such as ambient temperature, the lunar phases of the moon,
Neurocardiologic Mechanistic Risk Factors in SUDEP
13
Table 1.4â•… Genetic/Structural Mechanistic Factors Associated Changes Four main inherited arrhythmia syndromes that are thought to be responsible for sudden death. Two clinical cases exhibit both Brugada syndrome and epilepsy produced by sodium channel dysfunction (Lathers et al. 2010b, this book). Brugada syndrome is produced by a mutation in gene SCN5A, which encodes the alpha subunit of the cardiac sodium channel (Antzelevitch et al. 2005a, 2005b; Aurlien et al. 2009. Herreros (2010, Chapter 19) note that some epileptic syndromes (Graves 2006) are due to different mutations in genes encoding alpha subunits of neuronal sodium channels (SCN1A, SCN2A) or in the beta subunit (SCN1B), common for both cardiac and neuronal isoforms (Lehmann-Horn and Jurkat-Rott 1999). The long QT syndrome: A genetically transmitted cardiac arrhythmia due to ion channel protein abnormalities, affecting the transport of potassium and sodium ions across the cell membrane. Patients may present with syncope, seizures, or aborted cardiac arrest. Long QT syndrome is an important cause of unexplained sudden cardiac death in the young.
Cardiac hypertrophy: An independent predictor of cardiovascular morbidity and mortality, predisposition to heart failure, QT interval prolongation, and ventricular arrhythmias.
Mechanisms of Sudden Death Four syndromes: long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia reviewed by Herreros (2010, Chapter 19, this book). Additional clinical, electrocardiographic, and genetic studies are needed to improve individual risk stratiἀcation and to determine any relationship among sodium channel dysfunction, Brugada ECG, and idiopathic epilepsy. Two patients presented in the cases appear to support the possibility that a common pathophysiologic mechanism associated with sodium channel dysfunction may be common to ECG abnormalities of Brugada syndrome and some types of epilepsy. Many patients must be screened to conἀrm. Risks factors for sudden death must be deἀned and linked with mechanisms for death (Kornick et al. 2003; Lathers et al. 2008a, 2008b, 2008c; Herreros, 2010, Chapter 19; Lathers et al. 2010a, Chapter 20).
Diagnosis of long QT syndrome depends on an ECG showing a prolonged QT interval (Kiehne and Kauferstein 2007). Establishment of a registry and discovery of genetic mutations causing the syndrome contribute greatly to understanding this condition and impetus to understanding other inherited cardiac arrhythmias. Genotype-phenotype correlation studies allow risk stratiἀcation of long QT syndrome patients. Lifestyle modiἀcation to avoid triggers for malignant cardiac arrhythmias, and use of beta blockers, pacemakers, and implantable deἀbrillators may reduce mortality in these patients (Vohra 2007). Mutations of cardiac ion channel genes affecting repolarization cause the majority of congenital cases. Despite detailed molecular characterizations of mutated ion channels, understanding how individual mutations may lead to arrhythmias and sudden death requires study of intact heart and modulation by autonomic nervous system. Studies of molecularly engineered mice with mutations in genes known to cause long QT syndrome in humans and speciἀc to cardiac repolarization in mice are reviewed (Salama and London 2007). Cardiac angiotensin II overproduction leads to long QT syndrome, resulting from IK1 potassium-dependent prolongation of action potential duration via modulation of channel subunit expression (Domenighetti et al. 2007). (continued)
14 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.4â•… Genetic/Structural Mechanistic Factors (Continued) Associated Changes Inherited arrhythmia syndromes, channelopathies.
Short QT syndrome: ECGs show a shortened QT interval and tall and narrow T waves. The cause is mutation of the potassium channel genes. Cardiac hypertrophy: associated with a dramatic change in gene expression proἀle of cardiac myocytes. Many genes important during development of the fetal heart but repressed in adult tissue are reexpressed, resulting in gross physiological changes and arrhythmias, cardiac failure, and sudden death. One transcription factor possibly important in repressing expression of fetal genes in the adult heart is REST (repressor element 1-silencing transcription factor).
Genetic factors in SUDEP: Likely to reflect underlying heterogeneous mechanisms common to the brain and heart, as has been shown to be the case with sudden cardiac death and sudden infant death syndrome (Ghali and Nashef 2010, this book).
Mechanisms of Sudden Death Long QT syndrome (Kiehne and Kauferstein 2007), short QT syndrome, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, and overlapping phenotypes; established connections between these syndromes and idiopathic ventricular ἀbrillation (Sarkozy and Brugada 2005). Persons with short QT syndrome have increased familial risk of sudden cardiac death (Gaita et al. 2003, 2004). REST expression prevents increased BNP (Nppb) and ANP (Nppa) gene, encoding brain and atrial natriuretic peptides. Adult rat ventricular myocytes response to endothelin-1 and inhibition of REST results in increased expression of these genes in H9c2 cells. Increased expression of Nppb and Nppa correlates with increased histone H4 acetylation and histone H3 lysine 4 methylation of promoter-proximal regions of these genes. Deletions of individual REST repression domains combined activities of two domains of REST required to efficiently repress transcription of Nppb gene. A single repression domain is sufficient to repress Nppa gene. Data provide insight into molecular mechanisms for changes in gene expression proἀle cardiac hypertrophy (Bingham et al. 2006, 2007). Overlapping mechanisms. The increasing number of mongenically associated epilepsy syndromes raises the question of how epilepsy and arrythmogenic genetic disturbances may be concurrent. The association of uncontrolled epilepsy with risk of SUDEP leads to speculation that in some cases of idiopathic epilepsy, a genetic mutation may also cause a predisposition to fatal cardiac arrhythmias. The recent association of long QT syndrome with epilepsy suggests that ion channel gene mutations may be inherited susceptibility factors for neurogenic cardiac arrhythmia in some persons with epilepsy. Further investigation into overlap of epileptogenic and arrhythmogenic epidemiological and genetic factors is warranted.
and other factors (Table 1.8). As is evident from the listings in the above-mentioned tables, there is a likelihood that common risk factors for SUDEP and arrhythmogenic cardiac disease are related to centrally initiated peripheral autonomic dysfunction in association with epileptiform discharges and stress. Issues that need resolution include a better understanding of the individual risks, the mechanisms of cardiac arrhythmia and arrest in persons without a previously identiἀed structural heart disease, a deἀnition of abnormal interactions between the central nervous system (CNS) and the heart, the role of neurogenic pulmonary edema and central apnea in combination with cardiac autonomic neural and subtle anatomic and genetic factors as risk for SUDEP, and development of primary and secondary preventive measures along with educational programs to disseminate essential information to physicians, patients, and families.
Neurocardiologic Mechanistic Risk Factors in SUDEP
15
Table 1.5â•…Risk Factors for SUDEP SUDEP Risk Factors in a Swedish Population (Nilsson et al. 2001)
Retrospective Study of Risk Factors, United States Reviewed association between several clinical variables and SUDEP to elucidate risk factors. Characteristics of 67 cases correlated with published previous studies. Education of physicians about existence of SUDEP and risk factors is imperative to improving patient education and reduction in mortality (Lear-Kaul et al. 2005). Behavioral Risk Factor Surveillance System Data from South Carolina Compared health insurance coverage, health care visits, health-related behaviors among persons with epilepsy vs. general population (Ferguson et al. 2008).
Position of Patients at Night (Kinney et al. 2009; Monter et al. 2007; McGregor and Wheless 2006).
1. Higher number of seizures per year (relative risk of 10.16 in patients with more than 50 seizures/year compared to no more than 2 years) 2. Increased number of antiepileptic drugs (9.89 for three drugs vs. monotherapy) 3. Early vs. late onset epilepsy (7.72) 4. Frequent changes in antiepileptic drug dosage vs. unchanged dosage (6.08) 5. Risk and early onset and SUDEP risk and seizure frequency was weaker for females 6. Frequent dosage changes had a stronger association in females 7. Early age of onset and male sex 1. Long history of seizure disorder 2. Under medication or poorly controlled seizure activity 3. Male gender 4. Age younger than 40 years 5. Mental or physical stress
Persons with epilepsy: 1. Are more likely to smoke. 2. Have less physical activity. 3. Need better access to health care. 4. Need interventions focused on smoking cessation and increase in physical activity. 5. Lack money to visit a doctor. One-third of respondents with active epilepsy reported in past 12 months needed to see a doctor but could not because of cost. Note: Authors do not relate these behavior risk factors to increased likelihood of SUDEP per se, but one could also consider them to be risk factors for SUDEP. 1. Especially important in persons with uncontrolled epilepsy in institutional settings. 2. Avoid prone position and soft pillows when sleeping. 3. Use respiration monitors during sleep. 4. Train caregivers to be vigilant and to intervene to prevent respiratory compromise for institutionalized and at-home patients.
1.3â•… SUDEP Animal Models The importance of using many different animal models to study SUDEP in order to glean insights into the various mechanisms of risks and their contribution to the initiation of the death event is discussed by Lathers (2010a, Chapter 25) (Table 1.1). So (2008) emphasizes the signiἀcance of using audiogenic seizure mice to study postictal respiratory arrest. Postictal respiratory arrest was induced by serotonin receptor inhibition and prevented by
16 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.6â•… Therapies: Increased or Decreased Risk Symptoms and/or Changes
Mechanisms of Sudden Death
Increased risk SUDEP The putative advantage of new drugs is a smaller spectrum of Antiepileptic drugs—New antiepileptic possible adverse events, such as sedation and some may drugs, e.g., topiramate and lamotrigine, minimize noncompliance by reducing side effects of developed for chronic focal and secondarily lethargy and cognitive impairment. Many new antiepileptic generalized epileptic seizures. Therapeutic drugs do have less frequent interactions, leading to efficacy of these drugs does not seem to be improved tolerability with comedication (Lathers et al. superior to traditional anticonvulsants such 2003a, 2003b, 2003c; Walczak 2003). However, difficulty in as phenobarbital. achieving therapeutic dosage with some of the newer antiepileptic drugs because of side effects makes one question whether some newer agents are better than the older antiepileptic drugs. Suggests SUDEP rates reflect population rates and not a Risk of SUDEP rates in patients on speciἀc drug effect. FDA requires warning labels on the risk lamotrigine, gabapentin, topiramate, of SUDEP in association with use of each of the mentioned tigabine, and zonisamide are similar to drugs (Lathers and Schraeder 2002). those on standard antiepileptic drugs. Compliance with antiepileptic drugs In a coroner’s office review of forensic cases in Allegheny important in prevention of SUDEP. County for the year 2001, Lathers et al. (2003a, 2003b) found low, or no, levels of antiepileptic drugs postmortem in persons with epilepsy who died of SUDEP. Hughes (2009) deemed the most important SUDEP risk Noninterventional, single-arm study (Martin factor to be noncompliance with antiepileptic medication. et al. 2009). Explored the effectiveness and Ryvlin et al. (2009) found the risk of SUDEP is increased in behavioral outcomes in intellectually patients who have poor compliance and exhibit nocturnal disabled patients with topiramate for seizures and generalized tonic–clonic seizures. However, epilepsy. compliance is not the only therapeutic question to ask about victims of SUDEP. Others include: Is the correct dose of the antiepileptic drug being used? Was more than one drug prescribed and were there recent dose drug changes? All agree that maintenance of a stable therapeutic drug levels is crucial to avoid SUDEP. Some improvement in nearly all behavioral aspects was observed under concomitant topiramate therapy. In addition, seizure frequency decreased. Two unexpected deaths in patients taking the antiepileptic drug topiramate were attributed to SUDEP (Martin et al. 2009). A prolonged QT interval leads to increased risk for QT-prolonging drugs and risk of SUD. development of ventricular tachyarrhythmias, particularly Torsades de pointes is associated with early polymorphic ventricular tachycardia (torsades de pointes). cardiac depolarization. Drugs that prolong Polymorphic arrhythmia may rapidly develop into QT interval: class III antiarrhythmic agents, ventricular ἀbrillation and cause sudden death antimicrobial agents (fluoroquinolone and (Reingardiene and Vilcinskaite 2007). macrolide antibiotics), antipsychotic and antidepressant drugs, agents used in general anesthesia, and antimycotics (Reingardiene and Vilcinskaite 2007). Adverse cardiovascular effects of antipsychotic treatment: Cardiovascular Effects of Antipsychotics tachycardia, orthostatic hypotension, and rarely, SUD, Older antipsychotic literature was primarily muscarinic cholinergic antagonism, alpha(1)-adrenergic concerned with physiological consequences antagonism, or receptors associated with cardiac of muscarinic cholinergic antagonism, (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
17
Table 1.6â•… Therapies: Increased or Decreased Risk (Continued) Symptoms and/or Changes
Mechanisms of Sudden Death
Alpha(1)-adrenergic antagonism, or receptors associated with cardiac conduction, but current literature recognizes that, for most antipsychoticexposed patients, the more signiἀcant cardiovascular burden of treatment is mediated by metabolic adverse effects such as weight gain, dyslipidemia, and diabetes mellitus.
conduction, metabolic adverse effects of weight gain, dyslipidemia, and diabetes mellitus (Michelsen and Meyer 2007). High-dose methadone can induce QT prolongation by hERG inhibition, resulting in QT prolongation, but new evidence shows that QT prolongation can occur at much lower doses, even when the drug is not given IV.
Methadone produces QT prolongation, arrhythmias, and sudden death (Karch 2010, this book, Chapter 10).
May be acting directly on myocardial conduction to produce arrhythmia and death (Lathers and Lipka 1986, 1987; Lathers et al. 1986a; Lipka and Lathers 1987; Lipka et al. 1988).
Chlorpromazine or thioridazine do not appear to produce arrhythmia or death via a central locus in an experimental cat model. Decreased risk SUDEP The question must be asked if persons thought to be at risk for SUDEP should be placed on a beta blocker, in addition to the prescribed anticonvulsant(s). Beta blockers are also used to reduce stress and persons with epilepsy generally are stressed by the disease and associated problems (Lathers and Schraeder 2006). Beta blockers produce anticonvulsant activity whether administered via the intraosseous route or intravenously (Jim et al. 1988, 1989; Spivey et al. 1987a, 1987b; Lathers et al. 1989, 1990, 2008). Note the intraosseous and endotracheal routes of administration of antiepileptic drugs may be used when IV access is not available in status epilepticus. These routes are appropriate for emergency room pediatric seizures or cardiac arrest when unable to establish a traditional IV line (Rusli et al. 1987; Jim et al. 1988, 1989; Spivey et al. 1987a, 1987b; Lathers et al. 1989, 1990, 2008). Postmortem found no serious pathology in the tibia bone after intraosseous administration, other than the expected needle track (Lathers et al. 1989). Selective serotonin reuptake inhibitor drugs. Postictal respiratory arrest was induced by serotonin receptor May be protective in some persons at risk inhibition and prevented by selective serotonin reuptake for SUDEP with a component of apnea. inhibitor drugs. The role of serotonin in SUDEP must be examined in future animal studies (Tupal and Faingold 2006). Vagal nerve stimulation may decrease risk of SUDEP by 50% Vagal nerve stimulation may decrease (Annegars et al. 2000). susceptibility to ventricular tachycardias (Verrier et al. 2009; Verrier and Schachter 2010). Beta blockers exhibited anticonvulsant activity.
Source: Lathers C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
18 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.7â•… Psychological Factors Symptoms and/or Changes Scared to death. A 21-year-old student had generalized tonic–clonic seizures induced by mental image of human pain. One ictal event occurred while listening to a description of suffering, as read from Fox’s Book of Martyrs. While again listening to the offending passage during EEG and ECG monitoring, had 25 s of asystole terminating in electrocerebral silence and a generalized tonic, tonic–clonic seizure. A 24-hour ambulatory monitor recorded episodes of progressive sinus bradycardia concomitant with P–R interval prolongation and Wenckebach atrioventricular block. Sinoatrial conduction times and sinus node recovery times were normal on atrial pacing (Schraeder et al. 1983). Emotional trauma and psychological stress. Stress response is associated with increased sympathetic activity and catecholamine levels that may be associated with increased risk of cardiac arrhythmias, especially in context of epileptiform cerebral discharges (Pickworth et al. 1990). Stress is associated with changes in autonomic neural function. Its role as a potential risk factor for SUDEP is not known. Association of epilepsy with cardiac abnormalities, such as neurogenic arrhythmias and microscopic perivascular and interstitial ἀbrosis, and with depression and anxiety indicates emotional stress with related increases in catecholamines should be evaluated as a potential risk factor for SUDEP. Stress and anger. Compare morphology and initiation pattern between ventricular arrhythmias that are triggered by anger and those that are not. At the time of shock, patients with implantable cardioverter-deἀbrillators recorded levels of deἀned mood states preceding the shock in a diary. Stress risk factors and triggers of sudden death. An autopsy proven case-control study (Owada et al. 1999).
Mechanisms of Sudden Death Since implantation of a permanent pacemaker, has been asymptomatic. Patient demonstrates advantages of reproducing the circumstances associated with an unexplained loss of consciousness while monitoring EEG and ECG (Schraeder et al. 1983).
Arrhythmogenic effects of efferent sympathetic drive precipitate cardiac arrhythmia and sudden death. Patients with preexisting heart disease are particularly at risk. Generation of proarrhythmic activity patterns within cerebral autonomic centers may be ampliἀed by afferent feedback from a dysfunctional myocardium (Gray et al. 2007). Impact of adverse emotional states on autonomic control of cardiac rhythm is a known important factor leading to cardiac dysrhythmias in humans and other species. Interaction between emotional factors and arrythmogenic potential of epileptiform discharges and possibility of beneἀt from stress management intervention need to be investigated (Lathers and Schraeder 2006). Ventricular arrhythmias occurring in setting of anger are more likely pause dependent and polymorphic. Suggests that in predisposed populations anger may create an arrhythmogenic substrate susceptible to more disorganized rhythms, a possible mechanism linking emotion and sudden death (Stopper et al. 2006). Identiἀed risk factors and triggers of sudden death in cases where causes of death were deἀnitely proven by autopsy in Japan. Legal and medical records for 4 years were investigated. Of 271 cases, 176 patients, 20 to 59 yrs-old were cases of sudden death in working generations. Of these, 91 cases, 52% could be analyzed by telephone interviews from close family members. One examiner undertook all phone interviews with the case subjects. As control subjects, 1167 employed persons who consulted for a health check. Of sudden death cases, ἀnal diagnosis in 29 cases was coronary artery disease (31.9%), 18 acute cardiac dysfunction (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
19
Table 1.7â•… Psychological Factors (Continued) Symptoms and/or Changes
Retrospective study. Reviewed association between several clinical variables and SUDEP to elucidate risk factors. Characteristics of 67 cases correlated with published ἀndings in previous studies (Lear-Kaul et al. 2005).
Mechanisms of Sudden Death (19.8%), 6 other cardiac diseases (6.6%), 4 acute aortic dissection (4.4%), 4 cerebrovascular disease (4.4%), and 30 other diseases (32.9%). Through conditional logistic analysis, the following risk factors emerged as candidates: Long-term stress, history of heart disease, hypertension, chest symptoms, autonomic disturbance, short-term stress, and a smoking habit. Short-term stress, autonomic disturbance and a smoking habit increased the risk of sudden death due to coronary artery disease. Long-term stress was associated with an increased risk of sudden death due to acute cardiac dysfunction. Demonstrated that autonomic disturbance and stress were closely related to occurrence of sudden death (Owada et al. 1999). Attributes that deἀne an at-risk group of epileptics include: less than 40 years old, male, long history of seizure disorder, under medication or poorly controlled seizure activity, and mental or physical stress. Education of physicians about the existence of SUDEP and risk factors is imperative in improving patient education and reduction in mortality (Lear-Kaul et al. 2005).
Source: Lathers C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
selective serotonin reuptake inhibitor drugs. The possible role of serotonin in SUDEP must be examined in future animal studies (Faingold et al. 2010, Chapter 41). The ἀring pattern of cardiac parasympathetic neurons, as well as cardiac sympathetic postganglionic nerves, during an epileptic attack has been shown to change and has been termed the lockstep phenomenon (Lathers et al. 1987; Stauffer et al. 1989, 1990; Dodd-O and Lathers 1990; O’Rourke and Lathers 1990). The observation of autonomic neural discharges time-locked to cortical epileptiform is evidence that epileptogenic activation of the cardiac parasympathetic nerves, revealed by ictal bradyarrhythmias or cardiac asystole, may be one contributing cause of sudden death of patients with epilepsy. Likewise, epileptogenic activation of the cardiac sympathetic nerves may be another contributing cause of SUDEP. An imbalance between the two systems’ (i.e., the cardiac parasympathetic and the cardiac sympathetic) neural discharge patterns may contribute to SUDEP (Lathers and Schraeder 1982, 1986; Schraeder and Lathers 1983, 1989). Wang et al. (2006) provided supporting data for the LSP ἀnding. They examined blockade of inhibitory neurotransmission evoked seizure-like ἀring of cardiac parasympathetic neurons in brainstem slices of newborn rats. Speciἀcally, blockade of GABAergic and glycinergic receptors in medulla slices evoked intermittent seizure-like ἀring of cardiac parasympathetic neurons, suggesting the seizure-like pattern of ἀring during an epileptic attack may cause neurogenic ictal bradyarrhythmias, cardiac asystole, or even sudden death in persons with epilepsy. Nonuniform autonomic cardiac postganglionic neural discharges are associated with coronary occlusion of the left anterior descending coronary artery and/or ouabain toxicity in cats (Lathers et al. 1974a, 1974b, 1977a, 1977b, 1978; Lathers 1980, 1981). Nonuniform
20 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.8â•…Unusual Risk Factors Modify SUDEP Factor Unusual potential risk factors for SUDEP were examined by Scorza and colleagues (2008a, 2008b, 2010a, 2010b), Calderazzo et al. (2009), and Terra-Bustaman et al. (2008).
Physical activity (Scorza et al. 2008a).
SUDEP seems to occur more commonly during sleep (Asadi-Pooya and Sperling 2009). Chronobiology of acute pulmonary edema (Bilora et al. 1998).
Mechanism of Sudden Death Studies are needed to examine the role of unusual factors that are listed below to determine if they are applicable to SUDEP. These include life style modifying interventions with accepted public health beneἀts, but as yet with no consensus that they may or may not prevent sudden death. Animal studies and clinical studies are needed (Lathers et al. 2008b, reply; 2010c, Unanswered question). May modify the role of autonomic effects and cardiorespiratory disturbances. Beneἀts of physical activity may be related to reductions in sympathetic activity. Morbidity and mortality in cardiovascular disease are often associated with elevations in sympathetic activity (Scorza et al. 2008a; Schraeder et al. 1983). Increased physical action does have a beneἀcial cardiovascular effect. The question is, will increased physical activity be of beneἀt if one assumes cardiovascular sympathetic dysfunction or insufficiency in persons with epilepsy? In general, regular exercise does not have a downside, if the patient is cardiovascularly ἀt. The role of regular exercise in prevention of SUDEP is not established (Lathers et al. 2008b reply; 2010c, this book). Autonomic cardiorespiratory disturbances. Alterations in clinical parameters including ECG changes, blood pressure, respiration, and vasomotor tone (Hirsch and Martin 1971; Lathers and Schraeder 1982; Schraeder and Lathers 1983; Wannamaker 1985). ECG changes in experimental epilepsy include heart rate changes, arrhythmias, conduction blocks, altered ECG morphology, and QT interval). See discussion of Bilora et al. (1998) below and Chapter 23 by Hughes and Sato (2010, this book). Found pulmonary edema incidence higher during the night. No signiἀcant weekly or circannual rhythms detected. Examine possible relations with decreased heart output, increased sympathetic tone, or partial baroceptor desensitization occurring at night (Bilora et al. 1998). Evaluation of some cases of SUDEP and ners-SUDEP during long-term electroencephalography monitoring suggest that autonomic instability ending in cardiorespiratory arrest may be triggered by postictal suppression rather than by ictal activation of the autonomic nervous system. More epidemiologic studies on high-risk populations of persons with epilepsy are needed (Schuele 2009). The increase sympathetic tone or desensitization of baroceptors may contribute to occurrence of cardiac autonomic arrhythmias. See discussions of interictal activity and cardiac arrhythmias (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
21
Table 1.8â•…Unusual Risk Factors Modify SUDEP (Continued) Factor
Seizure activity and neurogenesis (Scorza et al. 2008b). Omega-3 fatty acid nutritional deἀciency (Scorza et al. 2008a).
Low temperature (Scorza et al. 2008a).
Winter temperatures may lead to cardiac abnormalities and, hence, to sudden death. Are they a risk factor for SUDEP? (Colugnati et al. 2008).
Role of heart rate in rats with epilepsy during low temperature exposure (Sonoda et al. 2008). Minimum external temperature, mean external temperature (Bell et al. 2009). Climate fluctuations (Calderazzo et al. 2009). Sunlight may be a beneἀt in that vitamin D deἀciency may increase risk of SUDEP (Scorza et al. 2010a).
Mechanism of Sudden Death and baroreceptor changes by Lathers (2010a, 2010b) and cardiac and pulmonary risk factors and pathomechanisms of SUDEP by Finisterer and Stollberger (2010, Chapter€42). Aberrant dentate granule cell neurogenesis may influence negatively the cardiovascular system of a patient with epilepsy and lead to cardiac abnormalities and risk of SUDEP. Beneἀcial effect of nutritional aspects of omega-3 fatty acid may decrease cardiac arrhythmias and sudden death (SUD) in patients at risk for cardiac disease. No established answer at this time. See comments by Lathers et al. (2008b). Questions have been raised (Lathers et al. 2008a, 2008b, 2008c, 2010c) that need to be addressed: 1. Exactly how does one deἀne a low temperature? 2. What is the degree range used to deἀne a low temperature? 3. What is the duration at this low degree range? 4. Is there a dose response so that there is an increased risk of sudden death related to the lowest temperature? Mammals hibernate as a strategy to survive cold conditions. Hibernating mammals inherit a stable cardiovascular function. They show resistance to hypothermia at a cellular level, the membrane potential and excitability are more stable in their cardiac cells. Aortic smooth muscle cells maintain ionic gradients upon prolonged exposure to low temperature, cardiac myocytes from the mammals maintain constant levels of intracellular free calcium and forceful contractility at 10°C or lower. Postulate hibernating mammals have cardiovascular particularities that confer heart protection. The relevance to persons with epilepsy is to be determined. Low temperature increased the heart rate of patients with epilepsy. Authors suggest exposure to low temperatures could be a risk factors for cardiovascular abnormalities and, thus, for SUDEP. Found no evidence of association between either mean temperature group or minimum temperature group and SUDEP but there was a slight excess of SUDEP in the coldest (mean temperature) groups. May have an effect on SUDEP occurrence. Some clinical studies suggest low vitamin D levels may be associated with death from heart failure and sudden cardiac death. There also appears to be an association between low vitamin D and seizure occurrence. Scorza et al. suggest vitamin D may exhibit anticonvulsant action. More data are needed. (continued)
22 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.8â•…Unusual Risk Factors Modify SUDEP (Continued) Factor The lunar phase (Terra-Bustamante et al. 2009).
Lunar phase, month, season: no association found between these factors and SUDEP (Bell et al. 2009).
Mechanism of Sudden Death An epilepsy unit performed an 8-year analysis, examining possible associations between the phase of the moon and SUDEP. Incidence of SUDEP was highest at full moon (70%), followed by waxing moon (20%), and new moon (10%). No SUDEPs occurred during the waning cycle. Preliminary ἀndings suggest the full moon correlates with occurrence of SUDEP. Dataset of National Sentinel Clinical Audit of EpilepsyRelated Deaths examined all death certiἀcates of those who died in England and Wales between 9/1999 and 8/2000 to see if epilepsy was mentioned. Of 2412 deaths, 409 were identiἀed as probable SUDEP.
(increases, decreases, and/or no change) autonomic neural postganglionic cardiac sympathetic discharge traveling through the stellate ganglia, causes cardiac arrhythmias, ventricular ἀbrillation, and/or sudden cardiac death in the manner described by Han and Moe (1964), i.e., nonuniform recovery of excitability in ventricular muscle. It was suggested that the modiἀcation of neural discharge is a way for drugs to modify the occurrence of arrhythmia and death (Lathers et al. 1974a, 1974b, 1977a, 1977b, 1978; Lathers 1980, 1981; Han and Moe 1964). Nonuniform autonomic cardiac postganglionic neural discharge was also found to be associated with pentylenetetrazol-induced interictal epileptogenic activity in cats. Nonuniform autonomic neural discharge and autonomic neural imbalance of postganglionic cardiac sympathetic and vagal discharge cause cardiac arrhythmias, ventricular ἀbrillation, asystole, and/or SUDEP. Regional differences in the beta adrenoceptor densities reflects differences in postganglionic cardiac sympathetic innervation of the myocardium (Randall 1977, 1984; Randall et al. 1984). These site differences will vary the release of norepinephrine in various sympathetic nerve terminals and sites in the heart to modify cardiac contractile function and may trigger development of arrhythmias and/or sudden death. Innervation density of beta adrenoceptor densities is high in the subepicardium and central conduction system. Nonuniform postganglionic cardiac-sympathetic cardiac innervation is related to the nonuniform beta-sympathetic receptor locations in the heart and affects cardiac contractility and development of arrhythmias and/or death. In diseased hearts, cardiac innervation density varies and may lead to sudden cardiac death (Lathers et al. 1985, 1986a, 1986b, 1988, 1990, 2010; Lathers and Levin 2010, Chapter 33, this book). Seizures exert effects on cardiac function (Schuele, 2009). Since tachyarrhythmias are common during epileptic seizures, whereas bradyarrhythmias or asystoles occur less frequently, Kerling et al. (2009) evaluated cardiac postganglionic denervation in patients with epilepsy to determine if this was responsible for ictal asystole. I-(123)-metaiodobenzylguanidine was used as a marker of postganglionic cardiac norepinephrine uptake, using single-photon emission computed tomography. They concluded that a pronounced reduction in cardiac single-photon emission computed tomography uptake of asystole patients indicates postganglionic cardiac catecholamine disturbance. Impaired sympathetic cardiac innervation limits adjustment and heart-rate modulation and may increase the risk of asystole and, eventually, sudden unexpected death in persons with epilepsy. These data support the ἀnding of Lathers and colleagues described above. The
Neurocardiologic Mechanistic Risk Factors in SUDEP
23
reader is also referred to the chapter by Lathers and Levin (2010) that examines nonuniform sympathetic innervation and beta-sympathetic receptor locations and discusses how these factors affect cardiac contractility and the development of cardiac arrhythmias and/ or sudden death. Cerebral ischemia is associated with neuron degeneration. Accumulation of excess excitatory amino acids in the synaptic clef, activation of excitatory amino acid receptors, and influx of calcium into neurons are involved in the development of ischemia-induced neuronal death. Schwartz et al. (1995) hypothesized that neuroprotection may occur if inhibitory transmission via gamma-aminobutyric acid (GABA) is enhanced to offset excitation. Diazepam, a drug known to increase GABA-induced chloride channel opening, was studied in rats after hippocampal GABA levels had returned to post-transient global ischemia basal levels. The authors concluded that delayed enhancement of GABAergic neurotransmission directly at the site of vulnerability after an ischemic event does protect the vulnerable neurons from death. This model should be adapted to an animal model of seizure activity to study the effect of diazepam on GABA-mediated effects that may prevent ischemia-induced neuronal death, prevent the worsening of central neuronal communication due to epileptogenic activity, and eventually contribute a protective CNS effect that lessens individual at risk for SUDEP. Table 1.2 discusses postmortem multiple areas of punctuate hemorrhages and large areas of gross hemorrhage and edema in animals dying after inducing epileptogenic activity, asystole, or ventricular ἀbrillation (Lathers and Schraeder 1982; Schraeder and Lathers 1983; Lathers et al. 1984; Carnel et al. 1985). Tissue hypoxia, hypercarbia, and alterations in the acid–base balance may have contributed to the results in our model of experimental epilepsy. Acid–base balance was maintained only within physiological range before the initiation of epileptogenic activity (Lathers and Schraeder 1982, 1987; Schraeder and Lathers 1983, 1989; Carnel et al. 1985; Stauffer et al. 1989, 1990). Changes in cardiac function alter cerebral blood flow, which, in turn, produces central hypoxia that results in epileptogenic activity. Some patients exhibit changes in cardiovascular status preceding the onset of convulsions (Schott et al. 1977; Schraeder et al. 1983). So (2008) has emphasized risk factors of postictal apnea and hypoxia, with or without pulmonary congestion, in combination with generalized tonic–clonic seizures and, to a lesser degree, with complex partial seizures and respiratory arrest as a mechanistic cause of SUDEP. So et al. (2000) also noted that, although epileptic seizures may be associated with arrhythmogenic actions of the heart, in their patient, the mechanism of marked central suppression of respiratory activity after seizures was clearly involved and almost always resulted in sudden death. This case, and the case of Schraeder et al. (1983), highlight that both respiratory and cardiac changes do occur in persons with epilepsy. The timing of events such as seizures, respiratory and/or laryngospasm, and cardiac EKG changes does vary in different patients. Ryvlin et al. (2009) note that the pathophysiology of SUDEP is not clear, but postictal central or obstructive apnea is one likely mechanism. However, as noted by Lathers (2010b, Chapter 44, this book): Caution must be exerted when concluding respiratory changes alone are the primary mechanism of death. At the ἀrst onset of the clinical problem cardiac arrhythmias may be felt by the patient but may not be visually detected by a witness. ‘Invisible’ cardiac arrhythmias may be initiated and then followed by ‘visible’ respiratory distress. Therefore, in addition to repositioning of the patient to ensure ease of respiration and/or stimulation of respiration, it is important, if possible, also to simultaneously monitor and medically support cardiac rate and rhythm.
24 Sudden Death in Epilepsy: Forensic and Clinical Issues
The reader is referred to additional discussion of actual case histories focused on arrhythmogenic, respiratory, and psychological risk factors in Chapter 44 of this book (Lathers 2010b). Most likely, different mechanisms and/or a different combination of mechanisms are responsible for death in different persons with epilepsy. 1.3.1â•… Therapies as Factors Data suggest that beta blockers exert a protective effect against seizure induction and/ or the development of cardiac arrhythmias with interictal and ictal activity (Spivey et al. 1987b; Jim et al. 1988, 1989; Lathers et al. 1989a, 1989b, 1990, 2008a) (Table 1.6). The question must be asked whether persons thought to be at risk for SUDEP should be placed on a beta blocker, in addition to the prescribed anticonvulsant(s). Celiker et al. (2008) reported clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia and concluded that medical treatment with propranolol and verapamil may decrease the incidence of arrhythmia. If patients are still refractory, implantation of intracardiac deἀbrillators should be considered. Obviously, a delay in diagnosis or inadequate treatment can result in sudden cardiac death. The same is true for persons at risk for SUDEP. See the case history of SUDEP by Schraeder (2010). Hughes (2009) addressed the issue of how to predict patients at risk for SUDEP by reviewing published reports of such deaths. With a mean incidence of SUDEP at 1.8/1000, a mean standardized mortality ratio of 6.8, and a mean percentage of SUDEP cases among deaths from epilepsy at 16.6%, the problem of SUDEP and risk factors is an important issue to be resolved. Hughes identiἀed 17 risk factors and concluded, just as Lathers et al. (2008a, 2008b, 2008c) stated, that a cardiac or pulmonary problem may be a primary risk factor in different patients. He deemed the most important risk factor to be noncompliance with antiepileptic medication. Maintenance of therapeutic drug levels is crucial to avoid SUDEP. Ryvlin et al. (2009) also found that the risk of SUDEP is increased in patients who have poor compliance, nocturnal seizures, and generalized tonic–clonic seizures. However, compliance is not the only risk factor to be addressed if a person is a victim of SUDEP. There are several postmortem questions to be asked (Lathers and Schraeder 2009) about a patient on an antiepileptic drug that still becomes a SUDEP victim. One must inquire whether the correct dose of the antiepileptic drug was being used to control seizures. Another clinical pharmacology question that must be asked is whether the patient was on the correct antiepileptic drug to control the particular type or mixture of seizures experienced. When evaluating the role of drugs as protectors of life, clinical pharmacologists (Lathers and Schraeder 2002) caution us to remember that the use of all drugs is a risk/beneἀt ratio evaluation (Lathers et al. 2003a, 2003b, 2003c). Thus, the use of antiepileptic drugs may not provide 100% protection to the patient against sudden death.
1.4â•…Case of SUDEP with a Premorbid Diagnosis of Nonepileptic Seizures Table 1.8 discusses unusual risk factors examined by the laboratory of Scorza to determine if they are risk factors for SUDEP and/or have been speculated to be risk factors. This includes asking whether the lunar phase has an effect on SUDEP (Terra-Bustamante et al. 2009). A retrospective examination of the incidence of SUDEP in an epilepsy unit over an
Neurocardiologic Mechanistic Risk Factors in SUDEP
25
A 35-year-old woman was found dead in bed by her parents. She had a longstanding psychiatric history with the occurrence of seizure-like events. On one occasion,€she had a nonepileptic seizure in her neurologist’s office consisting of sliding to the floor with bizarre asynchronous bilateral motor activity without loss of consciousness. This event occurred consequent to an emotionally tense situation at her home. Past observation of another type of event consisting of some automatisms and postÂ� ictal confusion complicated the history. Multiple routine EEGs over the years were unremarkable, save for one that showed unequivocal isolated left temporal interictal discharges. The patient was placed on carbamazepine and found to have consistent therapeutic levels. The patient recognized that the complex partial events were no longer occurring, but that others continued. After the retirement of her neurologist, the patient was seen at another center and subjected to several days of inpatient EEG monitoring, during which multiple clinical events were observed without any epileptiform activity being documented on any of the EEG recordings. As a result, the patient was informed that her seizures were nonepileptic and was advised to taper her antiepileptic medications. Several weeks later her parents notiἀed her former neurologist of her demise. Co mment s by L at hers, Schraeder, and Bung o Persons with only nonepileptic seizures would, by deἀnition, not be at risk for SUDEP. However, the unfortunate reality is that from 10% to 30% of persons who appear to have long-established nonepileptic seizures also have epilepsy (Betts 1997). Thus, although the majority of persons with nonepileptic seizures do not have concurrent epilepsy, in those who also have a bona-ἀde seizure disorder, as demonstrated in this case, there is a risk of SUDEP associated with withdrawal of antiepileptic drugs based on the observation of only nonepileptic events. The physician must consider all aspects of the history and all prior EEG data before having conἀdence that the antiepileptic medication can be safely withdrawn. One should also keep in mind that rapid discontinuation of medication that was at a therapeutic serum level could induce a withdrawal seizure even in a person without epilepsy, further clouding the issue of diagnosis. From Betts, T. 1997. Psychiatric aspects of nonepileptic seizures. In Epilepsy: A Comprehensive Textbook, ed. J. Engel and T. A. Pedley. Philadelphia, PA: LippincottRaven Publishers.
8-year period was reviewed to look for a possible association. The review found the number of SUDEP cases was highest at the time of a full moon (70%), followed by a waxing moon (20%), and a new moon (10%). There were no SUDEP cases during the waning cycle. The authors concluded that a full moon appears to correlate with SUDEP. This same laboratory has examined other factors that may be involved in SUDEP, from regular imbibing of sardines and salmon to the influence of climate fluctuations (Calderazzo et al. 2009). Scorza et al. (2008b) have raised the question of whether seizure activity also influences dentate granule cell neurogenesis, since neurogenesis persists throughout life in adult mammalian dentate gyrus and is regulated by environmental, physiological, and
26 Sudden Death in Epilepsy: Forensic and Clinical Issues
molecular factors. The presence of hilar ectopic dentate granule cells was studied after status-�epilepticus was induced experimentally and it was determined that these cells migrate aberrantly, are abnormally integrated, and that the resulting hyperexcitability may contribute to seizure generation and/or propagation. Since high seizure frequency is a potential risk factor for SUDEP, the authors hypothesize that cardiac arrhythmias during and between seizures or transmission of epileptic activity to the heart via the autonomic nervous system may play a role. Thus, the aberrant neurogenesis may negatively influence the cardiovascular system of the patient with epilepsy and lead to cardiac abnormalities and then to the unwanted event of SUDEP. Studies are needed to examine the role in SUDEP played by these unusual factors to determine if they are risk factors.
1.5â•…Discussion 1.5.1â•… Future Steps The American Epilepsy Society and the Epilepsy Foundation Joint Task Force on SUDEP (So et al. 2008) assessed knowledge about SUDEP and recommended the following steps: 1. Hold a multidisciplinary workshop to reἀne current lines of investigation and identify additional areas of research for mechanism underlying SUDEP. 2. Conduct a survey of patients, families, and caregivers to identify effective means of education to enhance participation in SUDEP research. 3. Campaign for emphasis of the need for complete autopsy examinations for patients with suspected SUDEP. 4. Secure infrastructure grants to fund a consortium of centers to conduct prospective clinical and basic research studies to identify preventable risk factors and mechanisms underlying SUDEP. During the interim before these steps have been achieved, it is most important to provide prompt and optimal control of seizures, especially generalized convulsive seizures, to prevent SUDEP. A global focus is needed to resolve the risk factors for and mechanisms of epilepsy and sudden death (Lathers 2009).
References Annegers, J. F., S. P. Coan, W. A. Hauser, and J. Leestma. J. 2000. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia 41: 549–553. Antzelevitch, C. 2005a. Cardiac repolarization. The long and short of it. Eurpace 7 (Suppl 2): 3–9. Antzelevitch, C. 2005b. Modulation of transmural repolarization. Ann N Y Acad Sci 1047: 314–323. Asadi-Pooya, A. A., and M. R. Sperling. 2009. Clinical features of sudden unexpected death in epilepsy. J Clin Neurophysiol Aug 24. [Epub ahead of print]. Aurelien, D., T. P. Leren, E. Taubøll, and L. Gjerstad. 2009. New SCN5A mutation in a SUDEP victim with idiopathic epilepsy. Seizure 18: 158–160. Bateman, L. M., C. S. Li, and M. Seyal. 2008. Ictal hypoxemia in localization-related epilepsy: Analysis of incidence, severity and risk factors. Brain 131: 3239–3245.
Neurocardiologic Mechanistic Risk Factors in SUDEP
27
Beauregard, L. A., R. Fabiszewski, C. H. Black et al. 1991. Combined ambulatory electroencephalographic and electrocardiographic recordings for evaluation of syncope. Am J Cardiol 68: 1067–1072. Bell, G. S., and J. W. Sander. 2006. Sudden unexpected death in epilepsy. Risk factors, possible mechanisms and prevention: a reappraisal. Acta Neurol Taiwan 15: 72–83. Bell, G. S., J. L. Peacock, and J. W. Sander. 2009. Seasonality as a risk factor for sudden unexpected death in epilepsy: A study in a large cohort. Epilepsia Oct 27. [Epub ahead of print]. Betts, T. 1997. Psychiatric aspects of nonepileptic seizures. In Epilepsy: A Comprehensive Textbook, ed. J. Engel and T. A. Pedley, Chapter 199. Philadelphia, PA: Lippincott-Raven. Bilora, F., G. Vettore, C. Maifredini, S. Rocco, M. Pastorello, and F. Petrobelli. 1998. Chronobiology of acute pulmonary edema in an emergency service. Cardiologia 43: 303–307. Bingham, A. J., L. Ooi, L. Kozera, E. White, and I. C. Wood. 2007. The repressor element 1-silencing transcription factor regulates heart-speciἀc gene expression using multiple chromatinÂ�modifying complexes. Mol Cell Biol 27: 4082–4092. Bingham, A. J., L. Ooi, and I. C. Wood. 2006. Multiple chromatin modiἀcations important for gene expression changes in cardiac hypertrophy. Biochem Soc Trans 34 (Pt 6): 1138–1140. Bobo, E. G., and M. Bonvallet. 1975. Amygdala and masseteric reflex: I. Facilitation, inhibition and diphasic modiἀcations of the reflex, induced by localized amygdaloid stimulation. Electroencephalogr Clin Neurophysiol 39: 329–339. Brodie, M. J., and G. L. Holmes. 2008. Should all patients be told about sudden unexpected death in epilepsy (SUDEP)? Pros and Cons. Epilepsia 49 (Suppl 9): 99–101. Calderazzo, L., R. M. Arida, R. M. Cysneiros, E. A. Cavalheiro, and F. A. Scorza. 2009. From sardines to salmon: Influence of climate fluctuations on sudden unexpected death in epilepsy. Epilepsy Behav Jan. 20. Carnel, S. B., P. L. Schraeder, and C. M. Lathers. 1985. The effect of phenobarbital pretreatment on cardiac neural discharge and pentylenetetrazolâ•‚induced epileptogenic activity. Pharmacology 20: 225–240. Celiker, A., I. Erdogan, T. Karagoz, and S. Ozer. 2008. Clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia. Cardiol Young 23: 1–8. Chen, L. Y., D. G. Benditt, and S. Win-Kuang. 2008. Management of syncope in adults: An update. Mayo Clin Proc 83: 1280–1293. Colugnati D. B., R. M. Arida, S. L. Cravo, G. H. Schoorlemmer, A. C. de Almeida, E. A. Cavalheiro, and F. A. Scorza. 2008. Hibernating mammals in sudden cardiac death in epilepsy: What do they tell us? Med Hypotheses 70: 929–932. Coulter, D. L. 1984. Partial seizures with apnea and bradycardia. Arch Neurol 41: 173–174. Di Maio, T. G., and J. V. M. Di Maio, eds. 2006. Excited Delirium Syndrome. Cause of Death and Prevention. Boca Raton, FL: CRC Press. Dodd-O, J. M., and C. M. Lathers. 1990. A characterization of the lock step phenomenon in Phenobarbital treated cats. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 13, 199–220. New York, NY: Marcel Dekker. Domenighetti, A. A., C. Boixel, D. Cefai, H. Abriel, and T. Pedrazzini. 2007. Chronic angiotensin II stimulation in the heart produces an acquired long QT syndrome associated with IK1 potassium current downregulation. J Mol Cell Cardiol 42: 63–70. Druschky, A., M. J. Hiltz, P. Hopp et al. 2001. Interictal cardiac autonomic dysfunction in temporal lobe epilepsy demonstrated by [123I]metaiodobenzylguanidine-SPECT. Brain 124: 372–382. Everengul, H., H. Tanriverdi, D. Dursunoglu et al. 2005. Time frequency domain analyses of heart rate variability in patients with epilepsy. Epilepsy Res 63: 131–139. Faingold, C. L., S. Tupal, Y. Mhaskar, and V. V. Uteshev. 2010. DBA mice as models of sudden unexpected death in epilepsy. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 41. Boca Raton, FL: CRC Press.
28 Sudden Death in Epilepsy: Forensic and Clinical Issues Ferguson, P. L., J. Chiprich, G. Smith et al. 2008. Prevalence of self-reported epilepsy, health care access, and health behaviors among adults in South Carolina. Epilepsy Behav 13: 529–534. Finsterer, J., and C. Stöllberger. 2010. Cardiac and pulmonary risk factors and pathomechanisms of sudden unexplained death in epilepsy patients (SUDEP). In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 42. Boca Raton, FL: CRC Press. Franco, F. A. 2007. Cerebral autoregulation and syncope. Prog Cardiovasc Dis 50: 49–80. Gaita, F., C. Giustetto, F. Bianchi et al. 2003. Short QT syndrome: A familial cause of sudden death. Circulation 108: 965–970. Gaita, F., C. Giustetto, F. Bianchi et al. 2004. Short QT syndrome: Pharmacological treatment. J Am Coll Crdiol 43: 1494–1499. Gary-Bobo, E. G., and M. Bonvalette. 1977. Commissural projection to the amygdala through the ἀmbria fornix system in the cat. Exp Brain Res 27: 61–70. Ghali and Nashef. 2010. Genetics of SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues,€ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 18. Boca Raton, FL: CRC Press. Gleick, J. 1987. Chaos: Making a New Science. New York, NY: Viking Press. Goldberger, A. L., V. Bhargava, and B. J. West. 1985. Nonlinear dynamics of the heart beat. Physica 17D: 207–214. Goodman, J. H., R. W. Homan, and I. L. Crawford. 1989. Kindled seizures activate both branches of the autonomic nervous system. Epilepsy Res 34: 169–176. Goodman, H. J., R. W. Homan, and I. L. Crawford. 1990. Kindled seizures elevate blood pressure and induce cardiac arrhythmias. Epilepsia 31: 489–495. Goodman, J. H., R. E. Berger, and T. K. Tcheng. 2005. Preemptive low-frequency stimulation decreases the incidence of amygdala-kindled seizures. Epilepsia 46: 1–7. Graves, T. D. 2006. Ion channels and epilepsy. Q J Med 99: 201–217. Gray, M. A., P. Taggart, P. M. Sutton et al. 2007. A cortical potential reflecting cardiac function. Proc Natl Acad Sci USA 104: 6818–6823. Grubb, B. P., G. Gerard, D. A. Wolfe et al. 1992. Syncope and seizures of psychogenic origin: identiἀcation with head-upright tilt table testing. Clin Cardiol 15: 839–842. Han, J., and G. K. Moe. 1964. Nonuniform recovery of excitability in ventricular muscle. Circ Res 14: 44–60. Hanna, N. J., and R. J. Panelli. 2010. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma, Chapter 57. Boca Raton, FL: CRC Press. Herreros, B. 2010. Cardiac channelopathies and sudden death. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 19. Boca Raton, FL: CRC Press. Hirsch, C. S., and D. L. Martin. 1971. Unexpected death in young epileptics. Neurology 21: 682–690. Hughes, J. R. 2009. A review of sudden unexpected death in epilepsy: Prediction of patients at risk. Epilepsy Behav 14: 280–287. Ieda, M., H. Kanazawa, Y. Ieda et al. 2006. Nerve growth factor is critical for cardiac sensory innervation and rescues neuropathy in diabetic hearts. Circulation 114: 2351–2363. Ieda, M., H. Kanazawa, K. Kimura et al. 2007. Sema3a maintains normal heart rhythm through sympathetic innervation patterning. Nat Med 13: 604–612. Ieda, M., K. Kimura, H. Kanazawa, and K. Fukuda. 2008. Regulation of cardiac nerves: a new paradigm in the management of sudden cardiac death? Curr Med Chem 15: 1731–1736. Jain, V. 2007. Clinical perspective of obstructive sleep apnea-induced cardiovascular complications. Antioxid Redox Signal 9: 701–710. Jehi, L., and I. M. Najm. 2008. Sudden unexpected death in epilepsy: Impact, mechanisms, and prevention. Clevel Clin J Med 75 (Suppl 2): S66–S70. Jim, K. F., C. M. Lathers, V. L. Farris, L. F. Pratt, and W. H. Spivey. 1989. Suppression of pentylenetetrazol elicited seizure activity by intraosseous lorazepam in pigs. Epilepsia 30: 480–486.
Neurocardiologic Mechanistic Risk Factors in SUDEP
29
Jim, K. F., C. M. Lathers, W. H. Spivey, W. D. Matthews, C. Kahn, and K. Dolce. 1988. Suppression of pentylenetetrazolâ•‚elicited seizure activity by intraosseous propranolol in pigs. J Clin Pharmacol 28: 1106–1111. Johnston, A., and P. Smith. 2007. Sudden unexpected death in epilepsy. Expert Rev Neurother 7: 1751–1761. Johnston, S. C., R. Siedenberg, J. K. Min, E. H. Jerome, and K. D. Laxer. 1997. Central apnea and acute cardiac ischemia in a sheep model of epileptic sudden death. Ann Neurol 42: 588–594. Johnston, S. C., J. K. Horn, J. Valente, and R. P. Simon. 1995. The role of hypoventilation in a sheep model of epileptic sudden death. Ann Neurol 37: 531–537. Karch, S. 2010. Drug abuse and SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 10. Boca Raton, FL: CRC Press. Kerling, F., M. Dutsch, R. Linke, T. Kuwert, H. Stefan, and M. J. Hilz. 2009. Relation between ictal asystole and cardiac sympathetic dysfunctions shown by MIBG-SPECT. Acta Neurol Scand 120: 123–129. Kiehne, N., and S. Kauferstein. 2007. Mutations in the SCN5A gene: Evidence for a link between long TQ syndrome and sudden death? Forensic Sci Int Genet 1: 170–174. Kimura, K. M. Ieda, H. Kanazawa et al. 2007. Cardiac sympathetic rejuvenation: a link between nerve function and cardiac hypertrophy. Circ Res 100 (12): 1755–1764. Kinney, H., A. Chadwick, L. A. Crandall, M. Grafe, D. L. Armstrong, W. J. Kupsky, F. L. Trachtenberg, and H. F. Krous. 2009. Sudden death, febrile seizures, and hippocampal maldevelopment in toddlers: A new entity. Pediatr Dev Pathol Jul 16: 1. [Epub ahead of print]. Kornick, C. A., M. J. Kilborn, J. Santiago-Palmer et al. 2003. QTc interval prolongation associated with intravenous methadone. Pain 105 (3): 499–506. Lathers, C. M. 1980. Effect of timolol on postganglionic cardiac and preganglionic splanchnic sympathetic neural discharge associated with ouabainâ•‚induced arrhythmia. Eur J Pharmacol 64: 95–106. Lathers, C. M. 1981. Carnivores. Induced disease. Myocardial infarction. In Mammalian Models for Research on Aging 224–228. Washington, DC: National Academy Press. Lathers, C. M. 1982. Lack of effect of methylprednisolone on cardiac neural discharge associated with coronary occlusionâ•‚induced arrhythmia and death. Eur J Pharmacol 85: 233–238. Lathers, C. M. 2009. Epilepsy and sudden death: Personal reflections and call for global action. Epilepsy Behav 15 (3): 269–277. Lathers, C. M. 2010a. Sudden death animal models to study nervous system sites of action for disease and pharmacological intervention. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 25. Boca Raton, FL: CRC Press. Lathers, C. M. 2010b. Arrhythmogenic, respiratory, and psychological risk factors for sudden unexpected death and epilepsy. Case histories. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma. Chapter 44. Boca Raton, FL: CRC Press. Lathers, C. M., and R. M. Levin. 2010. Animal model for sudden cardiac death. Sympathetic innervation and myocardial beta receptor densities. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma. Chapter 33. Boca Raton, FL: CRC Press. Lathers, C. M., and P. L. Schraeder. 1982. Autonomic dysfunction in epilepsy. Characterization of autonomic cardiac neural discharge associated with pentylenetetrazolâ•‚induced epileptogenic activity. Epilepsia 23: 633–648. Lathers, C. M., and P. L. Schraeder. 1987. Review of autonomic dysfunction, cardiac arrhythmias, and epileptogenic activity. J Clin Pharmacol 27: 346–356. Lathers, C. M., and P. L. Schraeder. 1990a. Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, 485–505. New York, NY: Marcel Dekker.
30 Sudden Death in Epilepsy: Forensic and Clinical Issues Lathers, C. M., and P. L. Schraeder. 1990b. Synchronized cardiac neural discharge and epileptogenic activity, the Lock Step Phenomenon. Lack of correlation with cardiac arrhythmias. In Epilepsy and Sudden Death, ed. C. M Lathers and P. L. Schraeder, Chapter 12, 187–198. New York, NY: Marcel Dekker. Lathers, C. M., and P. L. Schraeder. 2002. Clinical pharmacology: Drugs as a beneἀt and/or risk in sudden unexpected death in epilepsy? J Clin Pharmacol 42: 123–136. Lathers, C. M., and P. L. Schraeder. 2006. Stress and sudden death. Epilepsy Behav 9: 236–242. Lathers, C. M., and P. L. Schraeder. 2009. Verbal autopsies and SUDEP. Epilepsy Behav 14: 573–576. Lathers, C. M., and P. L. Schraeder. 2010. Antiepileptic drugs beneἀt/risk clinical pharmacology: Possible role in cause and/or prevention of SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma, Chapter 47. Boca Raton, FL: CRC Press. Lathers, C. M., R. F. Flax, and L. J. Lipka. 1986a. The effect of C1 spinal cord transection or bilateral adrenal vein ligation on thioridazineâ•‚induced arrhythmia and death in the cat. J Clin Pharmacol 26: 515–523. Lathers, C. M., R. M. Levin, and W. H. Spivey. 1986b. Regional distribution of myocardial receptors. Eur J Pharmacol 130: 111–117. Lathers, C. M., W. H. Spivey, L. E. Suter, J. P. Lerner, N. Tumer, and R. M. Levin. 1986c. The effect of acute and chronic administration of timolol on cardiac sympathetic neural discharge, arrhythmia, and beta adrenergic receptor density associated with coronary occlusion in the cat. Life Sci 39: 2121–2141. Lathers, C. M., J. L. Gerard-Ciminera, S. I. Baskin, J. C. Krusz, G. J. Kelliher, and J. Roberts. 1981. The action of reserpine, 6-hydroxydopamine, and bretylium on digitalis-induced cardiotoxicity. Eur J Pharmacol 76: 371–379. Lathers, C. M., K. F. Jim, and W. H. Spivey. 1989a. A comparison of intraosseous and intravenous routes of administration for antiseizure agents. Epilepsia 30: 472–479. Lathers, C. M., K. F. Jim, W. High, W. H. Spivey, W. D. Matthews, and T. Ho. 1989b. An investigation of the pathological and physiological effects of intraosseous sodium bicarbonate in pigs. J Clin Pharmacol 29: 354–359. Lathers, C. M., K. F. Jim, W. H. Spivey, C. Kahn, K. Dolce, and W. D. Matthews. 1990. Antiepileptic activity of beta-blocking agents. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 24, 485–505. New York, NY: Marcel Dekker. Lathers, C. M., G. J. Kelliher, and J. Roberts. 1974a. Correlation of ouabainâ•‚induced arrhythmia and nonuniformity in cardiac accelerator nerves. Clin Res 22: 682A. Lathers, C. M., G. J. Kelliher, J. Roberts, and A. B. Beasley. 1978. Nonuniform cardiac sympathetic nerve discharge: Mechanism for coronary occlusion and digitalisâ•‚induced arrhythmia. Circulation 57: 1058–1065. Lathers, C. M., G. J. Kelliher, J. Roberts, and A. B. Beasley. 1977a. Role of the adrenergic nervous system in arrhythmia produced by acute coronary artery occlusion. In Pathophysiology and Therapeutics of Myocardial Ischemia, ed. A. Lefer, G. Kelliher, and M. Rovetto, 123–147. Myocardial Ischemia Symposium, Philadelphia Physiological Society, May 6, 1976. New York, NY: Spectrum Publ. Lathers, C. M., J. Roberts, and G. J. Kelliher. 1977b. Correlation of ouabainâ•‚induced arrhythmia and nonuniformity in the histamineâ•‚evoked discharge of cardiac sympathetic nerves. J Pharmacol Exp Ther 203: 467–479. Lathers, C. M., S. A. Koehler, C. H. Wecht, and P. L. Schraeder. 2003a. Forensic antiepileptic drug levels in 2001 autopsy cases of sudden, unexpected deaths in persons with epilepsy in Allegheny County Pennsylvania. FDA Science Forum, Washington, DC. Lathers, C. M., S. A. Koehler, C. H. Wecht, and P. L. Schraeder. 2003b. Forensic antiepileptic drug levels in 2001 autopsy cases of sudden, unexpected deaths in persons with epilepsy in Allegheny County, Pennsylvania. Annual Meeting of the American College Clinical Pharmacology, Orlando, FL.
Neurocardiologic Mechanistic Risk Factors in SUDEP
31
Lathers, C. M., P. L. Schraeder, and H. G. Claycamp. 2003c. Clinical pharmacology of topirimate vs. lamotrigine vs. Phenobarbital: Comparison of efficacy and side effects using odds ratios. J Clin Pharmacol 43: 491–503. Lathers, C. M., and L. J. Lipka. 1986. Chlorpromazine: Cardiac arrhythmogenicity in the cat. Life Sci 38: 521–538. Lathers, C. M., and L. J. Lipka. 1987. Cardiac arrhythmia, sudden death, and psychoactive agents. J€Clin Pharmacol 27: 1–14. Lathers, C. M., L. J. Lipka, and H. A. Klions. 1988. Digitalis glycosides: A discussion of the similarities and differences in actions and existing controversies. Rev Clin Basic Pharmacol 7: 1–108. Lathers, C. M., and J. Roberts. 1980. Digitalis cardiotoxicity revisited. Life Sci 27: 1713–1733. Lathers, C. M., and J. Roberts. 1985. Are the sympathetic neural effects of digoxin and quinidine involved in their action on cardiac rhythm? J Cardiovasc Pharmacol 7: 350–360. Lathers, C. M., J. Roberts, and G. J. Kelliher. 1974b. Relationship between the effect of ouabain on€ arrhythmia and interspike intervals (ISI) of cardiac accelerator nerves. Pharmacologist 16:€201. Lathers, C. M., P. L. Schraeder, and M. Bungo. 2008a. Mystery of sudden death: Mechanisms for risks. Epilepsy Behav 12: 3–24. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008b. Reply. Epilepsy Behav 13: 265–269. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008c. Sudden death: Neurocardiologic mystery, Chapter 13. In: Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Chapter 13. New York, NY: Nova Science Publishers, Inc. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2010a. Sodium channel dysfunction. Common physiopathologic mechanism associated with sudden death ECG abnormalities in Brugada syndrome and some types of epilepsy. Case histories. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma, Chapter 20, Boca Raton, FL: CRC Press. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2010b. Syncope, seizures and SUDEP. Case histories. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 22. Boca Raton, FL: CRC Press. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2010c. Unanswered questions: SUDEP Clinical studies needed. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P.€L.€Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 4. Boca Raton, FL: CRC Press. Lathers, C. M., P. L. Schraeder, and S. B. Carnel. 1984. Neural mechanisms in cardiac arrhythmias associated with epileptogenic activity: The effect of phenobarbital in the cat. Life Sci 34: 1919–1936. Lathers, C. M., P. L. Schraeder, and N. Tumer. 1993. The effect of phenobarbital on autonomic function and epileptogenic activity induced by the hippocampal injection of penicillin in cats. J Clin Pharmacol 33: 837–844. Lathers, C. M., P. L. Schraeder, and F. L. Weiner. 1987. Synchronization of cardiac autonomic neural discharge with epileptogenic activity: The lock step phenomenon. Electroencephalogr Clin Neurophysiol 67: 247–259. Lathers, C. M., W. H. Spivey, and R. M. Levin. 1988. The effect of chronic timolol in an animal model for myocardial infarction. J Clin Pharmacol 28: 736–745. Lathers, C. M., W. H. Spivey, R. M. Levin, and N. Tumer. 1990. The effect of dilevalol on cardiac autonomic neural discharge, plasma catecholamines, and myocardial beta receptor density associated with coronary occlusion. J Clin Pharmacol 30: 241–253. Lear-Kaul, K. C., L. Coughlin, and M. J. Dobersen. 2005. Sudden unexpected death in epilepsy: a retrospective study. Am J Forensic Med Pathol 26: 11–17. Leestma, J. E., T. Walczak, J. R. Hughes, M. B. Kalelkar, and S. S. Teas. 1989. A prospective study on sudden unexpected death in epilepsy. Ann Neurol 26: 195–203. Lehmann-Horn F., and K. Jurkat-Rott. 1999. Voltage-gated ion channels and hereditary disease. Physiol Rev 79: 1317–1372.
32 Sudden Death in Epilepsy: Forensic and Clinical Issues Leiter, J. C., and I. Böhm. 2007. Mechanisms of pathogenesis in the sudden infant death syndrome. Respir Physiol Neurobiol 159(2): 127–138. Lipka, L. J., and C. M. Lathers. 1987. Psychoactive agents, seizure production, and sudden death in epilepsy. J Clin Pharmacol 27: 169–183. Lipka, L. J., C. M. Lathers, and J. Roberts. 1988. Does chlorpromazine produce cardiac arrhythmia via the central nervous system? J Clin Pharmacol 28: 968–983. Malow, B. A., K. Levy, K. Maturen, and R. Bowes. 2000. Obstructive sleep apnea is common in medically refractory epilepsy patients. Neurology 55: 1002–1007. Martin, P., A. Schreiner, K. Rettig, and B. Schauble. 2009. Topiramate in patients with epilepsy and intellectual disability. Epilepsy Behav 14: 496–502. Matschke, J., and R. Laas. 2007. Central alveolar hypoventilation syndrome causes SUD. Am J Forensic Med Pathol 28: 141–144. Michelsen, J. W., and J. M. Meyer. 2007. Cardiovascular effects of antipsychotics. Expert Rev Neurother 7: 829–839. McGregor, A., and J. Wheless. 2006. Pediatric experience with sudden unexplained death in epilepsy at a tertiary epilepsy center. J Child Neurol 21: 782–787. Monte, C. P., J. B. Arends, I. Y. Tan, A. P. Aldenkamp, M. Limburg, and M. C. de Krom. 2007. Sudden unexpected death in epilepsy patients: Risk factors. A systematic review. Seizure 16: 1–7. Nagele, H., S. Hashagen, M. Azizi, S. Behrens, and M. A. Castel. 2007. Analysis of terminal arrhythmias stored in the memory of pacemakers from patients dying suddenly. Europace 9: 380–384. Nashef, L., S. Garner, J. W. Sander, D. R. Fish, and S. D. Shorvon. 1998. Circumstances of death in sudden death in epilepsy: interviews of bereaved relatives. J Neurol Neurosurg Psychiatry 64: 349–352. Nashef, L., N. Hindocha, and A. Makoff. 2007. Risk factors in sudden death in epilepsy (SUDEP): The quest for mechanisms. Epilepsia 48: 859–871. Nilsson, L., U. Bergman, V. Diwan, B. Y. Farahmand, P. G. Persson, and T. Tomson. 2001. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: A case-control study. Epilepsia 42: 667–673. Novak, V., A. L. Reeves, P. Novak, P. A. Low, and F. W. Sharbrough. 1999. Time-frequency mapping of R–R interval during complex partial seizures of temporal lobe origin. J Auton Nerv Syst 24: 195–202. O’Rourke, K., and C. Lathers. 1990. Interspike interval histogram characterization of synchronized cardiac sympathetic neural discharge and epileptogenic activity in the electrocorticogram of the cat. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 13, 239– 260. New York, NY: Marcel Dekker. Owada, M., Y. Aizawa, K. Kurihara, N. Tanabe, T. Aizaki, and T. Izumi. 1999. Risk factors and triggers of sudden death in the working generation: An autopsy proven case-control study. Tohoku J Exp Med 189: 245–258. Paterson, D. S. 2010. Medullary serotonergic abnormalities in sudden infant death syndrome. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 5. Boca Raton, FL: CRC Press. Penἀeld, W., and H. Jasper. 1954. Summary of clinical analysis and seizure patterns. In Epilepsy and the Functional Anatomy of Human Brain, 830–831. Boston, MA: Little, Brown. Persson, H., E. Kumlien, M. Ericson, and T. Topmson. 2007. Circadian variation in heart-rate variability in localization-related epilepsy. Epilepsia 48: 917–922. Pezzella, M., P. Striano, C. Ciampa, L Errichiello, P. Penza, and S. Striano. 2009. Severe pulmonary congestion in a near-miss at the ἀrst seizure: further evidence for respiratory dysfunction in sudden unexpected death in epilepsy. Epilepsy Behav (in press). Pickworth, W. B., J. Gerard-Ciminera, and C. M. Lathers. 1990. Stress, arrhythmias and seizures. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 22, 417–446. New York, NY: Marcel Dekker.
Neurocardiologic Mechanistic Risk Factors in SUDEP
33
Quint, S. R., J. A. Messenheimer, and M. B. Tennison. 1990. Power spectral analysis: a procedure for assessing autonomic activity related to risk factors for sudden and unexplained death in epilepsy. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 16, 261–291. New York, NY: Marcel Dekker. Randall, W. C. 1977. Neural Regulation of the Heart, 1–440. New York, NY: Oxford University Press. Randall, W. C. 1984. Nervous Control of Cardiovascular Function, 1–476. New York, NY: Oxford University Press. Randall, W. C., J. X. Thomas, D. E. Euler, and G. J. Rozanski. 1978. Cardiac dysrhythmias associated with autonomic nervous system imbalance in the conscious dog. In Perspectives in Cardiovascular Research, Vol. 2, Neural Mechanisms in Cardiac Arrhythmias, ed. P. J. Schwartz, A. M. Brown, A. Malliani, and A. Zanchetti, 123–138. New York, NY: Raven Press. Reingardiene, D., and J. Vilcinskaite. 2007. QTc-prolonging drugs and the risk of sudden death. Medicina (Kaunas) 43: 347–353. Rusli, M., W. H. Spivey, H. Bonner, R. M. McNamara, C. K. Aaron, and C. M. Lathers. 1987. Pathological effects of endotracheal diazepam in cats. Ann Emerg Med 16: 314–318. Ryvlin, P., T. Tomson, and A. Montavont. 2009. Excess mortality and sudden unexpected death in epilepsy. Press Med 38 (6): 905–910. Saffitz, J. E. 2008. Sympathetic neural activity and the pathogenesis of sudden cardiac death. Heart Rhythm 5: 140–141. Salama, G., and B. London. 2007. Mouse models of long QT syndrome. J Physiol 578 (Pt 1): 43–53. Sarkozy, A., and P. Brugada. 2005. Sudden cardiac death: What is inside our genes? Can J Cardiol 21: 1099–1110. Schott, G. D., A. A. McLeod, and D. E. Jewitt. 1977. Cardiac arrhythmias that masquerade as epilepsy. Br Med J 1: 1454–1457. Schraeder, P. L. 1987. Adult respiratory distress syndrome (ARDS) associated with nonconvulsive status epilepticus. Epilepsia 28: 605. Schraeder, P. L. 2010. SUDEP case histories: Typical and atypical. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 52. Boca Raton, FL: CRC Press. Schraeder, P. L., and C. M. Lathers. 1983. Cardiac neural discharge and epileptogenic activity in the cat: An animal model for unexplained death. Life Sci 32: 1371–1382. Schraeder, P. L., and C. M. Lathers. 1989. Paroxysmal autonomic dysfunction, epileptogenic activity and sudden death. Epilepsy Res 3: 55–62. Schraeder, P. L., C. M. Lathers, and J. B. Charles. 1994. The spectrum of syncope. J Clin Pharmacol 34: 454–459. Schraeder, P. L., R. Pontzer, and T. R. Engel. 1983. A case of being scared to death. Arch Intern Med 143: 1793–1794. Schuele, S. U. 2009. Effects of seizures on cardiac function. J Clin Neurophysiol. Sep 11. [Epub ahead of print]. Schwartz, R. D., X. Yu, M. R. Katzman, D. M. Hayden-Hixson, and J. M. Perry. 1995. Diazepam, given postischemia, protects selectively vulnerable neurons in the rat hippocampus and striatum. J Neurosci 15 (1 Pt 2): 529–539. Scorza, F. A., A. M. Abreu, M. Albuquerque et al. 2007. Quantiἀcation of respiratory parameters in patients with temporal lobe epilepsy. Arq Neuropsiquiatr 65: 450–453. Scorza, F. A., M. Albuquerque, R. M. Arida, V. C. Terra, H. R. Machado, and E. A. Cavalheiro. 2010a. Beneἀts of sunlight: Vitamin D deἀciency might increase the risk of sudden unexpected death in epilepsy. Med Hypotheses 74: 158–161. Scorza, F. A., E. A. Cavalheiro, R. M. Arida et al. 2010b. Omega-3 fatty acids in SUDEP: Guardian of the brain-heart connection. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma. Chapter 3. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 22. Boca Raton, FL: CRC Press.
34 Sudden Death in Epilepsy: Forensic and Clinical Issues Scorza, F. A., R. M. Arida, and E. A. Cavalheiro. 2008a. Preventive measures for sudden cardiac death in epilepsy beyond therapies. Epilepsy Behav 13: 263–264. Scorza, F. A., R. M. Cysneiros, and R. M. Arida et al. 2008b. Adult hippocampal neurogenesis and sudden unexpected death in epilepsy: Reality or just an attractive history? Med Hypotheses 71: 914–922. Sharma, S., T. Ho, and B. K. Kantharia. 2010. Not seizure but syncope: Causes and investigations to establish the diagnosis. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma, Chapter 21. Boca Raton, FL: CRC Press. Simon, R. P., L. L. Bayne, R. F. Tranbaugh, and F. R. Lewis. 1982. Elevated pulmonary flow and protein content during status epilepticus in sheep. J Appl Physiol 52: 91–95. Sheldon, R. S., A. G. Sheldon, A. Serletis et al. 2007. Investigators of the prevention of syncope study. Worsening of symptoms before presentation with vasovagal syncope. J Cardiovasc Electrophysiol 18: 954–959. So, E. L. 2008. What is known about the mechanisms underlying SUDEP? Epilepsia 49 (Suppl 9): 93–98. So, E. L., J. Brainbridge, and J. R. Buchhalter et al. 2008. Report of the American Epilepsy Society and the Epilepsy Foundation Joint Task Force on sudden unexplained death in epilepsy. Epilepsia 50: 917–922. So, E. L., M. C. Sam, and T. L. Lagerlund. 2000. Postictal central apnea as a cause of SUDEP: Evidence from near-SUDEP incident. Epilepsia 41: 1494–1497. Sonoda E. Y., D. B. Colugnati, C. A. Scorza, R. M. Arida, A. P. Pansani, A. C. de Almeida, E. A. Cavalheiro, and F. A. Scorza. 2008. Is cold the new hot in sudden unexpected death in epilepsy? Effect of low temperature on heart rate of rats with epilepsy. Arq Neuropsiquiatr 66: 848–852. Spivey, W. H., and C. M. Lathers. 1985. Effect of timolol on the sympathetic nervous system in coronary occlusion in cats. Ann Emerg Med 134: 939–944. Spivey, W. H., C. M. Lathers et al. 1985. A comparison of intraosseous, central and peripheral routes of sodium bicarbonate administration during CPR in pigs. Ann Emerg Med 14: 1135–1139. Spivey, W. H., H. D. Unger, R. M. McNamara, M. M. LaManna, T. Ho, and C. M. Lathers. 1987a. The effect of intraosseous sodium bicarbonate on bone in swine. Ann Emerg Med 16: 773–776. Spivey, W. H., H. D. Unger, C. M. Lathers, and R. M. McNamara. 1987b. Intraosseous diazepam suppression of pentylentetetrazol-induced epileptogenic activity in pigs. Ann Emerg Med 16: 56–59. Stauffer, A. Z., J. Doddâ•‚O, and C. M. Lathers. 1989. The relationship of the lock step phenomenon and precipitous changes in mean arterial blood pressure. Electroencephalogr Clin Neurophysiol 72: 340–345. Stauffer, A. Z., J. M. Dodd-O, and C. M. Lathers. 1990. Relationship of the lockstep phenomenon and precipitous changes in blood pressure. In Epilepsy and Sudden Death, ed. C. M. Lathers and P.€L. Schraeder, Chapter 14, 199–220. New York, NY: Marcel Dekker. Strzelczyk, A., S. Bauer, S. Knake, W. H. Oertel, H. M. Hamer, and F. Rosenow. 2008. Ictal asystole in temporal lobe epilepsy before and after pacemaker implantation. Epileptic Disord 10: 39–44. Stopper, M., T. Joska, and M. M. Burg et al. 2006. Electrophysiologic characteristics of anger-Â�triggered arrhythmias. Heart Rhythm 4: 268–273. Tavee, J., and H. Morris 3rd. 2008. Severe postictal laryngospasm as a potential mechanism for sudden unexpected death in epilepsy: a near-miss in an EMU. Epilepsia 49: 2113–2117. Terra-Bustamante, V. C., C. A. Scorza, and M. de Albuquerque et al. 2009. Does the lunar phase have an effect on sudden unexpected death in epilepsy? Epilepsy Behav 14: 404–406. Terrence, C. E., G. R. Rao, and J. A. Perper. 1981. Neurogenic pulmonary edema in unexpected, unexplained death in epileptic patients. Ann Neurol 25: 594–595. Tomson, T. 2010. Compliance with antiepileptic drug treatment and the risk of SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapters 51 and 22. Boca Raton, FL: CRC Press.
Neurocardiologic Mechanistic Risk Factors in SUDEP
35
Tomson, T., L. Nashef, and P. Ryvlin. 2008. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol 7: 1021–1031. Tupal, S., and C. L. Faingold. 2006. Evidence supporting a role of serotonin in modulation of sudden death induced by seizures in DBA/2 mice. Epilepsia 47: 21–26. Tupal, S., and C. L. Faingold. 2006. Respiratory arrest mechanisms, modulated in part by serotonin, may cause SUDEP. Epilepsia 47: 21–26. Tumer, N., P. L. Schraeder, and C. M. Lathers. 1985. The effect of phenobarbital upon autonomic function and epileptogenic activity induced by the hippocampal injection of penicillin in cats. Epilepsia 26: 520. Verrier, R. L., K. Kumar, and B. D. Nearing. 2009. Basis for sudden cardiac death prediction by T-wave alternans from an integrative physiology perspective. Heart Rhythm 6 (3): 416–422. Verrier, R. L., and S. C. Schachter. 2010. Neurocardiac interactions in sudden unexpected death in epilepsy: Can ambulatory electrocardiogram-based assessment of autonomic function and T-wave alternans help to evaluate risk? In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo and J. E. Leestma, Chapters 43 and 22. Boca Raton, FL: CRC Press. Vindrola, O., M. Asai, M. Zubieta, E. Talavera, E. Rodriguez, and G. Linares. 1984. Pentylenetetrazol kindling produces a long-lasting elevation of IR-Met-enkephalin but not IR-Leu-enkephalin in rat brain. Brain Res 297: 121–125. Vohra, J. 2007. The Long QT Syndrome. Heart Lung Circ 16 (Suppl 3): S5–S12. Walczak, T. 2003. Do antiepileptic drugs play a role in sudden unexpected death in epilepsy? Drug Saf 26: 673–683. Walczak, T. 2010. Risk factors for SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 12. Boca Raton, FL: CRC Press. Wang, J., Y. Chen, K. Li, and L. Hou. 2006. Blockade of inhibitory neurotransmission evoked seizurelike ἀring of cardiac parasympathetic neurons in brainstem slices of newborn rats: Implications for sudden deaths in patients of epilepsy. Epilepsy Res 70: 172–183. Wannamaker, B. 1985. Autonomic nervous system and epilepsy. Epilepsia 26 (Suppl 1): S31–S39. Wichter, T., T. M. Paul, and L. Eckardt et al. 2005. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz 30: 91–101. Williams, L., and M. Frenneaux. 2007. Syncope in hypertropic cardiomyopathy mechanism and consequences for treatment. Europace 9 (9): 817–822. Winfree, A. T. 1987. When Time Breaks Down: The Three-Dimensional Dynamics of Electrochemical Waves and Cardiac Arrhythmias. Princeton, NJ: Princeton University Press.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
2
Jan E. Leestma
Contents 2.1 Background of Sudden or Unexpected Deaths 2.2 Forensic Issues Regarding Epilepsy and SUDEP Deaths 2.2.1 Classifying Deaths as SUDEP 2.3 Drowning 2.4 SUDEP Deaths in the Home or Workplace 2.5 SUDEP Deaths Outdoors 2.6 Role of SUDEP in Traffic Deaths 2.7 SUDEP and Deaths in Agitated Delirium or Restraint 2.8 SUDEP in Criminal Cases 2.9 SUDEP and Anticonvulsant Medication References
37 39 39 41 41 42 42 44 48 50 52
2.1â•… Background of Sudden or Unexpected Deaths Sudden and unexpected deaths generally occur outside hospitals, although victims may be brought to an emergency room. In most locales in the United States, and likely in other developed countries, such deaths are usually not attended by a physician and are without detailed historical or medical information. They will usually be brought to the attention of a medical examiner or coroner, who is responsible for determining the cause and manner of death and for generating a death certiἀcate before the remains may be interred or otherwise disposed of. These responsibilities are statutory in most jurisdictions, but how they are discharged varies widely (DiMaio and DiMaio 2001). When a coroner is the responsible party, this individual may be elected or appointed, and may or may not be a medical doctor. A local pathologist (forensically trained or not) will usually be employed to conduct an autopsy or other examination of the body to make the determination of cause and manner of death. When a medical examiner is involved, that individual is almost always a trained forensic pathologist or will employ a staff of forensic pathologists to perform the required examinations to determine the medical cause of the death and its manner, which by convention may be labeled as a homicide (death at the hands of another), suicide (death by one’s own hand), accident, natural (natural disease processes), or “undetermined.” The coroner or medical examiner may direct that an autopsy be performed and that other studies that may include toxicological examinations of tissues or body fluids be undertaken (DiMaio and DiMaio 2001; Knight 1996). 37
38 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 2.1â•… Manner of Death Statistics Manner of Death
Percentage of Death Certiἀcates (%)
Natural diseases Homicide Suicide Accidents Undetermined
64–66 10–11 4–5 20–22 4–5
Sources: Office of the Medical Examiner, Cook County, IL, Annual Report, 1977– 1979, Office of the Medical Examiner, Chicago, IL, 1979; Leestma, J. E., and E. W. Sharp, in Forensic Neuropathology, CRC Press, Boca Raton, FL, 2009. With permission.
So-called sudden deaths may or may not be truly sudden, with many deἀnitions that surround such deaths (Davis and Wright 1980; de la Grandmaison and Durigon 2002; Kuller 1966; Kuller et al. 1966; Luke and Helpern 1968; Moritz 1954). When one refers to sudden deaths, more often than not, one is really referring to the fact that the victim actually died unexpectedly and, perhaps, also suddenly. When such deaths are witnessed, death may be described as having occurred in minutes rather than hours or longer. When a death is not witnessed, but the victim is found in circumstances that indicate death occurred in the course of normal activities and does not suggest a protracted agonal period, the unexpected and sudden quality of the death can be presumed (Haerem 1978). Such circumstances often involve ἀnding the victim dead in bed, in the bathroom (not bathing), or in a den or living room (in a chair or on the floor). When the victim is found in the bath (submerged or not), swimming pool, sauna or Jacuzzi, near electrical equipment or machinery, or in a vehicle (not involved in a crash), interpretations regarding the exitus may become complicated. When death occurs in the context of an apparent accident, with or without trauma, many facts and factors will have to be considered in reaching a proper determination of cause and manner of death (Leestma 1990a) (see Table 2.1). Owing to the variability in coroners’ and medical examiners’ statistics, it is generally recognized that 10–15% of their cases occurred suddenly and/or unexpectedly (see Table 2.2). Not unexpectedly, the majority of these deaths are due to some form of heart attack. Often this cannot be proven anatomically, although it can be inferred (Haerem 1978; Fineschi et al. 2006; Greenberg and Dwyer 1982; Schwartz and Gerrity 1975). Most central nervous system diseases do not kill suddenly, even though they present suddenly
Table 2.2â•… Medical Causes of Death in Sudden and/or Unexpected Deaths Disease Process Heart and great vessels Respiratory system Brain or meninges Digestive or urogenital systems Miscellaneous
Percentage (%) 56.1 (±7.4%) 14.5 (±6.4%) 15.8 (±2.4%) 8 (±1.7%) 9.5 (±8.9%)
Sources: Kuller, L., J Chronic Dis, 19 (11), 1165–1192, 1966; Kuller, L., A. Lilienfeld, and R. Fisher, Circulation, 34 (6), 1056–1068, 1966; Leestma, J. E., in Forensic NeuroÂ� pathology, CRC Press, Boca Raton, FL, 2009. With permission.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
39
and unexpectedly as in strokes (Leestma 2009a). The largest group of CNS-related sudden deaths appear to occur in the context of epilepsy [sudden death in epilepsy (SUDEP)] (Leestma 2009a, 1990b; Lhatoo and Sander 2002). A number of chapters in this volume deal with population statistics for SUDEP and these data will not be repeated here. Suffice it to say that deaths classiἀed as SUDEP—not a cause of death, but a category of death for which no anatomically evident cause is found, much like the label sudden infant death syndrome (SIDS)—forms an important and nonrare problem for forensic pathologists. As noted before in previous publications (Leestma 1990a, 1990b; Leestma et al. 1989, 1997), the apparent incidence of SUDEP cases at a large metropolitan medical examiner’s facility (Chicago-Cook County, IL) is 60–80 cases per year (Leestma et al. 1989). A casual survey of other large metropolitan offices by the author indicates similar numbers of cases in all of them (Los Angeles, Denver, and Miami). Collecting precise and accurate statistics on SUDEP incidence is problematic because there is wide variation in practices among the forensic community on how such cases are labeled on death certiἀcates as Schraeder et al. (2006) have reported. This is a function of the awareness or lack of awareness of the phenomenon and/or philosophical positions on how, presumably, epilepsy-related deaths should be classiἀed or labeled by forensic pathologists. As alluded to earlier, it is the task and responsibility of the forensic pathologist to determine the medical cause and the manner of death if possible. If this is not possible, then, after all the evidence is gathered, the medical cause of death and, sometimes, the manner of death, must remain undeclared (undetermined). This circumstance is certainly intellectually disappointing and frustrating and may lead to unwarranted speculations on the part of family, friends, attorneys, the media, and colleagues. Such cases, whether assigned the SUDEP designation or not, may ἀnd their way into the legal system as civil cases (torts) or even as criminal cases. The following discussion will explore some of these possibilities and, when possible, provide case examples of the issues involved.
2.2â•…Forensic Issues Regarding Epilepsy and SUDEP Deaths 2.2.1â•…Classifying Deaths as SUDEP Which cases are labeled with the designation SUDEP can be difficult and sometimes controversial. An attempt to provide some guidelines was arrived at in conjunction with data collected during the development of lamotrigine (Lamictal) at the behest of the then Burroughs-Wellcome pharmaceutical company, now Glaxo-SmithKline, Inc. In the clinical trial databases that drew upon studies in many countries with 4700 patients (5747 patient years of exposure) over several years, 45 sudden and/or unexpected deaths were discovered in all arms of the study. It was important to evaluate, if possible, if there was a different incidence of SUDEP deaths between the treated and control groups. To this end, a study group of professionals that included epidemiologists, epileptologists, and pathologists was impaneled to review the data and to determine what criteria might be applied to the cases in order to stratify them for analysis (Leestma et al. 1997; Tennis et al. 1995). As might be expected, the quality and quantity of individual case data varied widely. It was not possible to obtain further data beyond that reported. Cases were stratiἀed according to the following classiἀcation (Leestma et al. 1997):
40 Sudden Death in Epilepsy: Forensic and Clinical Issues
• SUDEP (definite or highly probable) The victim suffered from epilepsy as deἀned by Gastaut (1969) and Gastaut and Zifkin (1985) and had been treated with one or more anticonvulsive agents, usually for many years, and died unexpectedly in a reasonable state of health. The fatal attack occurred suddenly, but death might not have occurred for several hours, when it was usually associated with cardiorespiratory arrest, resuscitative efforts, and their complications. The attack occurred during normal activities in benign circumstances. An obvious medical cause of death was not found after autopsy. Cardiac arrhythmia may have been observed after the attack. If the victim was found in the bath but did not show evidence of drowning, the death may be assignable as SUDEP. If status epilepticus or acute neurotrauma occurred during seizure, the case was excluded. • Possible SUDEP These cases met most or all of the SUDEP criteria, but data suggested more than one possible cause of death associated with seizures, such as death while bathing, swimming, or due to aspiration, with or without an observed seizure. • Other non-SUDEP These cases could not be assigned to either of the ἀrst two categories and an obvious or likely cause of death had been established. • Insufficient data These cases could not be interpreted because of lack of information or ambiguous data concerning the circumstances of death or concurrent medical conditions in the victim. There are and were inevitable issues with the above classiἀcations, owing to all the informational problems that are inherent to any patient-based study. A particularly thorny one was the role of possible drowning in some of the victims, which is discussed later. Other confounding variables include the role of concurrent diseases in the victim, especially heart disease in the older victim, as well as conditions related to alcohol and drug abuse. There are a host of issues in infants and children that include possible SIDS-type deaths. Highly important to any death investigation of an individual who apparently dies suddenly and/or unexpectedly is the death scene investigation (DiMaio and DiMaio 2001; Knight 1996; Leestma 2009b). The physical death scene environment must be documented and carefully inspected. It is important to note if the body is in a position or location that would be consistent with normal activity that was interrupted by the fatal attack. The presence of bruises on the face, head, and extremities does not necessarily mean that the victim was assaulted; rather that if a seizure occurred, the victim may have fallen and been injured or become injured during the clonic phase of a seizure. Context and common sense in evaluating the scene is vital. Furthermore, the investigator should search for and collect any pill bottles that are present and any materials that suggest illicit drug use. The pill bottles may indicate the use of anticonvulsant medications and can provide the names of the pharmacies that dispensed the drug and the physician who prescribed it, who may be contacted later for additional information. If the pill bottles have pills in them and the date of prescription is on the label, or if the bottle is empty, one can make a judgment regarding medication compliance by the victim. If other medications are present, this can also give a
Forensic Considerations and Sudden Unexpected Death in Epilepsy
41
clue as to other medical problems the victim may have had and can provide some guidance as to which toxicological examinations may need to be made. If any witnesses to the attack are present, a detailed description of what was seen is vital. If the attack was not witnessed, it may be possible to determine the timeframe of the attack by inference (when the individual was last seen and found). If friends or relatives are available, they may have knowledge about the health status of the decedent and, speciἀcally, if the victim was epileptic. To aid investigators in collecting this vital information, the author has previously described a “check sheet” that can serve as a template for investigators at death scenes where the victim was epileptic and sudden or unexpected death has occurred (Leestma et al. 1989; Leestma 1990b, 2009b).
2.3â•…Drowning Epileptic individuals are frequently found dead in bathtubs, swimming pools, hot tubs, and natural bodies of water in conjunction with swimming. It is a common instruction to epileptic persons not to bathe upon arising or immediately before going to bed, rather to bathe at another time of the day to avoid the increased likelihood of seizures that occur proximate to sleep (Laidlaw and Richens 1982; Engel and Pedley 2008). The postmortem diagnosis of drowning is imprecise and subject to many evidentiary problems that are well-known to any forensic pathologist such as the so-called “wet” and “dry” forms of drowning (DiMaio and DiMaio 2001; Knight 1996); thus, it cannot be known with complete assurance that a victim who was found submerged in the bathtub or swimming pool, and whose lungs did not show evidence of water aspiration, did not drown (laryngospasm), but rather died from the supposed mechanism(s) typical of SUDEP and simply sank into the water after the attack, when the victim was lifeless. If the potential drowning occurred in a natural body of water, such as a stream, lake, or ocean, it may be possible to recover diatoms and other small particles from the water in the lower respiratory passages, which may indicate aspiration. The forensics of this process and its reliability is controversial (Piette and De Letter 2006; Modell et al. 1999; Pachar and Cameron 1993). If the victim is found in the bathtub but the head is not immersed, this does not necessarily mean that drowning did not occur. The onset of rigor mortis may have shifted the position of the body after death, causing the head to rise out of the bath water. A careful examination of the oral cavity at autopsy may reveals bites of the tongue, lips, or buccal mucosa, which is presumptive evidence that a recent seizure occurred but still does not necessarily mean that drowning did not occur (Ulrich and Maxeiner 2003).
2.4â•…SUDEP Deaths in the Home or Workplace The most common location for SUDEP deaths is in the home, in locations that bespeak an attack that took place during normal activity (Leestma et al. 1989; Leestma 1990b). The most common of these is in the bedroom. The victim may be found in bed in a normal position, or one that suggests some movement, as in a seizure with disordered bedding apparent. The victim may also be found on the floor in the bedroom dressed in normal
42 Sudden Death in Epilepsy: Forensic and Clinical Issues
clothing or in bed clothes beside the bed or in another position that suggests that the fatal attack took place proximate to going to bed. The association of SUDEP, and for that matter epileptic seizures in general (Laidlaw and Richens 1982; Engel and Pedley 2008), with sleep is well known and it is also not uncommon to ἀnd SUDEP victims dead in an easy chair in a den or living room, sometimes with the television on, which suggests that the victim may have been sleeping or dozing when the attack occurred. Death in the bathroom, discussed earlier with respect to drowning, may have no connection with bathing when the victim is found dead on the bathroom floor. In such circumstances, various injuries from the impact of the body surfaces with bathroom ἀxtures is common and may confuse the interpretation of the death scene, suggesting a homicidal attack or perhaps a suicide. A careful documentation of the death scene and blood spatter or blood flow (DiMaio and DiMaio 2001; James et al. 2005) as well as the autopsy may clear up suspicion of foul play. The body of a SUDEP victim may be found in other areas of the home, in the garage or workshop area, or in a workplace area that raises the issue of other means of death than a seizure-related cause. A careful scene inspection and investigation will go a long way in ruling in or out electrocution or intoxication, be they accidental or self-inflicted. Deaths may not be discovered immediately in SUDEP victims and the body may have begun to decompose, making interpretations complex and making a proper scene investigation even more germane. The process of decomposition has been the subject of careful study by forensic scientists and there is a large body of literature on the subject (Milroy 1999; Knight 1996). Occasionally, a body that is not immediately found in a home may be subject to predation by insects, rodents, or pets. Most experienced forensic pathologists are familiar with these phenomena and can differentiate marks upon the body from premortem injuries.
2.5╅SUDEP Deaths Outdoors While it is not common, SUDEP victims can experience a fatal attack outdoors with prompt or delayed discovery of the body. Obviously, the longer a body has lain outside, the more decomposition and environmental effects such as insects, vermin, and other animals will complicate examination of determinations on the body. Even in decomposed bodies, it may be possible to glean valuable information that may make a diagnosis of SUDEP practicable (Milroy 1999; Knight 1996). As with an indoor death scene investigation, the outdoor death scene can yield important information about what happened to the victim and rule in or€out foul play, suicide, or accident. The following case example (Case A) is illustrative.
2.6â•…Role of SUDEP in Traffic Deaths A not uncommon type of forensic case is that involving vehicular crashes in which the driver appears to have experienced some sort of attack that rendered that person unable to control the vehicle. These may be single-vehicle or multivehicle incidents. Such cases are often very difficult to evaluate from a pathological point of view, owing to the often overlying trauma to the body and brain caused by the accident, and also the coexistence of other disease processes, the most important and common being cardiovascular disease.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
43
Case A A middle-aged man had been complaining of headaches and “strange” feelings and set out toward his automobile to go to his family physician for an examination. The man’s wife observed the man fall to the ground and apparently jerk beside his car. When she reached her husband, he was apparently dead. Autopsy revealed a 2.5-cm unruptured, encapsulated mass ἀlled with brownish greasy material indenting the right inferior frontal lobe anterior to the amygdala. Microscopic examination revealed the mass to be an epidermoid cyst. The remainder of the autopsy was unremarkable. It appeared that this man died from an attack that represented a generalized convulsion (GTC), apparently his ἀrst and last, from a lesion in a commonly epileptogenic region of the brain. From the standpoint of SUDEP criteria, this man was not known to be epileptic, although it appears that at the time of his death he experienced a GTC event and, thus, it could be argued the death was SUDEP.
A not uncommon cause of vehicular accidents is an epileptic attack that causes the driver-victim to lose control of the vehicle and incur injuries that may or may not prove to be fatal. In the case of fatal accidents, an examination of the vehicle, its contents, and condition may provide important information for the forensic pathologist. As is always the case, witness accounts and a medical history of the victim may point the way for further inquiry, especially if the victim was suffering from epilepsy and did not appear to have died from traumatic injuries. As in other cases of SUDEP, an effort should be made to determine what drugs the victim was taking, who prescribed them, and if the victim was compliant. A thorough autopsy examination will generally reveal if there are signiἀcant traumatic injuries and a similar thorough neuropathological examination will reveal any acute lesions, or chronic lesions in the brain that might have been epileptogenic. Examples of such lesions are old traumatic contusions, vascular anomalies, tumors, and congenital malformations (Leestma et al. 1989; Leestma 2009b). Autopsies of non-SUDEP deaths in epileptic persons generally show a relatively low incidence of structural lesions in the brain (about 10%), whereas SUDEP victims have a much higher incidence, between 50% and 70% (Leestma et al. 1985, 1989; Monte et al. 2007; Shields et al. 2002; Thom et al. 1999). Not all studies have shown signiἀcant neuropathology, however (Morentin and Alcaraz 2002). If there are acute traumatic lesions in the central nervous system, it may still be possible to determine if there are more chronic lesions present. It may, however, be unlikely to determine if the older lesions had anything to do with the vehicle crash, although sometimes collateral information may suggest a causal event. Examination of the oropharynx may reveal tongue, lip, or buccal bites that may indicate a recent seizure (Ulrich and Maxeiner 2003). Toxicological examination will reveal if anticonvulsants were present and if they were within therapeutic range. While many studies of SUDEP victims have shown that they have been or are taking multiple anticonvulsant medications, they are more likely than not to be noncompliant with respect to anticonvulsant medications (Bell and Sander 2006; George and Davis 1998; Langan 2000; Langan et al. 2005; Lear-Kaul et al. 2005; Lund and Gormsen 1985; McKee and Bodἀsh 2000; Monte et al. 2007; Nilsson et al. 1999; Tomson et al. 2005; Vlooswijk et al. 2007; Walczak 2003).
44 Sudden Death in Epilepsy: Forensic and Clinical Issues
Not all studies have shown this (Opeskin et al. 1999, 2000; Schwender and Troncoso 1986; Walczak et al. 2001), and some have suggested that toxicological studies may not truly reflect proper or improper drug levels (McGugan 1999), thus the role of medications on the risk of SUDEP is, at present, suggestive but has not been proven. Some have suggested that carbamazepine may play some role in SUDEP, either by some idiosyncratic reaction or in connection with changes in dosage of this drug (Hitiris et al. 2007; Nilsson et al. 1999, 2001; Timmings 1993; Walczak 2003). A thorough pathological examination of the heart must be performed to deἀne the extent of arteriosclerotic cardiovascular disease, previous areas of myocardial scarring or necrosis, and any other morphological abnormality of the heart or its valves. One inevitably encounters some degree of cardiovascular disease in accident victims and in sudden or unexpected deaths, and it becomes difficult to compare the importance of what is found to the death circumstances (Natelson et al. 1998; Scorza et al. 2007). There is a robust literature on the heart and sudden death (Okada and Kawai 1983; Rossi 1982; Schwartz and Gerrity 1975; Schwartz and Walsh 1971; Fineschi et al. 2006; Greenberg and Dwyer 1982; Bharati and Lev 1990) and on the so-called neurocardiology (Armour and Ardell 1984; Johnson et al. 1984), which cannot be reviewed here but the issue of cardiac dysfunction and pathology is discussed in detail elsewhere in this volume. Since SUDEP deaths are apparently physiological in the sense that the process that leads to SUDEP is electrophysiological and, thus, may or may not have a morphological counterpart such as a conduction system defect in the heart, an ion channelopathy, or some other deἀnable and demonstrable disease process, the science of forensic pathology can only go so far in determining the mechanism of death in some traffic-related deaths.
2.7â•…SUDEP and Deaths in Agitated Delirium or Restraint There is a category of sudden death in which the victim dies suddenly and unexpectedly while in a state of delirium that may involve an arrest or restraint circumstance, during which the victim dies. This problem has been the subject of a robust literature over many years and recent monographs by DiMaio and DiMaio (2006) and by Ross and Chan (2006) review much of it. It is germane to this discussion that some victims are epileptic. A typical restraint death circumstance is one where an individual is involved in an assault, robbery, disturbance, or some other event that may result in law enforcement personnel, emergency personnel, or rescue personnel being summoned to the scene. Once on the scene, there may be an apparent offender who is violent, disoriented, or delusional and may seem to need to be restrained or taken into custody to prevent flight, injury to the offender or to others. In the course of the activity of restraining the individual, many personnel may become involved in trying to subdue the violent person and in so doing may place handcuffs or restraint ties to the person and may place the individual in the prone position, “hog tie” them, and perhaps overlie the individual with several people. In this circumstance, the violent person may suddenly become quiet or complain of not being able to breathe and suffer a cardiorespiratory arrest from which the victim may or may not be able to be resuscitated. Such events almost inevitably result in some form of litigation in which the personnel involved in the restraint are held to account for what actions they may or may not have
Forensic Considerations and Sudden Unexpected Death in Epilepsy
Case B This 29-year-old man had apparently had a seizure disorder since childhood, for which he had been treated with a variety of anticonvulsant medications and a vagal nerve stimulator (about 3 years before this admission) in an effort to suppress his frequent seizures. On a recent occasion, he had been admitted to a hospital after having suffered a seizure. During admission the patient experienced a cardio/pulmonary arrest from which he was successfully resuscitated. The patient had a history of respiratory troubles including asthma. A brain CT on this admission was said to be negative. The shortness of breath the patient had complained of was thought possibly to be due to aspiration. As the patient began to emerge from his postictal state and resuscitation procedures, he was disoriented and agitated, for which he was medicated. He recovered from this episode. Seven months later in the presence of his mother, the patient experienced a seizure event and apparently, while postictal, he became delirious and combative and assaulted his mother, who called for assistance. Police and ἀre department personnel responded and subdued the man by placing him in handcuffs and hobbles in a prone position on a litter. Soon afterward, he became unconscious and pulseless. Immediately after emergency medical personnel arrived, the patient had a heart rate of 140 and a respiratory rate of 28, but then became pulseless. Resuscitative treatment was begun and the man was conveyed to an emergency facility where he was reported to be asystolic on admission. During resuscitation, the patient urinated and vomited. Resuscitation did not succeed and the patient was pronounced dead. The victim was known to be hypertensive and to have had temporal lobe epilepsy for many years. When he was postical, it was not uncommon for him to be delusional and agitated. Autopsy examination reported a body weight of 251 lb and a height of about 72 in. A number of bruises and abrasions to the face, arms, and hands were noted. There were petechial hemorrhages of the lip mucosa and right flank. A subcutaneous hemorrhage was noted near the left occiput. There was evidence of food aspiration. Heart–blood toxicological examination revealed 10 µg/ml barbiturates, <10 µg/ml Lamotrigine, 25 µg/ml Oxcarbazepine, and no Phenytoin. A vagus nerve stimulator was encountered and removed (no testing done). The internal autopsy examination reported no injuries or obstructions to the neck organs. No injury to the lungs was noted and no pneumothorax was noted. The heart weighed 450 g but no obvious atheromata were noted, although abundant epicardial fat that inἀltrated the myocardium and moderately severe myoἀber scarring and hypertrophy were found. The liver was enlarged (2840 g). Neuropathology examination revealed Purkinje cell loss and cortical atrophy of the cerebellum, mild early hypoxic/ischemic changes in neurons, no apparent abnormality of the hippocampal regions beyond extensive corpora amylacea deposition in the subpial region, and no obvious lesion to account for the epilepsy. Microscopically, the heart showed extensive myocardial ἀbrosis. The medical examiner ruled the manner of death a homicide. A succession of lawsuits ensued against the police and ἀre department personnel who had responded in the incident. It was alleged that the man died because of positional asphyxia and compressive forces on the man’s thorax during the restraint.
45
46 Sudden Death in Epilepsy: Forensic and Clinical Issues
Case C This was a 38-year-old white male who apparently suffered an epileptic seizure while at a university campus where he was attending classes. He allegedly exhibited bizarre behavior and began to bang his head and face against a wall and then experienced what was described as a generalized tonic–clonic (GTC) seizure by many observers. After the seizure he became agitated, delusional, and combative. Police were called and they attempted to restrain the man by handcuffing him in a prone position. Emergency medical personnel were called and transported him to hospital, arriving at 1909 hours. While being transported after glucagon was administered (blood sugar found to be 34), he became still and experienced cardiorespiratory arrest. He was cyanotic and pulseless, with ἀxed and dilated pupils. Cardiac monitoring revealed asystole. Resuscitative measures were instituted without success. He was pronounced dead at 1926 hours. The victim’s history was that he had been epileptic since childhood and two craniotomies had been performed on his right temporal region in an attempt to correct his epilepsy. He continued to have seizures that were described as GTC, for which he was treated with carbamazepine. In spite of medication, he would have periodic seizures with an aura, not described. He was somewhat impulsive and apparently either slightly aphasic or dyslexic, which caused him some frustration. He apparently did not use alcohol or drugs. His medical records indicated he had had diabetes insipidus, in conjunction with one of his craniotomies. A history of diabetes mellitus was unsubstantiated. Autopsy revealed evidence of medical treatment, and that he was somewhat plethoric and had a blotchy erythema of the face with several abrasions apparently due to his head-banging and also to efforts to subdue him. There was blood in the mouth and a large tongue bite was found. The autopsy pathologist did not describe petechial hemorrhages in eyes, viscera, or face and discounted the erythema of the skin as being petechial hemorrhages due to suffocation. He had a number of bruises and abrasions of the elbows, knees, etc., due to scuffling. His heart weighed 490 g and showed <30% atheroma of right coronary, left circumflex, but the left anterior descending artery showed 50% occlusion, and the aorta showed moderate atheroma with no obvious infarct. The lungs were 800 and 680 g, congested and wet. No airway obstruction nor injury to neck or hyoid was noted. The liver was 2600 g and congested, as was the spleen (300 g). The brain was 1320 g with evidence of prior surgery in the right temporal side. No subdural hemorrhage was found, and no traumatic injury noted. The case was ἀled as manner of death undetermined with seizure disorder with delirium, coronary artery disease, and positional restraint.
performed. Inevitably, their training and education regarding proper procedures for “take downs” are scrutinized, along with what sort of supervision occurred during the event (Ross and Chan 2006). Death during restraint victims quite frequently are obese, hypertensive, diabetic, or under the influence of substances such as cocaine, amphetamines, phencyclidine (“angel
Forensic Considerations and Sudden Unexpected Death in Epilepsy
47
dust” or PCP), alcohol, cannabis, barbiturates, or opiates, as well as tranquilizers, antipsychotic medication, anticonvulsants, and other drugs (DiMaio and DiMaio 2006). Often, the use of many drugs is demonstrated. Not infrequently, the victims are found to be hyperpyrexic, have cocaine in their blood, and may show myoglobinuria (Ruttenber et al. 1997, 1999; Ross and Chan 2006). Cardiovascular disease demonstrated at autopsy is common. Some victims have a history of epilepsy and may have been apparently postictal when they were in their delirious state. The following are two cases that illustrate the latter, and most of the problems associated with that. This case, like the previous one, was the subject of civil litigation against the responding personnel and their organizations. In both cases, ultimately, either settlements were reached or no judgments were returned against the defendants or their organizations. Both cases illustrate the complexities that may occur when an agitated or delirious epileptic patient needs to be restrained to prevent self-injury or injury to those nearby. It seems painfully obvious that some action on the part of responding personnel, be they police, ἀremen, emergency personnel, or bystanders may be called for in situations like those described above, and also that it seems inevitable when tragedy occurs that they will be blamed, appropriately or not (Ross and Chan 2006). The causal issue of prone restraint, so-called “hog tying,” and overlaying of the agitated and delirious victim is controversial and is still being debated in scientiἀc and forensic circles and in the courts. Other tactics used in restraint of violent persons may involve one or more variants of the chokehold, which may occlude the airway and/or compress the carotid artery and produce death by these means (Vilke 2006, Reay and Holloway 1982; Reay and Eisele 1982). With respect to “hog tying” and prone restraint, Reay et al. (1988, 1992) and O’Halloran et al. (O’Halloran and Lewman 1993; O’Halloran and Frank 2000; O’Halloran 2004) postulated that when in the prone position “hog tied” and when personnel overlay the agitated individual, respiratory function may become impaired and cause death. From a study of restraint deaths, it was common to ἀnd victims to be obese and it was inferred that when placed in the prone position their obesity may impede diaphragmatic movements and respiratory function. The term positional asphyxia has been applied to this and related phenomena. Other reports highlighted not only the position and manner of restraint but the frequent accompanying excited delirium and its physiological effects as causes of death in such cases (Stratton et al. 1995; Pollanen et al. 1998; DiMaio and DiMaio 2006). In experimental studies reported by Chan et al. (1997, 2004), volunteers were placed in the sitting, supine, and prone positions, restrained and loaded after a period of exercise, and their pulmonary function monitored. Chan et al. (1997, 2004) found no evidence that body position while hog-tied or hobbled could in itself cause asphyxiation and that other factors beyond body position were probably more important in restraint deaths. The authors did not rule out that very obese individuals, who were not tested, might have some special risk of asphyxia due to their obesity. Others have expressed concerns that restraint circumstances, including the body habitus of the victim, may produce respiratory embarrassment (Parkes 2008; DiMaio and DiMaio 2006; Pollanen et al. 1998). A factor in the excited and delirious victim deaths is the stressful general physiological state that exists when violent, struggling, and agitated conditions occur. Some have referred to this state as “catecholamine” storm (LaPosata 2006; DiMaio and DiMaio 2006). From the extensive reviews in other chapters of this volume, the importance of catecholamine excess and autonomic imbalance or over-activity in the pathomechanism of SUDEP cases,
48 Sudden Death in Epilepsy: Forensic and Clinical Issues
it is not surprising that it may come into play when some epileptic individuals become delirious and agitated, perhaps in the postictal state, as illustrated in the previous cases. These types of cases, like all the remainder without epilepsy, are difficult to analyze and develop an unambiguous cause and mechanism of death. One can only collect as much information as one can about a given case, and somehow rank the factors that are present in coming to a causal judgment, if one can. Like Case B, sometimes forensic pathologists feel compelled to render a manner of death that might seem provocative, such as homicide. In such cases, one must remember that “homicide” is not necessarily murder but simply death at the hands of another. In this case, the pathologist somehow felt the preponderance of the evidence indicated that someone was responsible. His pronouncement was challenged, of course, in the legal proceedings that followed. In general, it is probably most rational unless very special circumstances are present to make use of the “undetermined” manner of death designation.
2.8â•…SUDEP in Criminal Cases In Chapter 24 of this book, Dr. Wanamaker recounts the case of an unfortunate woman who was assaulted by a home intruder and, as a result, suffered permanent and debilitating head injuries that caused her to become epileptic. Many years after the beating, she was found dead at home in her bathroom with no obvious anatomic cause of death. Her death was judged to be a SUDEP, which, according to the judgment of the U.S. attorney (the
Case D This 14-year-old girl was born with a large ventriculoseptal heart defect and tricuspid valve abnormality, for which surgery had been performed. Apparently, the surgery was a so-called Fontan procedure, which essentially diverted venous blood from the right atrium to the pulmonary trunk, bypassing the right ventricle (Kerendi et al. 2009). This is a treatment for tricuspid atresia, which she had. Within a few years of€ birth, she also developed a seizure disorder that was characterized as being of the€GTC variety, for which she was medicated with phenytoin with variable success. Not long after her heart surgery, it was necessary for her to be anticoagulated and to be treated with digitalis. About 2 months before she died for unknown reasons, her anticonvulsant medication was discontinued. A few weeks before her death, she was given a number of immunizations that caused her to become quite ill and necessitated her being conἀned to bed. A week before death, she commenced her menarche and had difficulties with maintaining her International Normalized Ratio (INR) in acceptable ranges. It appears she also experienced one or more seizures, with one of them causing a bite on her tongue that continued to bleed. She complained of headaches. She was found dead beside her bed in the morning after having been ill for about 2 weeks. An autopsy was performed that showed evidence of a head impact in the left temporal region, an acute subdural hemorrhage, an apparent basal skull fracture, a large
Forensic Considerations and Sudden Unexpected Death in Epilepsy
laceration with hemorrhage of the tongue with aspiration of blood, a number of focal hemorrhagic sites in the gut, mesentery bladder, spleen, and kidney, and some bruising on the legs. The autopsy pathologist concluded that the girl had been assaulted and classiἀed her death as being due to blunt force injuries with manner of death as undetermined. The local prosecutor was pursuing an indictment against the mother of the child for homicide. Independent examination of the autopsy tissues with microscopic examinations indicated that the subdural hematoma was relatively thin and was 1 to 2 weeks old by histological criteria. A skull fracture was present. It was reasonable to attribute the numerous areas of hemorrhage to dosage problems with her anticoagulant and not to having been assaulted. As to the mechanism(s) of death, the victim clearly had serious cardiovascular disease, which in and of itself could account for a sudden death, but there was evidence of recent seizure activity as exempliἀed by the hemorrhagic tongue bite and aspiration of blood and the position of the body beside the bed. It might be said that SUDEP was a reasonable possibility, but could not be proven. The case has languished for many years and it is unlikely to be adjudicated.
Case E A 10-year-old boy who had experienced a birth-related injury that left him with a spastic form of diplegia, intractable epilepsy, and mental retardation had been cared for in various institutions and by the parents in the child’s home over his lifetime. The child was capable of ambulating but with difficulty, could not speak intelligibly but apparently could understand spoken language, and was not apparently visually impaired. After a number of years of gastrostomy feedings, the child was capable of being fed manually and even managed to partially feed himself. The child had a ventriculoperitoneal shunt for hydrocephalus with several shunt revisions, but apparently the hydrocephalus had stabilized. The child’s abiding problem was one of seizures that were cyclical in severity and frequency. A number of anticonvulsant medications had been tried, but never fully controlled the child’s epilepsy which was of the GTC type. One morning, the child was found dead in bed by the parents. An autopsy was performed by a medical examiner facility and the child was found to have some contractures of the lower extremity and many bruises on them and on the upper extremities. Several bruises were found on the child’s face and head. A number of healing abrasions were found on the arms and legs. There were no fractures. No pneumonia or other infections were found. The child’s brain showed typical rostral cortical atrophy with some cyst formation in the white matter, hydrocephalus that was not severe, and bilateral subdural hematoma membranes with a minimal amount of recent hemorrhage. The viscera were within normal limits. The autopsy pathologist concluded that the child had died from blunt force injuries that were inflicted and the manner of death was deemed homicide. The parents were charged with homicide.
49
50 Sudden Death in Epilepsy: Forensic and Clinical Issues
An independent examination of the case and the autopsy materials revealed the obvious cerebral palsy pathology of the child and revealed the subdural hematoma to be likely many years old and essentially undatable with accuracy. The recent hemorrhage was minimal. The skin bruises were of different ages by visual inspection, as were the healing abrasions. Put in the context of how the child functioned (impaired mobility, frequent falls with and without seizures), the injuries were not inconsistent with the circumstances of the child. No acute signiἀcant impact site was found on the head. The subdural hematoma bleeding was found to be typical for any chronic subdural hematoma and could not speciἀcally be related to any known traumatic episode. Given the location of the body (in bed), the chronic problem of seizures, and no anatomic cause of death, the child’s death was concluded to be SUDEP. Eventually, charges were dropped against the parents.
assault occurred on a federal reservation), was directly caused by the assailant who became known to him and was charged. Such a case is distinctly unusual, not only because of the basic facts of the case, but also because of the time that had elapsed between the inflicted injury and the woman’s death and when her assailant was brought to justice. Most criminal cases that might involve a SUDEP scenario are much less complex or unusual but nonetheless can be challenging if not controversial. A not uncommon circumstance that may involve criminal prosecution is the death of a neurologically compromised child, usually at home but occasionally in some form of care facility. In many of these cases, the child suffered from congenital brain malformations or birth-related injury (cerebral palsy) associated with chronic seizures. Sometimes, the child may have been the victim of an acute life-threatening event (ALTE) with persistent neurological impairment that may have been due to inflicted injury (abuse), accident, or to a circumstance that is never explained. When such a child dies, commonly due to aspiration and pneumonia, urinary tract infection, shunt malfunction, or other issue related to chronic illness, these conditions can usually be identiἀed and put in their proper context with a competent autopsy. Occasionally, the child will not have an obvious anatomic cause of death and may ἀt into the SUDEP category. The forensic pathologist must be mindful of this latter form of death and not leap to the conclusion that, absent an obvious cause of death, someone must have caused it. Cases such as this one point out the many challenges of evaluating and interpreting infant and childhood deaths, which almost invariably have a cloud of abusive injury hovering over them, deserved or not.
2.9â•…SUDEP and Anticonvulsant Medication Whether anticonvulsant medication by some aberrant pharmacological reaction, noncompliance, under-dosage, or cessation of administration can lead to SUDEP remains a controversial subject and is dealt with in detail in several chapters in the volume. This
Forensic Considerations and Sudden Unexpected Death in Epilepsy
51
discussion will not be repeated here. Suffice it to say that this issue can have forensic and litigative consequences. Dr. Wanamaker has highlighted some case examples of this problem that largely center about physician-patient interactions, namely the responsibility of the doctor to warn an epileptic patient about the possibility of SUDEP when prescribing, switching drugs, tapering, or discontinuing anticonvulsant drugs. Such cases come, not infrequently, to civil litigation. The above case is similar to many that have reached litigation in the United States and elsewhere in recent years. In many cases, the doctor has no record of patient conversations or instructions, relying on memory or usual practice. Recently such conversations are recorded, videotaped, or immortalized in some fashion, sometimes along with a signed statement by the patient that they were informed of risks of medication and its discontinuance, including the facts about SUDEP. Informational packets have been prepared by some physicians to aid in this process. To the author’s knowledge, the majority of SUDEP-related
Case F This 28-year-old woman had been epileptic since childhood, suffering ἀrst from absence seizures that then gave way to GTC seizures as an adult. Other than her epilepsy, she had enjoyed good health and had recently gotten married. Her seizure frequency was very low, and it had been several years since she had had a seizure. Since her marriage, she had wanted to become pregnant and had indeed done so, visiting her neurologist once she was aware of her pregnancy to seek advice about her anticonvulsant medication and its potential effects on her unborn baby. The doctor, who immortalized his conversation with his patient in a very brief note in his office records, indicated that probably the risk to the baby was quite low, but that if the patient was concerned about her medication, in the face of no seizures for several years, it would be appropriate to taper the medication and discontinue it for the duration of the pregnancy. He pointed out that if a seizure were to occur, they would simply begin medication again and go on. A few months later, the woman was found dead in bed. Autopsy revealed the pregnancy, but no anatomic cause of death. The husband reported that he had never observed a seizure in his wife nor had she said anything about having had a seizure. A lawsuit stipulating neglectful treatment and wrongful death was brought against the neurologist. At trial, the doctor’s records were offered in evidence to support the fact that he had a treatment plan and had discussed it with his patient, but apparently did not feel bound to warn her about the risk of SUDEP. At trial, various experts offered testimony regarding what SUDEP was, how it was diagnosed, and, probably, what caused it. The issue of anticonvulsant medication in relation to the possible cause and prevention of SUDEP was explored. The defense expert presented the results of several of his own studies and those of others and indicated that, while many studies showed a statistical correlation of subtherapeutic or no anticonvulsant medication with SUDEP, others did not and it could not be inferred that stopping medication was causal or could predict SUDEP. The jury in the case acquitted the doctor in the action.
52 Sudden Death in Epilepsy: Forensic and Clinical Issues
litigations have been adjudicated in favor of the physicians. Suffice it to say that it is vital that physicians share information with their patients and document that this occurred and what was communicated and when.
References Armour, J. A., and J. L. Ardell, eds. 1984. Neurocardiology. New York, NY: Oxford University Press. Bell, G. S., and J. W. Sander. 2006. Sudden unexpected death in epilepsy. Risk factors, possible mechanisms and prevention: A reappraisal. Acta Neurol Taiwan 15 (2): 72–83. Bharati, S., and M. Lev. 1990. The Cardiac Conduction System in Sudden Unexplained Death. Mt. Kisco, NY: Futura. Chan, T. C., G. M. Vilke, T. Neuman, and J. L. Clausen. 1997. Restraint position and positional asphyxia. Ann Emerg Med 30 (5): 578–586. Chan, T. C., T. Neuman, J. Clausen, J. Eisele, and G. M. Vilke. 2004. Weight force during prone restraint and respiratory function. Am J Forensic Med Pathol 25 (3): 185–189. Davis, J. H., and R. K. Wright. 1980. The very sudden cardiac death syndrome—a conceptual model for pathologists. Hum Pathol 11 (2): 117–121. de la Grandmaison, G. L., and M. Durigon. 2002. Sudden adult death: A medico-legal series of 77 cases between 1995 and 2000. Med Sci Law 42 (3): 225–232. DiMaio, T. G., and V. J. M. DiMaio, eds. 2006. Excited Delirium Syndrome. Cause of Death and Prevention. Boca Raton, FL: CRC Press. DiMaio, V. J., and D. DiMaio. 2001. Forensic pathology. In Practical Aspects of Criminal and Forensic Investigations, ed. V. Geberth. Boca Raton, FL: CRC Press. Engel, J., Jr., and T. A. Pedley, eds. 2008. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins. Fineschi, V., G. Baroldi, and M. D. Silver. 2006. Pathology of the Heart and Sudden Death in Forensic Medicine. Boca Raton, FL: CRC Press. Gastaut, H. 1969. Classiἀcation of the epilepsies. Proposal for an international classiἀcation. Epilepsia 10 (Suppl): 14–21. Gastaut, H., and B. G. Zifkin. 1985. Classiἀcation of the epilepsies. J Clin Neurophysiol 2 (4): 313–326. George, J. R., and G. G. Davis. 1998. Comparison of anti-epileptic drug levels in different cases of sudden death. J Forensic Sci 43 (3): 598–603. Greenberg, H. M., and E. M. Dwyer Jr., eds. 1982. Sudden Coronary Death, Vol. 382, Annals of the New York Academy of Sciences. New York, NY: New York Academy of Sciences. Haerem, J. W. 1978. Sudden, unexpected coronary death. The occurrence of platelet aggregates in the epicardial and myocardial vessels of man. Acta Pathol Microbiol Scand Suppl (265): 1–47. Hitiris, N., S. Suratman, K. Kelly, L. J. Stephen, G. J. Sills, and M. J. Brodie. 2007. Sudden unexpected death in epilepsy: A search for risk factors. Epilepsy Behav 10 (1): 138–141. James, S. H., P. E. Kish, and T. P. Sutton. 2005. Principles of bloodstain pattern analysis. Theory and practice. In Practical Aspects of Criminal and Forensic Investigations, ed. V. Geberth. Boca Raton, FL: CRC Press. Johnson, R. H., D. G. Lambie, and J. M. K. Spalding, eds. 1984. Neurocardiology, Major Problems in Neurology, Vol. 13, ed. J. Walton. Philadelphia, PA: W. B. Saunders. Kerendi, F., Z. B. Kramer, W. T. Mahle, B. E. Kogon, K. R. Kanter, and P. M. Kirshbom. 2009. Perioperative risks and outcomes of atrioventricular valve surgery in conjunction with Fontan procedure. Ann Thorac Surg 87 (5): 1484–1488; discussion 1488–1489. Knight, B. 1996. Forensic Pathology. 2nd ed. London: Arnold. Kuller, L. 1966. Sudden and unexpected non-traumatic deaths in adults: A review of epidemiological and clinical studies. J Chronic Dis 19 (11): 1165–1192.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
53
Kuller, L., A. Lilienfeld, and R. Fisher. 1966. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease. Circulation 34 (6): 1056–1068. Laidlaw, J., and A. Richens, eds. 1982. A Textbook of Epilepsy. Edinburgh: Churchill Livingstone. Langan, Y. 2000. Sudden unexpected death in epilepsy (SUDEP): Risk factors and case control studies. Seizure 9 (3): 179–183. Langan, Y., L. Nashef, and J. W. Sander. 2005. Case-control study of SUDEP. Neurology 64 (7): 1131–1133. LaPosata, E. A. 2006. Restraint stress. In Sudden Deaths in Custody, ed. D. L. Ross and T. C. Chan. Totowa, NJ: Humana Press. Lear-Kaul, K. C., L. Coughlin, and M. J. Dobersen. 2005. Sudden unexpected death in epilepsy: A retrospective study. Am J Forensic Med Pathol 26 (1): 11–17. Leestma, J. E. 1990a. Natural history of epilepsy. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder. New York, NY: Marcel Dekker. Leestma, J. E. 1990b. Sudden unexpected death associated with seizures: A pathological review. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder. New York, NY: Marcel Dekker. Leestma, J. E. 2009a. Forensic aspects of adult general neuropathology. In Forensic Neuropathology, ed. J. E. Leestma. Boca Raton, FL: CRC Press. Leestma, J. E. 2009b. Forensic aspects of complex neural function. In Forensic Neuropathology, ed. J.€E. Leestma. Boca Raton, FL: CRC Press. Leestma, J. E., and E. W. Sharp. 2009. Pathology and neuropathology in the forensic setting. In Forensic Neuropathology, ed. J. E. Leestma. Boca Raton, FL: CRC Press. Leestma, J. E., J. F. Annegers, M. J. Brodie, S. Brown, P. Schraeder, D. Siscovick, B. B. Wannamaker, P. S. Tennis, M. A. Cierpial, and N. L. Earl. 1997. Sudden unexplained death in epilepsy: Observations from a large clinical development program. Epilepsia 38 (1): 47–55. Leestma, J. E., J. R. Hughes, S. S. Teas, and M. B. Kalelkar. 1985. Sudden epilepsy deaths and the forensic pathologist. Am J Forensic Med Pathol 6 (3): 215–218. Leestma, J. E., T. Walczak, J. R. Hughes, M. B. Kalelkar, and S. S. Teas. 1989. A prospective study on sudden unexpected death in epilepsy. Ann Neurol 26 (2): 195–203. Lhatoo, S. D., and J. W. Sander. 2002. Sudden unexpected death in epilepsy. Hong Kong Med J 8 (5): 354–358. Luke, J. L., and M. Helpern. 1968. Sudden unexpected death from natural causes in young adults. A review of 275 consecutive autopsied cases. Arch Pathol 85 (1): 10–17. Lund, A., and H. Gormsen. 1985. The role of antiepileptics in sudden death in epilepsy. Acta Neurol Scand 72 (4): 444–446. McGugan, E. A. 1999. Sudden unexpected deaths in epileptics—A literature review. Scott Med J 44 (5): 137–139. McKee, J. R., and J. W. Bodἀsh. 2000. Sudden unexpected death in epilepsy in adults with mental retardation. Am J Ment Retard 105 (4): 229–235. Milroy, C. M. 1999. Forensic taphonomy: The postmortem fate of human remains. BMJ 319 (7207): 458. Modell, J. H., M. Bellefleur, and J. H. Davis. 1999. Drowning without aspiration: Is this an appropriate diagnosis? J Forensic Sci 44 (6): 1119–1123. Monte, C. P., J. B. Arends, I. Y. Tan, A. P. Aldenkamp, M. Limburg, and M. C. de Krom. 2007. Sudden unexpected death in epilepsy patients: Risk factors. A systematic review. Seizure 16 (1): 1–7. Morentin, B., and R. Alcaraz. 2002. Sudden unexpected death in epilepsy in children and adolescents. Rev Neurol 34 (5): 462–465. Moritz, A. R. 1954. Sudden and unexpected death due to disease. GP 10 (6): 35–42. Natelson, B. H., R. V. Suarez, C. F. Terrence, and R. Turizo. 1998. Patients with epilepsy who die suddenly have cardiac disease. Arch Neurol 55 (6): 857–860.
54 Sudden Death in Epilepsy: Forensic and Clinical Issues Nilsson, L., B. Y. Farahmand, P. G. Persson, I. Thiblin, and T. Tomson. 1999. Risk factors for sudden unexpected death in epilepsy: A case-control study. Lancet 353 (9156): 888–893. Nilsson, L., U. Bergman, V. Diwan, B. Y. Farahmand, P. G. Persson, and T. Tomson. 2001. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: A case-control study. Epilepsia 42 (5): 667–673. Office of the Medical Examiner, Cook County, IL. 1979. Annual Report, 1977–1979. Chicago, IL: Office of the Medical Examiner. O’Halloran, R. L. 2004. Reenactment of circumstances in deaths related to restraint. Am J Forensic Med Pathol 25 (3): 190–193. O’Halloran, R. L., and J. G. Frank. 2000. Asphyxial death during prone restraint revisited: A report of 21 cases. Am J Forensic Med Pathol 21 (1): 39–52. O’Halloran, R. L., and L. V. Lewman. 1993. Restraint asphyxiation in excited delirium. Am J Forensic Med Pathol 14 (4): 289–295. Okada, R., and S. Kawai. 1983. Histopathology of the conduction system in sudden cardiac death. Jpn Circ J 47 (5): 573–580. Opeskin, K., A. S. Harvey, S. M. Cordner, and S. F. Berkovic. 2000. Sudden unexpected death in epilepsy in Victoria. J Clin Neurosci 7 (1): 34–37. Opeskin, K., M. P. Burke, S. M. Cordner, and S. F. Berkovic. 1999. Comparison of antiepileptic drug levels in sudden unexpected deaths in epilepsy with deaths from other causes. Epilepsia 40 (12): 1795–1798. Pachar, J. V., and J. M. Cameron. 1993. The diagnosis of drowning by quantitative and qualitative diatom analysis. Med Sci Law 33 (4): 291–299. Parkes, J. 2008. Sudden death during restraint: Do some positions affect lung function? Med Sci Law 48 (2): 137–141. Piette, M. H., and E. A. De Letter. 2006. Drowning: Still a difficult autopsy diagnosis. Forensic Sci Int 163 (1–2): 1–9. Pollanen, M. S., D. A. Chiasson, J. T. Cairns, and J. G. Young. 1998. Unexpected death related to restraint for excited delirium: A retrospective study of deaths in police custody and in the community. CMAJ 158 (12): 1603–1607. Reay, D. T., and J. W. Eisele. 1982. Death from law enforcement neck holds. Am J Forensic Med Pathol 3 (3): 253–258. Reay, D. T., and G. A. Holloway Jr. 1982. Changes in carotid blood flow produced by neck compression. Am J Forensic Med Pathol 3 (3): 199–202. Reay, D. T., C. L. Fligner, A. D. Stilwell, and J. Arnold. 1992. Positional asphyxia during law enforcement transport. Am J Forensic Med Pathol 13 (2): 90–97. Reay, D. T., J. D. Howard, C. L. Fligner, and R. J. Ward. 1988. Effects of positional restraint on oxygen saturation and heart rate following exercise. Am J Forensic Med Pathol 9 (1): 16–18. Ross, D. L., and T. C. Chan, eds. 2006. Sudden Deaths in Custody. Totowa, NJ: Humana Press. Rossi, L. 1982. Pathologic changes in the cardiac conduction and nervous system in sudden coronary death. Ann N Y Acad Sci 382: 50–68. Ruttenber, A. J., J. Lawler-Heavner, M. Yin, C. V. Wetli, W. L. Hearn, and D. C. Mash. 1997. Fatal excited delirium following cocaine use: Epidemiologic ἀndings provide new evidence for mechanisms of cocaine toxicity. J Forensic Sci 42 (1): 25–31. Ruttenber, A. J., H. B. McAnally, and C. V. Wetli. 1999. Cocaine-associated rhabdomyolysis and excited delirium: Different stages of the same syndrome. Am J Forensic Med Pathol 20 (2): 120–127. Schraeder, P. L., K. Delin, R. L. McClelland, and E. L. So. 2006. Coroner and medical examiner documentation of sudden unexplained deaths in epilepsy. Epilepsy Res 68 (2): 137–143. Schwartz, C. J., and R. G. Gerrity. 1975. Anatomical pathology of sudden unexpected cardiac death. Circulation 52 (6 Suppl): III18–III26. Schwartz, C. J., and W. J. Walsh. 1971. The pathologic basis of sudden death. Prog Cardiovasc Dis 13 (5): 465–481.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
55
Schwender, L. A., and J. C. Troncoso. 1986. Evaluation of sudden death in epilepsy. Am J Forensic Med Pathol 7 (4): 283–287. Scorza, F. A., M. Albuquerque, R. M. Arida, and E. A. Cavalheiro. 2007. Cardiovascular alterations and sudden death in epilepsy. Arq Neuropsiquiatr 65 (2B): 461–466. Shields, L. B., D. M. Hunsaker, 3rd, J. C. Hunsaker, and J. C. Parker Jr. 2002. Sudden unexpected death in epilepsy: Neuropathologic ἀndings. Am J Forensic Med Pathol 23 (4): 307–314. Stratton, S. J., C. Rogers, and K. Green. 1995. Sudden death in individuals in hobble restraints during paramedic transport. Ann Emerg Med 25 (5): 710–712. Tennis, P., T. B. Cole, J. F. Annegers, J. E. Leestma, M. McNutt, and A. Rajput. 1995. Cohort study of incidence of sudden unexplained death in persons with seizure disorder treated with antiepileptic drugs in Saskatchewan, Canada. Epilepsia 36 (1): 29–36. Thom, M., B. Griffin, J. W. Sander, and F. Scaravilli. 1999. Amygdala sclerosis in sudden and unexpected death in epilepsy. Epilepsy Res 37 (1): 53–62. Timmings, P. L. 1993. Sudden unexpected death in epilepsy: A local audit. Seizure 2 (4): 287–290. Tomson, T., T. Walczak, M. Sillanpaa, and J. W. Sander. 2005. Sudden unexpected death in epilepsy: A review of incidence and risk factors. Epilepsia 46 (Suppl 11): 54–61. Ulrich, J., and H. Maxeiner. 2003. Tongue bite injuries—a diagnostic criterium for death in epileptic seizure? Arch Kriminol 212 (1–2): 19–29. Vilke, G. M. 2006. Neck holds. In Sudden Deaths in Custody, ed. D. L. Ross and T. C. Chan. Totowa, NJ: Humana Press. Vlooswijk, M. C., H. J. Majoie, M. C. De Krom, I. Y. Tan, and A. P. Aldenkamp. 2007. SUDEP in the Netherlands: A retrospective study in a tertiary referral center. Seizure 16 (2): 153–159. Walczak, T. 2003. Do antiepileptic drugs play a role in sudden unexpected death in epilepsy? Drug Saf 26 (10): 673–683. Walczak, T. S., I. E. Leppik, M. D’Amelio, J. Rarick, E. So, P. Ahman, K. Ruggles, G. D. Cascino, J. F. Annegers, and W. A. Hauser. 2001. Incidence and risk factors in sudden unexpected death in epilepsy: A prospective cohort study. Neurology 56 (4): 519–525.
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy Guardian of the Brain–€Heart Connection
3
Fulvio A. Scorza Esper A. Cavalheiro Ricardo M. Arida Vera C. Terra Carla A. Scorza Eliza Y. F. Sonoda Roberta M. Cysneiros
Contents 3.1 General Aspects of Sudden Unexpected Death in Epilepsy 3.2 Evidence for the Cardiovascular Beneἀts of Omega-3 3.3 The Potential Role of Omega-3 in the Management of Epilepsy 3.4 Final Considerations and Future Remarks Acknowledgment References
57 59 59 62 63 63
3.1â•…General Aspects of Sudden Unexpected Death in Epilepsy Epilepsy is the most common serious chronic neurological condition in the world. Approximately 50 million people worldwide have epilepsy (Annegers 1997; Sander 2003; Yuen and Sander 2004). Epidemiological studies suggest that, with proper treatment, between 70% and 80% of people developing epilepsy will go into remission, while the remaining patients continue to have seizures and are refractory to treatment with the currently available therapies (Sander 1993; Kwan and Sander 2004). The most common risk factors for epilepsy are cerebrovascular diseases, brain tumors, alcohol, traumatic head injuries, malformations of cortical development, genetic inheritance, and infections of the central nervous system (Halatchev 2000). In resource-poor countries, endemic infections, such as malaria and neurocysticercosis, seem to be major risk factors (Duncan et al. 2006). Temporal lobe epilepsy (TLE) is the most common form of partial epilepsy, affecting at least 20% of all patients with epilepsy (Babb 1999), and is the most common form of drugrefractory epilepsy (Engel 1993). Atrophy of mesial temporal structures is well known to be associated with TLE and hippocampal sclerosis, which is a very frequent histological abnormality in this form of epilepsy (Cendes et al. 1993). Sudden unexpected death in epilepsy (SUDEP) represents the leading cause of mortality€ in adults with refractory epilepsy (Tomson et al. 2005). SUDEP is deἀned as sudden, 57
58 Sudden Death in Epilepsy: Forensic and Clinical Issues
unexpected, witnessed or unwitnessed, nontraumatic, and nondrowning deaths in patients with epilepsy, with or without evidence of a seizure and excluding documented status epilepticus, in which postmortem examination does not reveal a toxicological or anatomical cause of death (Nashef 1997). Comparisons of incidence estimates for SUDEP are difficult since different deἀnitions of SUDEP are used, not all patients have a postmortem examination, and case ascertainment methods and source populations are varied (Tomson et al. 2005). The reported incidence of sudden unexpected deaths has been variably estimated as 3.5/1000 person-years* in a Lamotrigine clinical trial (Leestma et al. 1997), 0.5–1.4/1000 person-years in people with treated epilepsy (Tennis et al. 1995), 5.9/1000 person-years in outpatients with epilepsy at a tertiary referral center (Nashef et al. 1995), 9/1000 person-years in candidates for epilepsy surgery, and 0.35/1000 person-years in the general population (Ficker et al. 1988). Only one death attributable to SUDEP has been recorded in approximately 8000 personyears of follow-up in the National General Practice Study of Epilepsy in the United Kingdom, a community-based prospective observational study of incidence cases with epilepsy realized in a population of 792 patients with newly diagnosed epilepsy (Lhatoo et al. 1999). The results of the Medical Research Council Antiepileptic Drug Withdrawal Study showed that SUDEP among patients with epilepsy in remission is a rare event (Medical Research Council 1991). Information concerning risk factors for SUDEP is conflicting, but potential risk factors include age (Tennis et al. 1995), early onset of epilepsy (Nilsson et al. 1999), duration of epilepsy (Walczak et al. 2001), uncontrolled seizures, mainly TLE (Sperling et al. 1999; Langan et al. 2005), seizure frequency (Sperling et al. 1999; Walczak et al. 2001; Langan et al. 2005), seizure type (Kloster and Engelskjon 1999; Walczak et al. 2001; Langan et al. 2005), AED numbers (Nilsson et al. 1999; Walczak et al. 2001), and winter temperatures (Scorza et al. 2007). More recently, an elegant review article by Lathers and colleagues (2008) addressed other risk factors that could be operant in SUDEP and in cardiac disease, such as psychological factors (stress/anxiety/depression states and anger/frustration), patients’ lifestyle (e.g., cigarette smoking), and high prevalence of metabolic syndrome (obesity, dyslipidemia, glucose intolerance, and hypertension). Additionally, potential pathomechanisms for SUDEP are unknown, but a number of interictal, ictal, and postmortem cardiac abnormalities account for the possibility of seizure-induced cardiogenic SUDEP (Tomson et al. 2005; Scorza et al. 2007). Along these lines, early animal studies have also examined the role of the autonomic nervous system and cardiac arrhythmias, interictal and ictal epileptogenic activity, and SUDEP (Lathers and Schraeder 1982). Speciἀcally, Lathers and Schraeder demonstrated that intravenous pentylenetetrazol in anesthetized cats induced autonomic dysfunction associated with both interictal and ictal epileptogenic activity. The autonomic dysfunction was manifested by the fact that autonomic cardiac nerves did not always respond in a predictable manner to changes in blood pressure, the development of a marked increase in variability in mean autonomic cardiac nerve discharge, and the appearance of a very large increase in the variability of the discharge rate of parasympathetic nerves, ἀrst and then second, in sympathetic discharge. The authors concluded that altered autonomic cardiac nerve discharge was associated with interictal epileptogenic activity and arrhythmia, which may contribute to sudden unexplained death in patients with epilepsy (Lathers and Schraeder 1982).
* Person-years: the specific amount of time (years) members of the population experience over the risk period.
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy
59
3.2â•…Evidence for the Cardiovascular Benefits of Omega-3 The beneἀcial effects of omega-3 fatty acids in the cardiovascular system have been described since the 1970s. Dyerberg and Bang (1979) suggested the low prevalence of cardiac diseases in Eskimos might be due to high dietary ingestion of omega-3 fatty acids. In the same decade, a number of experimental studies showed an antiarrhythmic role of the omega-3 fatty acid (Gudbjarnason and Hallgrimsson 1976). McLennan et al. (1992) conducted several experiments to conἀrm the possible antiarrhythmic role of omega-3. Initially, it was demonstrated that a diet high in ἀsh oil (tuna) could prevent the ventricular ἀbrillation in rats induced by coronary artery occlusion following reperfusion (McLennan et al. 1992; McLennan 1993). Subsequent studies conἀrmed their previous data (McLennan et al. 1992; Yang et al. 1993; Jacobsen et al. 1997). Billman and colleagues (1997), using a sudden cardiac death model in dogs, observed a reduction of arrhythmias and sudden cardiac death following induction of ischemia after omega-3 administration (Billman et al. 1994, 1997). Moreover, several work studies demonstrated positive effects of omega-3 in arrhythmia reduction (Kang and Leaf 1994; Xiao et al. 1995; Kang and Leaf 1996; Xiao et al. 1997, 2000). The antiarrhythmic mechanism induced by omega-3 was modulated by Na+ and Ca2+ currents in cardiac cells (Leaf et al. 2003). In the same way, positive effects of omega-3 have also been observed in clinical studies. Accordingly, several studies in the 1990s demonstrated that ἀsh consumption one or two times per week was associated with a 50% reduction of sudden cardiac death (Albert et al. 1998; Siscovick et al. 2003). Furthermore, a clinical study for infarct prevention conducted by an Italian group (GISSIPrevenzione), using a dose of 850 mg/day of omega-3 in 11,324 subjects presenting a ἀrst myocardial infarction episode, observed a signiἀcant reduction of death caused by cardiovascular complications (30%) as well as in sudden death (45%) when compared to control subjects, suggesting an antiarrhythmic role of omega-3 (Marchioli 1999; Marchioli et al. 2002). In conclusion, human and animals studies have demonstrated a possible action of omega-3 in the prevention of cardiovascular abnormalities and the reduction of occurrence of sudden cardiac death.
3.3â•…The Potential Role of Omega-3 in the Management of Epilepsy As discussed above, SUDEP is the most important direct epilepsy-related situation of death (Tomson et al. 2005) and cardiovascular abnormalities during and between seizures is directly related to a high frequency of SUDEP (Stollberger and Finsterer 2004). In addition, substantial evidence from epidemiological and case-control studies indicates that omega-3 reduces the risk of cardiovascular mortality, with an especially potent effect on sudden cardiac death (Calder 2004). Thus, a possible relationship between omega-3, epilepsy, and SUDEP could be considered. Along these lines, some animal and clinical studies have shown that omega-3 could be useful in the prevention and treatment of epilepsy. In 1998, Voskuyl and colleagues, using the cortical stimulation seizure model in rats, demonstrated a modest anticonvulsant effect of long duration with the polyunsaturated fatty acids. Moreover, pharmacology studies show that polyunsaturated fatty acids applied extracellularly raise the stimulatory thresholds of CA1 neurons in hippocampal slices (Xiao and Li 1999). Recently, our group was the ἀrst to demonstrate that chronic treatment with omega-3 promotes neuroprotection
60 Sudden Death in Epilepsy: Forensic and Clinical Issues
and increases parvalbumin-positive neurons in the hippocampal formation of rats with epilepsy (Ferrari et al. 2008), suggesting that omega-3 leads to prominent positive plastic changes in the hippocampal formation of rats with epilepsy (Figure 3.1). From a clinical viewpoint, Schlanger et al. (2002) reported on an open clinical trial in which ἀve patients took omega-3 supplements. In this study, a special food spread containing 65% omega-3 fatty acids was added to the daily diet of ἀve patients with epilepsy. The patients consumed 5 g of this spread at every breakfast for 6 months and all of them showed a marked reduction in both frequency and severity of epileptic seizures, suggesting that a dietary supplement containing omega-3 may be beneἀcial in the suppression of some cases of epileptic seizures. Recently, in the ἀrst randomized, placebo-controlled, parallel group of omega-3 supplementation, seizure frequency was reduced over the ἀrst 6 weeks of treatment in the supplement group, but this effect was not sustained (Yuen and Sander 2004). The authors think the decrease in seizures following the initial 6 weeks is a result of omegaÂ�-3 preparations, doses, treatment duration, and sample sizes. Speciἀcally, the researchers used a total daily dose of approximately 1.7 g omega-3, approximately 1 g eicosapentaenoic acid (EPA)
CV
CW
CA1
EV
EW
HILUS CA3
CA1
CA3
Hilus
Figure 3.1╇ Photomicrographs of PV-stained coronal sections in the hippocampal formation (CA1, CA3 regions and hilus of the dentate gyrus) of animals treated daily with vehicle (cremophor 0.009%) (CV); animals treated daily with 85 mg/kg omega-3 (CW); animals with epilepsy treated with vehicle (EV) and animals with epilepsy treated with 85 mg/kg omega-3, on a daily basis (EW). PV-positive neurons are significantly higher in animals with epilepsy treated with omega-3 (EW) when compared with untreated animals with epilepsy (EV), and control animals (CV, CW). (Scale bar, 800 µm.)
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy
61
and 0.7 g docosahexaenoic acid (DHA), and suggested that additional doses and omega-3 preparations should be tested. Concerning treatment duration and sample sizes, a 12-week, double-blind, placebo-controlled, parallel group trial of omega-3 supplementation in 57 patients with refractory epilepsy was evaluated. Since a reduction in seizures within the ἀrst 6 weeks of starting supplementation with omega-3 was observed, the authors also purposed that studies using longer treatment durations with larger sample sizes should be undertaken. As omega-3 fatty acids, per se, have been shown to reduce cardiac arrhythmias and sudden cardiac deaths (Calder 2004), Yuen and Sander (2004) proposed the interesting hypothesis that omega-3 fatty acid supplementation in patients with refractory seizures may reduce seizures and seizure-associated cardiac arrhythmias and, hence, SUDEP. According to this reasoning, two experimental studies developed by our group could reinforce this hypothesis. First, we evaluated the heart rate, using in vivo (ECG) and isolated ex vivo preparations (Langendorf preparation) of rats with epilepsy (Colugnati et al. 2005). Our results showed signiἀcant differences in the mean heart rate in vivo between the groups. In contrast, we did not ἀnd differences during isolated ex vivo situations, suggesting a central nervous system modulation on the heart, which could explain a risk for SUDEP (Figure€3.2). Quite interestingly, Scorza and colleagues (unpublished data) evaluated the same set of experiments (heart rate in vivo and isolated ex vivo preparation) in rats
(a) 300 200 100 0
Heart rate in vitro (bpm)
200
Control
Rats with epilepsy Ventricular pressure (mm Hg) in vitro
Heart rate in vivo (bpm)
400
(b)
150 100 50 0
Control
Rats with epilepsy
80 70
(c)
60 50 40 30 20 10 0
Control
Rats with epilepsy
Figure 3.2╇ Results obtained by Colugnati, Gomes, and Arida (2005). (a) Heart rate in vivo; Heart rate of isolated ex vivo preparation (b); Ventricular pressure of isolated ex vivo situation (c) from control and rats with epilepsy. Note that heart rate in vivo is significantly higher in rats with epilepsy. *p < 0.05.
62 Sudden Death in Epilepsy: Forensic and Clinical Issues
with epilepsy before and after chronic omega-3 administration. The results showed differences in the mean heart rate in vivo but, surprisingly, no differences in heart rates could be observed in the isolated ex vivo condition. It has been suggested that the use of certain antiepileptic drugs, especially carbaÂ� mazepine (CBZ), may predispose patients to SUDEP (Stollberger and Finsterer 2004). Furthermore, carbamazepine has been shown to affect the autonomic nervous system and the conduction system of the heart, mainly when associated with elevated plasma levels above 40 µmol/l (Stollberger and Finsterer 2004). Following this reasoning, Yuen and coworkers (2008) reported very recently the fatty acids (FAs) proἀles in red blood cells and plasma obtained prior to and following omega-3 FA supplementation in 56 patients with epilepsy, providing an opportunity to examine potential effects of antiepileptic drugs on FA proἀles (Yuen et al. 2008). They showed that patients on CBZ exhibited a less favorable FAs proἀle, associated with a greater risk of coronary heart disease mortality. In summary, the authors concluded that, as arrhythmias are thought to be important mechanisms in coronary heart disease mortality and SUDEP, the effect of CBZ in reducing omega-3 FAs might potentially explain some cases of SUDEP among patients prescribed the antiepileptic drug. Taking all of the data together, the ἀrst randomized, placebo-controlled parallel group study of omega-3 supplementation in patients with chronic epilepsy showed only a transient effect on seizure frequency that was not conἀrmed by other research groups, but indicates that additional trials are required (DeGiorgio and Miller 2008; Scorza et al. 2008). These results did not totally conἀrm that omega-3 fatty acids reduce the frequency of epileptic seizures in patients with intractable epilepsy; however, they established the safety of omega-3 supplementation in people with epilepsy (DeGiorgio and Miller 2008). Quite interestingly, there is now great interest in n-3 fatty acids for the prevention of SUDEP (DeGiorgio and Miller 2008; Scorza et al. 2008) and we have to bear in mind that, as omega-3 fatty acids have been shown to reduce cardiac arrhythmias and sudden cardiac deaths, it could be suggested that omega-3 fatty acid supplementation in patients with refractory seizures may reduce seizures and seizure-associated cardiac arrhythmias and, hence, SUDEP. Nonetheless, it is very important to emphasize that nutritional therapy (e.g., omega-3 supplementation) is not a substitute for anticonvulsant medications.
3.4â•…Final Considerations and Future Remarks Polyunsaturated fatty acids are present at high levels in the brain (DeGiorgio and Miller 2008). The 04 polyunsaturated fatty acids are EPA and DHA, which are n-3 fatty acids (omega-3) and dihomogammalinolenic acid (DGLA) and arachidonic acid (AA), which are n-6 fatty acids (omega-6) (Calon and Cole 2007; Ohara 2007). Dietary consumption of the long-chain omega-3 fatty acids, commonly found in ἀsh and ἀsh oil, not only contribute to human central nervous system development, but also may modify the risk for certain adult nervous system diseases, including epilepsy (Voskuyl et al. 1998; Bourre 2004). Following this reasoning, eating ἀsh is certainly a good way to improve the development of the brain, ranging from the composition of cell membranes to cerebral function. All omega-3 fatty acids are important for treatment or prevention of cardiovascular and neurological diseases (Bourre and Paquotte 2008; Scorza et al. 2008). The only foods that provide large amounts of omega-3 are seafood such as certain types of ἀnἀsh and shellἀsh. The highest
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy
63
omega-3 concentrations with the lowest levels of mercury are anchovies, Atlantic herring, Atlantic mackerel, scallops, wild salmon, canned salmon, sardines, and trout (Smith and Sahyoun 2005; Bourre and Paquotte 2008). In sum, a number of different dietary modiἀcations, nutritional supplements, and hormones may help prevent seizures or improve other aspects of health in patients with epilepsy (Gaby 2007). Based on this, new diet-based supplementary therapeutic strategies should be developed with the aim of decreasing seizure frequency and severity in people with epilepsy. Concerning cardioprotective omega-3, it has long been believed that a daily intake of 3000 to 4000 mg of ἀsh oil supplements or two to three servings of fatty ἀsh per week are safe and effective for adults in general, including those with neurological, inflammatory, and neurodegenerative diseases, such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease (Mazza et al. 2007). While it is very important to emphasize that nutritional therapy (including omega-3 supplementation) is not a substitute for anticonvulsant medications, experimental, epidemiological, and clinical studies should be evaluated to establish with precision the possible supplementary beneἀt of omega-3 in the treatment of epilepsy.
Acknowledgment The authors thank Danuza Ferrari for technical assistance, and FAPESP, CInAPCeFAPESP, and CNPq for supporting this study.
References Albert, C. M., C. H. Hennekens, C. J. O’Donnell, et al. 1998. Fish consumption and risk of sudden cardiac death. JAMA 279: 23–28. Annegers, J. F. 1997. Epidemiology of epilepsy. In The Treatment of Epilepsy: Principles and Practice, 2nd ed., ed. E. Wyllie, 165–172. Baltimore, MD: Williams & Wilkins. Babb, T. L. 1999. Synaptic reorganizations in human and rat hippocampal epilepsy. Adv Neurol 79: 763–779. Billman, G. E., H. Hallaq, and A. Leaf. 1994. Prevention of ischemia-induced ventricular ἀbrillation by omega 3 fatty acids. Proc Natl Acad Sci U S A (91): 4427–4430. Billman, G. E., J. X. Kang, and A. Leaf. 1997. Prevention of ischemia-induced cardiac sudden death by n-3 polyunsaturated fatty acids in dogs. Lipids 32: 1161–1168. Bourre, J. M. 2004. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during aging. J Nutr Health Aging 8: 163–174. Bourre, J. M., and P. Paquotte. 2008. Seafood (wild and farmed) for the elderly: Contribution to the dietary intakes of iodine, selenium, DHA and vitamins B12 and D. J Nutr Health Aging 12: 186–192. Calder, P. C. 2004. N-3 fatty acids and cardiovascular disease: Evidence explained and mechanisms explored. Clin Sci 107: 1–11. Calon, F., and G. Cole. 2007. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: Evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 77: 287–293. Cendes, F., F. Leproux, D. Melanson, et al. 1993. MRI of amygdala and hippocampus in temporal lobe epilepsy. J Comput Assist Tomogr 17: 206–210. Colugnati, D. B., P. A. Gomes, R. M. Arida, et al. 2005. Analysis of cardiac parameters in animals with epilepsy: Possible cause of sudden death? Arq Neuropsiquiatr 23: 1035–1041.
64 Sudden Death in Epilepsy: Forensic and Clinical Issues DeGiorgio, C. M., and P. Miller. 2008. N-3 fatty acids (eicosapentanoic and docosahexanoic acids) in epilepsy and for the prevention of sudden unexpected death in epilepsy. Epilepsy Behav 13: 712–713. Duncan, J. S., J. W. Sander, S. M. Sisodiya, and M. C. Walker. 2006. Adult epilepsy. Lancet 367: 1087–1100. Dyerberg, J., and H. O. Bang. 1979. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 2: 433–435. Engel, Jr., J. 1993. Update on surgical treatment of the epilepsies. Summary of the Second International Palm Desert Conference on the Surgical Treatment of the Epilepsies. Neurology 43: 1612–1617. Ferrari, D., R. M. Cysneiros, C. A. Scorza, et al. 2008. Neuroprotective activity of omega-3 fatty acids against epilepsy-induced hippocampal damage: Quantiἀcation with immunohistochemical for calcium-binding proteins. Epilepsy Behav 13: 36–42. Ficker, D. M., E. L. So, W. K. Shen, et al. 1998. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 515: 1270–1274. Gaby, A. R. 2007. Natural approaches to epilepsy. Altern Med Rev 12: 9–24. Gudbjarnason, S., and J. Hallgrimsson. 1976. Prostaglandins and polyunsaturated fatty acids in heart muscle. Acta Biol Med Ger 35: 1069–1080. Halatchev, V. N. 2000. Epidemiology of epilepsy—recent achievements and future. Folia Med (Plovdiv) 42: 17–22. Jacobsen, A. N., X. J. Du, A. M. Dart, and E. A. Woodcock. 1997. Ins (1, 4, 5) P3 and arrhythmogenic responses during myocardial reperfusion: Evidence for receptor speciἀcity. Am J Physiol 273: H1119–H1125. Kang, J. X., and A. Leaf. 1994. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A 91: 9886–9890. Kang, J. X., and A. Leaf. 1996. Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies. Circulation 94: 1774–1780. Kloster, R., and T. Engelskjon. 1999. Sudden unexpected death in epilepsy (SUDEP): A clinical perspective and a search for risk factors. J Neurol Neurosurg Psychiatry 67: 439–444. Kwan, P., and J. W. Sander. 2004. The natural history of epilepsy: An epidemiological view. J Neurol Neurosurg Psychiatry (75): 1376–1381. Langan, Y., L. Nashef, and J. W. Sander. 2005. Case-control study of SUDEP. Neurology 64: 1131–1133. Lathers, C. M., and P. L. Schraeder. 1982. Autonomic dysfunction in epilepsy: Characterization of autonomic cardiac neural discharge associated with pentylenetetrazol-induced epileptogenic activity. Epilepsia 23: 633–647. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008. The mystery of sudden death: Mechanisms for risks. Epilepsy Behav 12: 3–24. Leaf, A., J. X. Kang, Y. F. Xiao, and G. E. Billman. 2003. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 ἀsh oils. Circulation 107: 2646–2652. Leestma, J. E., J. F. Annegers, M. J. Brodie, et al. 1997. Sudden unexplained death in epilepsy: Observations from a large clinical development program. Epilepsia 38: 47–55. Lhatoo, S. D., Y. Langan, B. K. MacDonald, S. Zeidan, and J. W. Sander. 1999. Sudden unexpected death: A rare event in a large community based prospective cohort with newly diagnosed epilepsy and high remission rates. J Neurol Neurosurg Psychiatry 66: 692–693. Marchioli, R. 1999. Results of GISSI Prevenzione: Diet, drugs, and cardiovascular risk. Researchers of GISSI Prevenzione. Cardiologia 44: 745–746. Marchioli, R., F. Barzi, E. Bomba, et al. 2002. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 105: 1897–1903.
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy
65
Mazza, M., M. Pomponi, L. Janiri, P. Bria, and S. Mazza. 2007. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Prog Neuropsychopharmacol Biol Psychiatry 31: 12–26. McLennan, P. L. 1993. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rats. Am J Clin Nutr 57: 207–212. McLennan, P. S., T. M. Bridle, M. Y. Abeywardena, and J. S. Charnock. 1992. Dietary lipid modulation of ventricular ἀbrillation threshold in the marmoset monkey. Am Heart J 123: 1555–1561. Medical Research Council. 1991. Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 337: 1175–1180. Nashef, L. 1997. Sudden unexpected death in epilepsy: Terminology and deἀnitions. Epilepsia 38: S6–S8. Nashef, L., D. R. Fish, J. W. Sander, and S. D. Shorvon. 1995. Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre. J Neurol Neurosurg Psychiatry 58: 462–464. Nilsson, L., B. Y. Farahmand, P. G. Persson, I. Thiblin, and T. Tomson. 1999. Risk factors for sudden unexpected death in epilepsy: A case-control study. Lancet 353: 888–893. Ohara, K. 2007. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31: 469–474. Sander, J. W. 1993. Some aspects of prognosis in the epilepsies: A review. Epilepsia 34: 1007–1016. Sander, J. W. 2003. The epidemiology of epilepsy revisited. Curr Opin Neurol 16: 165–170. Schlanger, S., M. Shinitzky, and D. Yam. 2002. Diet enriched with omega-3 fatty acids alleviates convulsion symptoms in epilepsy patients. Epilepsia 43: 103–104. Scorza, F. A., M. Albuquerque, R. M. Arida, and E. A. Cavalheiro. 2007. Sudden unexpected death in epilepsy: Are winter temperatures a new potential risk factor? Epilepsy Behav 10: 509–510. Scorza, F. A., R. M. Cysneiros, R. M. Arida, V. C. Terra-Bustamante, M. de Albuquerque, and E. A. Cavalheiro. 2008. The other side of the coin: Beneἀciary effect of omega-3 fatty acids in sudden unexpected death in epilepsy. Epilepsy Behav 13: 279–283. Siscovick, D. S., R. N. Lemaitre, and D. Mozaffarian. 2003. The ἀsh story: A diet-heart hypothesis with clinical implications: n-3 polyunsaturated fatty acids, myocardial vulnerability, and sudden death. Circulation 107: 2632–2634. Smith, K. M., and N. R. Sahyoun. 2005. Fish consumption: Recommendations versus advisories, can they be reconciled? Nutr Rev 63: 39–46. Sperling, M. R., H. Feldman, J. Kinman, J. D. Liporace, and M. J. O’Connor. 1999. Seizure control and mortality in epilepsy. Ann Neurol 46: 45–50. Stollberger, C., and J. Finsterer. 2004. Cardiorespiratory ἀndings in sudden unexplained/unexpected death in epilepsy (SUDEP). Epilepsy Res 59: 51–60. Tennis, P., T. B. Cole, J. F. Annegers, J. E. Leestma, M. McNutt, and A. Rajput. 1995. Cohort study of incidence of sudden unexplained death in persons with seizure disorder treated with antiepileptic drugs in Saskatchewan, Canada. Epilepsia 36: 29–36. Tomson, T., T. Walczak, M. Sillanpaa, and J. W. Sander. 2005. Sudden unexpected death in epilepsy: A review of incidence and risk factors. Epilepsia 46: 54–61. Voskuyl, R. A., M. Vreugdenhil, J. X. Kang, and A. Leaf. 1998. Anticonvulsant effect of polyunsaturated fatty acids in rats, using the cortical stimulation model. Eur J Pharmacol 341 (2–3): 145–52. Walczak, T. S., I. E. Leppik, M. D’Amelio, et al. 2001. Incidence and risk factors in sudden unexpected death in epilepsy: A prospective cohort study. Neurology 56: 519–525. Xiao, Y., and X. Li. 1999. Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res 846: 112–121. Xiao, Y. F., A. M. Gomez, J. P. Morgan, W. J. Lederer, and A. Leaf. 1997. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A 94: 4182–4187. Xiao, Y. F., J. X. Kang, J. P. Morgan, and A. Leaf. 1995. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A 92: 11000–11004.
66 Sudden Death in Epilepsy: Forensic and Clinical Issues Xiao, Y. F., S. N. Wright, G. K. Wang, J. P. Morgan, and A. Leaf. 2000. Coexpression with beta(1)subunit modiἀes the kinetics and fatty acid block of hH1(alpha) Na(+) channels. Am J Physiol Heart Circ Physiol 279: H35–H46. Yang, B. C., T. G. Saldeen, J. L. Bryant, W. W. Nichols, and J. L. Mehta. 1993. Long-term dietary ἀsh oil supplementation protects against ischemia–reperfusion-induced myocardial dysfunction in isolated rat hearts. Am Heart J 126: 1287–1292. Yuen, A. W., and J. W. Sander. 2004. Is omega-3 fatty acid deἀciency a factor contributing to refractory seizures and SUDEP? A hypothesis. Seizure 13: 104–107. Yuen, A. W., J. W. Sander, D. Flugel, et al. 2008. Erythrocyte and plasma fatty acid proἀles in patients with epilepsy: Does carbamazepine affect omega-3 fatty acid concentrations? Epilepsy Behav 12: 317–323.
Unanswered Questions SUDEP Studies Needed Claire M. Lathers Paul L. Schraeder Michael W. Bungo
4
Contents 4.1 Omega-3 Fatty Acid Nutritional Deἀciency 4.2 Low Temperatures as a Risk Factor for Cardiovascular Abnormalities and Sudden Death 4.3 Mechanisms of SUDEP: Possible Role of Autonomic Effects Such as Cardiorespiratory Disturbances 4.3.1 Beneἀcial Effects of Physical Activity Related to Reductions in Sympathetic Activity 4.3.2 Autonomic Cardiorespiratory Disturbances as Factors for SUD or SUDEP 4.3.3 Langendorf Isolated Heart Preparation References
67 68 69 69 69 71 72
Our recent review article entitled “Mystery of Sudden Death: Mechanisms for Risks” (Lathers et al. 2008a) examined the overlapping mechanisms that apply to the risk of sudden unexpected death occurring in epilepsy (SUDEP) and in cardiac disease. The information in this article has been updated in Chapter 1 of this book (Lathers et al. 2010). The role of central and peripheral autonomic nervous systems and the cardiopulmonary systems and the interaction between them was explored. The potential interactive role of genetically determined subtle cardiac risk factors for arrhythmias with a predisposition for seizure-Â�related cardiac arrhythmias and the possible mechanisms that are operant in producing both epileptogenic and cardiogenic arrhythmias were addressed. Potential preventive measures to minimize risk of both SUDEP and sudden cardiac death were presented. This information has been updated in several chapters in this book (Lathers 2010, animal models; Lathers and Schraeder 2010b, AED; Lathers and Schraeder 2010c, SUDEP animal model). Scorza et al. (2008, 2010, Chapter 3), raised important issues above and beyond standard medical intervention for the prevention of sudden death in cardiac patients, or in patients with epilepsy at risk for sudden death, by focusing on the importance of lifestyle issues. We discuss these lifestyle issues and comment on several points of clariἀcation of the information presented by Scorza et al. (2008, 2010, Chapter 3).
4.1â•…Omega-3 Fatty Acid Nutritional Deficiency The beneἀcial effect of nutritional aspects of omega-3 fatty acids may decrease cardiac arrhythmias and sudden death (SUD) in patients with cardiac disease. Some questions must be raised for future studies; for example: 67
68 Sudden Death in Epilepsy: Forensic and Clinical Issues
1. Does a nutritional deἀciency in omega-3 fatty acids become a risk factor for SUDEP? Today, there is no answer. Whether Omega-3 fatty acids deἀciency is a risk factor for the relatively young population prone to SUDEP, mean age 32.5–43.5 years (Leestma 1990), is unknown. Studies designed to address this question are needed. Unless someone has familial hypercholesterolemia with very high levels of cholesterol at a young age, we do not see that cholesterol is a clinically signiἀcant risk or predisposition to cardiac disease for the young population at risk for SUDEP. The beneἀcial cardiovascular effect of omega-3 fatty acids to decrease sudden death in cardiac patients may be due to actions on cholesterol levels. 2. Will this cardioprotective effect, independent of the effect on cholesterol levels, be of beneἀt to patients with epilepsy? The answer does not exist at this time, but there is nothing bad to be said for including omega-3 fatty acids in your diet to gain long term nutritional beneἀts, since eating ἀsh containing omega-3 fatty acids may decrease the risk of sudden cardiac death. We do not see a downside to consuming omega-3 fatty acids to decrease the risk of SUDEP, even though at this time there is no proven possibility that omega-3 fatty acids may also have a speciἀc beneἀcial effect on SUDEP. While nutritional therapy that includes omega-3 fatty acids supplementation is not a substitute for anticonvulsant medications, there may be a role for these fatty acids as a supplement to antiepileptic drugs (Scorza et al. 2008).
4.2â•…Low Temperatures as a Risk Factor for Cardiovascular Abnormalities and Sudden Death Scorza et al. (2008) discussed low ambient temperatures as a potential risk factor for cardiovascular abnormalities and, possibly, sudden death. When considering the possible role of low temperatures as a risk factor, several questions must be raised: 1. Exactly how does one deἀne low temperatures? 2. What is the degree range used to deἀne low temperatures and the duration necessary in this low degree range? 3. Is there a dose response with an increased risk of sudden death related to the lower temperatures? 4. If low temperatures are a risk factor for sudden death, how does one counsel patients to avoid cold? Should patients be advised to not ski, snow shoe, ice skate, or walk in the cold and be advised to dress warmly, avoid hypothermia, and move to Houston, Florida, or Southern Spain? During the winter, increases in hemoconcentration (erythrocyte count, plasma cholesterol, and plasma ἀbrinogen levels) occur and may contribute to arterial thrombosis (Neild et al. 1994). It is important to differentiate between the pathological and normal response of the body for protection versus the response to hypothermia. If these physiological changes are normal defense mechanisms, they may be difficult to modify except for a physical move to a temperate climate. One would also not expect patients living in a colder climate to stop participation in outdoor winter activities. Additional studies are needed to
Unanswered Questions: SUDEP Studies Needed
69
conἀrm the basis of this cold theory since it has been challenged by several epidemiological studies, including the study of Kloner et al. (1999).
4.3â•…Mechanisms of SUDEP: Possible Role of Autonomic Effects Such as Cardiorespiratory Disturbances 4.3.1â•…Beneficial Effects of Physical Activity Related to Reductions in Sympathetic Activity Morbidity and mortality in cardiovascular disease are often associated with elevations in sympathetic nervous system activity (Scorza et al. 2008). Increased physical activity does have a beneἀcial cardiovascular interaction. This raises the question: “Will increased physical activity be of beneἀcial input if one assumes cardiovascular sympathetic dysfunction or insufficiency in persons with epilepsy?” In general, exercise does not have a downside, if the patient is sufficiently cardiovascularly ἀt to perform the exercise regimen selected. If exercise is beneἀcial in preventing SUDEP, it will be a great ἀnding. However, even if there is no protective or preventive effect for sudden death resulting from exercise, there is certainly no reason for a patient with epilepsy not to exercise. 4.3.2â•…Autonomic Cardiorespiratory Disturbances as Factors for SUD or SUDEP Autonomic involvement in SUDEP is associated with even minimal epileptogenic activity and may cause altered autonomic activity and balance (Scorza et al. 2008). This may be characterized by alterations in cardiorespiratory parameters including ECG changes, blood pressure, respiration, and vasomotor tone (Hirsh and Martin 1971; Lathers and Schraeder 1982; Schraeder and Lathers 1983; Wannamaker 1985). ECG changes observed in experimental epilepsy include heart rate changes, arrhythmias, conduction blocks, altered ECG morphology, and QT interval changes (Lathers and Schraeder 1982, 1987; Schraeder and Lathers 1983; Lathers et al. 1987; Mameli et al. 1988). Paroxysmal autonomic dysfunction associated with epileptogenic discharges may be a factor in sudden death as they cause a disruption of cardiac and/or respiratory function (Schraeder and Lathers 1990; Lathers and Schraeder 2010c, Chapter 28). Stress itself must also be considered in sudden death, since the occurrence of a seizure may cause the release of catecholamines from the adrenal glands (Doba et al. 1975) and may predispose the heart to development of arrhythmias when confronted with a sudden sympathetic neural barrage induced by epileptogenic discharges (Lathers et al. 2008a, 2008b; Schraeder and Lathers 1990; Pickworth et al. 1990; Lathers and Schraeder 2006, 2010a, 2010b, 2010c). The central nervous system modiἀes the heart in response to environmental stress (Lathers and Schraeder 2006, 2010a). Adverse emotional states impact the autonomic control of cardiac rhythm and are known factors leading to cardiac dysrhythmias in humans. Interactions between emotional factors and the arrythmogenic potential of epileptiform discharges, as well as the possible beneἀt from stress management intervention have yet to be investigated (Lathers and Schraeder 2006). Central nervous system modulation of peripheral autonomic neural discharges to the heart is a risk factor for sudden death in patients with cardiac disease (Lathers et al.
70 Sudden Death in Epilepsy: Forensic and Clinical Issues
1977, 1978; Evans and Gillis 1978) and is also a risk factor for sudden death in persons with epilepsy. Lathers and Schraeder (1982) and Schraeder and Lathers (1983) developed a cat model with an intact central nervous system to explore epilepsy/autonomic neural/ cardiopulmonary system relationships as possible mechanisms of SUDEP. They reported cardiac sympathetic neural nonuniform discharges in association with seizure discharges congruent with increased temporal dispersion of the recovery of ventricular excitability, leading to an underlying electrical instability that predisposes the ventricular myocardium to arrhythmia (Han and Moe 1964). Druschky et al. (2001) reported sympathetic dysfunction in the form of altered postganglionic cardiac sympathetic innervation in patients with chronic temporal lobe epilepsy and suggested altered postganglionic cardiac sympathetic innervation may increase risk of cardiac abnormalities and/or SUDEP. Studies are needed to explore both the developmental and regulatory mechanisms responsible for determining the density and pattern of cardiac sympathetic innervation and the exact role of disturbances associated with the exact location of the innervation in arrhythmogenesis (see discussion by Lathers and Levin 2010, Chapter 33). When evaluating mechanisms of SUDEP, one must also consider that there may be an underlying, undeἀned genetic predisposition to arrhythmias. Thus, it is very likely that the mechanism of sudden death varies from patient to patient, depending on a predisposition to neurogenically induced autonomic dysfunction, be it sympathetic or parasympathetic, and on the status of symptoms and disease present at the time of death. Animal data (Lathers et al. 1987; Stauffer et al. 1989; Lathers et al. 1990) demonstrated the lockstep phenomenon (LSP), postganglionic cardiac sympathetic and vagal discharges that were time-locked to ictal and interictal cortical epileptiform activity. It was suggested that the LSP may explain propagation of electrical impulses to autonomic nervous system regulatory centers, thus initiating arrhythmogenic potentials and premature ventricular contractions, ST/T changes, and conduction blocks occurring concurrently with the cerebral discharges (see Chapter 28, Lathers and Schraeder 2010c, LSP). Numerous experimental preparations could be devised to study in vivo and in vitro methods to modify function of the central nervous system and peripheral autonomic neural activity—reserpine, 6-OH dopamine or bretylium denervation, surgical denervation, adrenalectomy, and various combinations (Lathers et al. 1981, 1982; Lathers 2010, animal models). Epileptogenic activity is associated with cardiac rate and rhythm changes (Howell and Blumhardt 1990). Quint et al. (1990) discussed power spectral analysis of the heart rate as a technique to assess autonomic activity related to risk factors for SUDEP. Goodman et al. (1990; 2010, Chapter 40) found a typical cardiovascular response during a generalized kindled seizure in rats consisted of a large increase in blood pressure accompanied by a profound bradycardia during the ἀrst 20–30 seconds of the seizure. Lathers and Schraeder (1982) reported bradycardia associated with interictal subconvulsant epileptogenic in cats that died in asystole; an increase in heart rate occurred in animals dying in ventricular ἀbrillation. GABA neurotransmission regulates, in part, the central control of cardiovascular function (Schwartz and Lathers 1990). Inhibition of central GABAergic tone using picrotoxin or bicuculline results in enhanced sympathetic outflow to the heart and increased coronary resistance and arrhythmias (Segal et al. 1984). GABAA, introduced into the cerebroventricles prior to the agonist muscimol, prevents these cardiac changes. It may be clearly seen that neuronal excitability/inhibitory state in the central nervous system is important for development of seizures and cardiovascular abnormalities, including arrhythmias. When patients with generalized tonic–clonic seizures on no medications were compared with normal controls, the patients exhibited higher standard deviation of all R–R
Unanswered Questions: SUDEP Studies Needed
71
intervals, standard deviation of mean R–R intervals in 5-min recordings, and heart rate variability compared to normal controls. Heart rate variability exhibited a reduction in high-frequency parasympathetic activity and an increase in low-frequency sympathetic values (Everengul et al. 2005). Heart rate variability in epilepsy patients is lower at night than during the daytime, indicating subtle autonomic dysfunction at night, when risk of SUDEP is greatest (Woodley et al. 1977). Control of the heart rate is perturbed by alterations in neuroautonomic function in clinical syndromes of sudden cardiac death, congestive failure, space sickness, and physiologic aging. Fractal mechanisms in cardiac electrophysiology suggest that loss of normal fractal complexity in the interbeat interval dynamics may not be detected using conventional statistics but are quantiἀed using methods derived from the “chaos theory” (Goldberger 1991). There is a loss of complex physiological variability in pathological conditions, including heart rate dynamics, before sudden death. Cardiac chaos is prevalent in healthy hearts and a decrease of cardiac chaos occurs in congestive heart failure (Poon and Merrill 1997). Use of detrended fluctuation analysis of heart beat time series may distinguish healthy from pathologic data sets (Peng et al. 1995). Studies on patients need to be done to determine how to identify which persons with epilepsy are at risk for SUDEP. Arrhythmogenesis and acute hypoxia have been shown to interact in a negative manner and the combination becomes a risk factor for SUDEP. Acute pulmonary edema may develop during a clinical seizure and lung weights are known to be increased in animal studies (Lathers and Schraeder 1982; Carnel et al. 1985) and in victims of SUDEP (Koehler et al. 2010, Chapter 9). Simon et al. (1982) and Johnston et al. (1995, 1997) demonstrated that seizure induction in a sheep model produced acute pulmonary edema and a neurogenically induced increase in pulmonary microvascular pressure with an accompanying prolonged change in endothelial conductance to protein. In some animals, the neurogenic pulmonary edema was linked to seizures associated with central nervous system–induced apnea. Thus, when an increased risk for arrhythmias is combined with acute hypoxemia associated with the occurrence of neurogenic pulmonary edema and/or associated central apnea, sudden death may be the outcome. For additional information about the role of arrhythmogenesis and acute hypoxia as risk factors for SUDEP, the reader is referred to Lathers et al. (2008), Mameli and Alessandro (2010, Chapter 37), and Lathers et al. (2010, Chapter 1). 4.3.3â•…Langendorf Isolated Heart Preparation Cardiac arrhythmias may trigger sudden death in cardiac patients, originating from three sources: directly from the heart; from the peripheral autonomic nervous system; from the central nervous system; or from combinations of some or all of these factors (Lathers et al. 1977, 1978). Central and peripheral autonomic neural input is not present in the Langendorf isolated beating heart preparation. This preparation is used to examine drug actions on the heart, independent of autonomic neural input and independent of circulating substances such as catecholamines (Lathers et al. 1981, 1982). In vivo animal data may be compared with data obtained in the Langendorf preparation to study the contributory role of the autonomic nervous system to cardiac arrhythmias and/or death. Langendorf hearts may be obtained from animals denervated chemically by pretreatment with reserpine, bretylium or 6-hydroxydopamine, or from rats whose hearts were surgically denervated. Comparison of data from these various animal models reveals data about the role
72 Sudden Death in Epilepsy: Forensic and Clinical Issues
of the actual heart rate in initiation of cardiac arrhythmias and/or sudden death. Thus, the various experimental designs allow clariἀcation of the role of autonomic innervation and influences of the central and peripheral nervous system in relation to epileptogenic activity, heart rate, arrhythmias, and sudden death. Comparison of mean heart rates in vivo and in isolated ex vivo preparation (Langendorf preparation) in rats with epilepsy has been done (Colugnati et al. 2005). Data showed differences in mean heart rates in vivo, but no differences in heart rate in ex vivo, suggesting a central nervous system modulation of the heart may lead to SUDEP. This conclusion seems logical since the Langendorf preparation is an isolated heart preparation devoid of input from the central nervous system. The Langendorf preparation has been used to study the ability of digitalis glycosides to induce arrhythmias and seizures (Lathers, 1990). In conclusion, mechanisms of SUDEP include risk categories of arrhythmogenic factors, respiratory factors and hypoxia, and psychological factors (Lathers et al. 2008a, 2008b). Clariἀcation of risk factors and establishment of the mechanisms of SUDEP will help to develop preventative measures for SUDEP. It appears to be most important to attempt full seizure control. Scorza et al. (2008) encourage patients with epilepsy to receive nonmedical, lifestyle-modifying interventions that have accepted public health beneἀts, even though there is as